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Diabetes mellitus (DM) is a metabolic disease defined by dysregulation of blood glu-
cose levels.1 DM is classified in type 1 DM and type 2 DM by the American Diabetes 
Association.2 Type 1 DM is characterized by insulin deficiency as a result of destruc-
tion of insulin producing beta cells in the pancreas through an auto-immune response. 
Consequently, type 1 DM can be diagnosed by demonstration of antibodies.
In contrast, type 2 DM is caused by insulin resistance. Insulin resistance is raised by 
increasing fat mass and therefore, the risk to develop type 2 DM is higher in obese 
subjects.3 The presence of DM type 2 is often accompanied by one or more other cardio-
vascular risk factors, such as obesity, hypertension and dyslipidemia. As compared to 
type 1 DM, DM type 2 is more common and develops at a later age.
The global prevalence of DM is strongly increasing and has been estimated to rise from 
360 million in 2011 to 552 million in 2030.4 Also in Europe, the prevalence of DM will 
increase from 53 million to 64 million.5 
High blood glucose levels of DM induce endothelial dysfunction and atherosclerosis, 
causing micro- and macrovascular disease.3 Therefore, patients with DM often have 
retinopathy, nephropathy and neuropathy and are at increased risk for stroke, coronary 
artery disease (CAD) and peripheral artery disease. One of the most important compli-
cations of DM is CAD.6 
DM and CAD
Patients with DM have an increased risk of CAD and high prevalence of cardiac morbid-
ity and mortality. In a Dutch population cohort, an incidence rate ratio for CAD of 2.81 
was demonstrated for DM patients as compared to non-DM subjects.7
However, identification of CAD in patients with DM is difficult, because CAD mostly 
progresses without symptoms. Moreover, available cardiovascular risk prediction mod-
els based on patients clinical and demographic parameters seem inadequate for the 
identification of diabetic patients at high risk for cardiovascular events.8 Consequently, 
CAD is not recognized and proper treatment is delayed, leading to more extensive CAD 
and a higher incidence of cardiovascular events. This underlines the need for sensitive 
diagnostic tools to improve the early identification of CAD and allow for the initiation 
of individually tailored therapeutic strategies. Accordingly, identified high-risk patients 
should receive cardiovascular medication that is effective in reducing cardiac morbidity 
and mortality and can be referred for further diagnostic and therapeutic procedures.
Cardiovascular risk assessment in patients with diabetes
Cardiovascular risk assessment in diabetic patients remains challenging. Risk scores 
to predict cardiovascular risk are widely used, but the risk scores are developed in the 
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general population and tend to underestimate the cardiovascular risk of DM patients. 
Risk scores developed in diabetic populations to estimate cardiovascular risk have dem-
onstrated good calibration and discriminations indices. However, external validation 
is still needed. A recent meta-analysis which reviewed 17 risk scores showed that the 
predictive ability of these scores developed in diabetic populations is not superior to 
those scores developed in general population.9 Accordingly, the additional use of other 
biomarkers or imaging tools seems a good alternative to better risk stratify diabetic 
patients.
This thesis evaluates the application and performance of non-invasive cardiac imaging 
tests for cardiovascular risk assessment and management of DM patients. Identification 
of new markers of CAD derived from non-invasive cardiac imaging might result in a 
broader applicability of cardiovascular risk assessment. Non-invasive cardiac imaging 
tests might evaluate target organ damage as well as the presence, severity and extent of 
subclinical atherosclerosis preceding overt clinical CAD. By this means, high-risk pa-
tients for CAD can be identified and further decision making of each DM patient can be 
tailored in order to improve the clinical outcomes at long-term follow-up.
4
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Outline of the thesis
The aim of this thesis is to study the application and performance of various non-inva-
sive imaging tests in cardiovascular risk stratification and management of DM patients.
Chapter 2 provides an overview of mechanisms and mediators involved in the patho-
physiology of obesity leading to CAD and the applicability of such mediators for the 
identification of patients at high risk of CAD. Chapter 3 describes non-invasive cardiac 
imaging of coronary artery anatomy with computed tomography coronary angiography 
(coronary CTA) and coronary artery function with single-photon emission computed to-
mography (SPECT) myocardial perfusion imaging (MPI) and clinical value of combined 
anatomic and functional imaging. Chapter 4 investigates the relation of non-invasively 
measured arterial stiffness with stress perfusion defects on SPECT MPI.
 Chapter 5 studies the relation of indices of arterial stiffness with left ventricular (LV) 
diastolic function as assessed with echocardiography. Chapter 6 assesses the change 
in LV function after 2 years follow-up, using conventional and 2-dimensional speckle 
tracking echocardiography in clinically stable type 2 DM patients. 
In Chapter 7, the feasibility of analysis of atherosclerosis in the descending thoracic 
aorta (DTA) on coronary CTA was evaluated in patients with suspected CAD with or 
without DM. Subsequently, associations of DTA atherosclerosis with CAD were deter-
mined. In Chapter 8 analysis of DTA atherosclerosis on coronary CTA was used in DM 
patients to study the association of DTA atherosclerosis with indices of arterial stiffness 
and measures of renal function (estimated glomerular filtration rate (eGFR) and urinary 
albumin creatinine clearance (UACR)). 
Chapter 9 compares the presence, severity and extent of CAD on coronary CTA in type 
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Cardiovascular metabolic syndrome: 
mediators involved in the pathophysiology from 
obesity to coronary heart disease






Patients with obesity and diabetes mellitus are at increased risk for cardiovascular events 
and have a higher cardiovascular morbidity and mortality. This worse prognosis is partly 
explained by the late recognition of coronary heart disease in these patients, due to the 
absence of symptoms. Early identification of coronary heart disease is vital, to initiate 
preventive medical therapy and improve prognosis. At present, with the use of cardiovas-
cular risk models, the identification of coronary heart disease in these patients remains 
inadequate. To this end, biomarkers should improve the early identification of patients 
at increased cardiovascular risk. The first part of this review describes the pathophysi-
ologic pathway from obesity to coronary heart disease. The second part evaluates several 
mediators from this pathophysiologic pathway for their applicability as biomarkers for 




The global prevalence of obesity and diabetes mellitus (DM) is increasing.1 Patients with 
obesity and DM are at high risk for cardiovascular events, because the presence and 
progression of coronary atherosclerosis is often asymptomatic.2 Consequently, there is a 
delayed clinical presentation with more severe coronary heart disease (CHD) and higher 
cardiovascular morbidity and mortality amongst these patients. This emphasizes the 
importance of the early recognition of CHD, in order to start preventive medical therapy 
and improve the prognosis. At present, with the available cardiovascular risk prediction 
models, the identification of those patients who are prone to cardiovascular events is 
still inadequate.3 Therefore, biomarkers that improve the early identification of CHD in 
this population are required. For this purpose, many kinds of potential biomarkers of 
atherosclerosis have been evaluated for their predictive value of CHD.4 Accordingly, the 
applicability of mediators involved in the pathophysiology of atherosclerosis as biomark-
ers of CHD has been investigated. Such mediators can be derived from the interplay 
between obesity, inflammation, DM and CHD.5-10 Obesity is currently considered as a 
constant state of low-grade inflammation that provides a direct link with atheroscle-
rosis. Inflammation in obesity results from an altered secretion of mediators, such as 
adipokines and cytokines, by the increased adipose tissue mass. Besides increasing 
inflammation, these mediators give rise to the development of DM and the metabolic 
syndrome (MetS) by inducing insulin resistance, hypertension and dyslipidemia. This 
further contributes to the pro-inflammatory milieu that enables the progression of ath-
erosclerosis and development of significant CHD.8, 11
Of note, this review describes only a selection of the involved mediators and does not 
attempt to provide a complete overview of all the factors involved. The first part of this 
review provides a pathophysiologic background that describes a set of important media-
tors involved in each clinical condition and, subsequently, how these mediators interact 
with the other clinical conditions. Thereafter, several of these mediators are further dis-
cussed for their applicability as biomarker of CHD. To this end, for each mediator a 
description is given of how it influences insulin resistance and atherosclerosis, its per-
formance in prediction of CHD events and its impact on CHD risk prediction beyond 
established risk factors.
Obesity and inflammation
Adipose tissue and secretion of adipokines and cytokines
Obesity is characterized by an increased adipose tissue mass which expands the subcu-
taneous, visceral and perivascular fat depots. Adipose tissue is considered an endocrine 
organ involved in the regulation of an individual’s metabolism and state of inflamma-
tion.7, 9 Adipose tissue is made up by adipocytes and vascular stromal components, which 
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include macrophages, fibroblasts, lymphocytes, endothelial cells, and preadipocytes.12 
Adipocytes synthesize a large array of substances that are not only involved in metabolic 
processes such as energy balance, appetite, insulin sensitivity and regulation of fat mass, 
but also in blood pressure, coagulation, immunity and inflammation. Examples of these 
adipocyte products are adipokines such as adiponectin, leptin, resistin, and visfatin.7, 13 
Moreover, cytokines, chemokines and proteins such as monocyte chemo attractant pro-
tein-1 (MCP-1), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and plasminogen 
activator inhibitor-1 (PAI-1) are released by the stromal vascular components of adipose 
tissue, and are involved in local and systemic inflammation.
Adipose tissue causes inflammation by altered secretion of adipokines and 
cytokines 
Several studies have demonstrated a dose-response-like relation between obesity and 
inflammation by showing that an increase in adipose tissue mass in obese individuals is 
associated with an increased release of proinflammatory mediators, whereas the produc-
tion of adiponectin, which is an anti-inflammatory mediator, is decreased (Figure 1).9, 14 
Besides this, the increased visceral adipose tissue mass releases more free fatty acids 
(FFAs) into the circulation. FFAs activate nuclear factor-κB (NF-κB) via Toll-like recep-
tor-4 expressed on macrophages present in the adipose tissue. Activated NF- κB, in turn, 
increases the release of TNF-α from these macrophages, which induces the transcription 
of intracellular adhesion molecule-1 (ICAM-1), IL-6, and MCP-1.14, 15 Via these factors 
monocytes are attracted from the blood, and their migration into the adipose tissue and 
differentiation into macrophages is facilitated.16 This raises the macrophages content of 
adipose tissue in obese subjects and causes a higher cytokine release (Figure 1).14, 17 Of 
note, adiponectin is an important anti-inflammatory mediator that counteracts all steps 
of this inflammatory mechanism. Consequently, obesity is regarded as a current state 
of low-grade inflammation originating from alterations in the secretion of adipocytes 
and cytokines.
Oxidative stress and inflammation
Another factor of influence on inflammation in obese subjects is oxidative stress. 
Oxidative stress is mediated by reactive oxygen species (ROS) which are highly reac-
tive and cytotoxic.18 ROS are generated during the metabolic processing of high-energy 
substrates, such as FFAs and glucose.19, 20 ROS are scavenged by antioxidants, but 
when antioxidant defenses fail the remaining ROS can cause oxidative stress.21 As a 
consequence, lipid oxidation, expression of ICAM-1, as well as vascular cell adhesion 
molecule-1 (VCAM-1), apoptosis, and gene expression of NF-κB are all increased.18 
When ROS target low-density lipoprotein (LDL), oxidized LDL is formed, which, in 
the intima of the vascular wall, leads to foam cell formation.8 Foam cells are the char-
acteristic inflammatory cells of the first stage of atherosclerosis. Oxidized LDL in the 
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intima of the vascular walls also induces the expression of ICAM-1 and VCAM-1 on 
endothelial cells. ICAM-1 and VCAM-1 contribute to inflammation by facilitating the 
attraction and migration of monocytes from the blood into the subendothelial space. 
Another effect of ROS, similar to several released proinflammatory mediators (cytokines 
and chemokines), is increased platelet reactivity.22 Activated platelets participate in the 
inflammatory process and support the atherogenic process via the release of mediators 
facilitating coagulation, and promoting platelet and leukocyte adhesion to the suben-
dothelial matrix.23
Reduced bioavailability nitric oxide
Nitric oxide (NO) is a potent vasodilator and is produced by endothelial NO synthase 
(eNOS).24 NO bioavailability is reduced by several mechanisms.25 Oxidized LDL reduces 
NO production by reduction of the eNOS transcription rate. Moreover, both oxidized 
Figure 1. Development of low-grade inflammation in the adipose tissue of obese individuals
Increased adipose tissue mass has an altered secretion, comprised of an increased release of proinflamma-
tory adipokines, cytokines and FFAs, whereas the release of anti-inflammatory adiponectin is reduced. This 
induces a vicious circle, because the proinflammatory mediators facilitate the attraction and accumulation of 
macrophages in the adipose tissue, which in turn produce proinflammatory cytokines.
Abbreviations +: increase; -: decrease; FFAs: free fatty acids; NO: nitric oxide; ROS: reactive oxygen species
12
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LDL and TNF-α enhance the degradation of eNOS mRNA.26, 27 Another role player is 
asymmetric dimethylarginine, which is known to inhibit NO generation by eNOS.28 
Increased levels of asymmetric dimethylarginine are present in patients with diabetes 
and/or hypercholesterolemia and consequently lower their NO production. In addition, 
the NO concentration is diminished when NO acts as an antioxidant by binding to 
superoxide radicals and peroxynitrite is formed.29 Vasodilation and several beneficial 
anti-inflammatory actions of insulin are mediated via NO pathways and are attenuated 
when NO bioavailability is reduced.5 Importantly, reduced NO bioavailability contrib-
utes to endothelial dysfunction, which refers to a state of the endothelium prone to the 
development of atherosclerosis.11 A key feature of endothelial dysfunction is a decreased 
vasodilation in response to stimuli, such as acetylcholine or mechanical stress, which 
induce the release of endothelial vasodilators such as NO. Besides this, there are other 
disturbances of normal endothelium functioning that result in reduced anticoagulant 
properties, increased adhesion molecule expression and production of ROS from the 
endothelium.
Diabetes mellitus type 2
Obesity and inflammation contribute to insulin resistance
DM develops when insulin resistance increases and the adaptive increase of insulin 
production by pancreatic β-cells fails to overcome this resistance.30 In obese patients, 
there are several mechanisms that enhance insulin resistance (Figure 2). First, increased 
concentrations of FFAs in plasma block insulin signal transduction, potentially by com-
petitive cellular uptake and metabolism with glucose.31 
Insulin normally blocks ‘hormone sensitive lipase’ in adipocytes, where this enzyme 
stimulates hydrolysis of triglycerides and thereby the production of FFAs. This leads to a 
vicious circle, as an insulin resistance state causes the concentrations of FFAs to increase.32 
Second, since pancreatic β-cells have low levels of antioxidants, these cells are vulnerable 
to oxidative stress. As explained earlier, the metabolism of FFAs increases the production 
of ROS and subsequent oxidative stress. The lack of sufficient antioxidants in β-cells in 
the presence of high concentrations of FFAs increases pancreatic β-cell dysfunction and 
insulin resistance.30 Third, decreased adiponectin levels in obese individuals result in the 
decline of insulin sensitivity, as adiponectin is known to exert an insulin-sensitizing ef-
fect, as well as an increased glucose uptake and NO production.33 In addition, adiponectin 
protein expression is suppressed by Angiotensin II.34 Besides an increase in angiotensin 
II concentration via the renin-angiotensin-aldosterone system, angiotensin II is formed 
locally in adipose tissue from angiotensinogen secreted by adipocytes in response to over-
feeding.35 Two final contributors to insulin resistance are the inflammatory markers IL-6 
and TNF-α, which impair intracellular insulin signaling. IL-6 impairs insulin signaling 
in the liver, leading to decreased levels of glycogen synthase and decreased glucose up-
take.36 TNF-α inhibits insulin signaling in fat, skeletal muscle and peripheral tissues.37 
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Figure 2. Obesity, inflammation, insulin resistance and atherosclerosis
The pathophysiologic pathway from obesity to atherosclerosis. Increased adipose tissue mass has an altered 
secretion, including an increased release of proinflammatory adipokines, cytokines and FFAs, whereas the 
release of anti-inflammatory adiponectin is reduced. This causes an increased insulin resistance in the liver 
and skeletal muscle. Circulating FFAs raise the insulin resistance in the vasculature and increase ROS, which 
in turn lowers NO bioavailability. This increases both insulin resistance and inflammation. The loss of insulin 
signaling reduces its anti-inflammatory actions and further contributes to inflammation. Endothelial cells 
express ICAM-1 and VCAM-1 in response to inflammatory mediators, which attract immune cells to the 
subendothelial space. The penetration of LDL and its oxidative modification in the intima of the arterial wall 
induces local inflammation and the formation of foam cells. Foam cells secrete proinflammatory mediators 
and express Toll-like receptors that act as pattern-recognition molecules, which, upon binding an antigen, 
can activate T-cells and intracellular NF-κB. 
Abbreviations +: increase; -: decrease; CRP: C-reactive protein; FFAs: free fatty acids; LDL: low-density lipo-




The MetS is defined by the clustering of at least three out of five defined diagnostic cri-
teria, consisting of cardiovascular risk factors associated with obesity, including obesity 
(defined as increased waist circumference) and DM (hyperglycemia). Therefore, besides 
obesity and DM, one more of the following criteria is required for the diagnosis of MetS; 
either increased blood pressure or dyslipidemia caused by elevated triglycerides or de-
creased high-density lipoprotein cholesterol.38 In addition, the presence of the MetS in 
patients without DM strongly predicts the development of DM.39 
The interaction between hypertension, dyslipidemia, and obesity has been thor-
oughly reviewed by Chapman and Sposito.25 Hypertension in obesity is the result of 
an increased vascular tone induced by FFAs and oxidative stress. Vasoconstriction is 
enhanced in these obese subjects by an increased sympathetic tone and increased angio-
tensin concentration, whereas insulin-mediated vasodilation is inhibited by the reduced 
bioavailability of NO. Dyslipidemia is induced by raised circulating levels of FFAs from 
visceral adipose tissue and is typically comprised of elevated triglycerides and decreased 
high-density lipoprotein.32 
Loss of insulin signaling promotes inflammation
The previously described factors, such as increased concentrations of FFAs, pancreatic 
β-cell failure, decreased levels of adiponectin and inflammatory mediators, augment 
insulin resistance and cause impaired insulin signaling. Insulin itself is a potent anti-
inflammatory factor that suppresses the proinflammatory transcription factor NF-κB, 
NF-κB binding activity, ROS and ICAM-1.40 Furthermore, insulin reduces platelet 
reactivity and has an anti-aggregating effect through a NO-dependent mechanism.41 
Insulin resistance, by contrast, aggravates inflammation and augments oxidative stress, 
which is associated with reduction of NO and endothelial dysfunction (Figure 2).11, 40 
Importantly, ROS activate platelets where the counteracting effect of insulin on platelet 
activation is reduced.41, 42 Thus, more platelets are activated by ROS and these platelets 
release pro-inflammatory mediators and ease coagulation because of their tendency to 
aggregate. Indeed, subjects with diabetes and hyperglycemia have increased markers of 
oxidative stress, as well as activated platelets.22 Moreover, oxidative stress is associated 
with the formation of advance glycosylation end products, which in turn increase ROS 
production.21 
Perivascular adipose tissue
Perivascular adipose tissue (PAT) has gained interest because there is increasing evidence 
that it has a regulatory function in the microcirculation via local vasocrine signaling, 
and contributes to insulin resistance and blood pressure.43 Obese subjects have increased 
PAT, which secretes adipokines and cytokines and, via vasocrine signaling, modulates 
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vascular tone. To this end, decreased levels of adiponectin and increased levels of TNF-α 
induce vasoconstriction.43, 44 In fact, PAT augments insulin resistance through the raised 
TNF-α levels, which inhibit insulin signaling and thereby impair insulin’s vasodilato-
ry actions mediated through the NO pathway.45 This hampers the ability of insulin to 
increase microvascular muscle perfusion for the uptake of plasma glucose. Moreover, 
several studies demonstrated that an increased epicardial adipose tissue volume, which 
directly surrounds the coronary arteries, is associated with an increased risk for CHD.46 
Further research is necessary to elucidate the physiological functions of PAT.
Coronary heart disease
The interplay between inflammation, atherosclerosis and CHD is reviewed by Hansson 
and is briefly discussed here.8 Coronary atherosclerosis precedes overt CHD and is 
strongly associated with inflammation. The progression of atherosclerosis is controlled 
by the balance between inflammatory and anti-inflammatory activity. Hence, the 
previously discussed pro-inflammatory mediators, oxidative stress and endothelial dys-
function, generate a favorable milieu for the development of atherosclerosis. The first 
stage of atherosclerosis is the formation of a fatty streak, which is composed of foam 
cells. These foam cells boost local inflammation by the expression of receptors that at-
tract more inflammatory cells, which induce the activation of the adaptive immune 
system and the release of proinflammatory mediators. The atherosclerotic plaque devel-
ops by progressive inflammation to a characteristic vulnerable plaque with a necrotic 
core and thin fibrous cap. This vulnerable plaque is considered to be prone to rupture 
and can cause myocardial infarction.8 
The initial step in the atherosclerotic cascade is the infiltration and retention of LDL in 
the intima of the arterial wall (Figure 2).25 Hypercholesterolemia in obese subjects with 
a characteristically high LDL portion delivers a higher substrate level for this step.47 
After infiltration, LDL becomes oxidatively modified, and this oxidized LDL triggers 
the activation of endothelial cells and the expression of ICAM-1, VCAM-1 and inflam-
matory genes.8, 48 The increased oxidative stress resulting from the metabolism of FFAs, 
loss of insulin sensitivity and reduced bioavailability of NO enhances the oxidative 
modification of LDL. Subsequently, chemokines, ICAM-1 and VCAM-1 facilitate the 
attraction and diapedesis of monocytes from the blood. In the subendothelial space 
monocytes differentiate into macrophages to internalize and destroy proinflammatory 
oxidized LDL particles.16 49 However, due to increased influx of LDL particles into the 
subendothelial space, LDL particles will accumulate in the macrophages and the latter 
change into foam cells (Figure 2). Foam cells and other attracted immune cells express 
Toll-like receptors, which act as pattern-recognition molecules and bind antigens. These 
pattern-recognition molecules bind antigens derived from oxidized LDL and, in turn, 
can activate intracellular T cells or NF-κB. Activated T-cells can initiate an activation 
cascade, which causes the expression of more cytokines. Several more mediators con-
tribute to increased local inflammation in the atherosclerotic plaque and promote its 
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progression to a vulnerable plaque.8 However, a complete overview of all involved me-
diators is beyond the scope of this review.
Biomarkers
There is a great need for a biomarker that improves the early identification of CHD in 
the subset of individuals at higher risk for CHD with obesity and DM. As mentioned, 
CHD in these individuals often has a late clinical presentation, due to asymptomatic 
progression of coronary atherosclerosis and inadequate risk assessment with established 
cardiovascular risk factors. As a result, CHD is more severe at the time of diagnosis, 
which implicates a worse prognosis, comprising a higher incidence of cardiovascular 
morbidity and mortality. The early identification of CHD is vital, because it allows early 
initiation of proper preventive medical therapy and thereby improves clinical outcome. 
Thus, a biomarker of CHD enables the prevention of cardiovascular events, mortality 
and morbidity by the early identification of CHD and consequent initiation of preventive 
medical treatment. 
The ideal biomarker should enable the accurate prediction or exclusion of CHD, and also 
the monitoring of the effect of therapy on CHD. Besides identification of CHD, such a 
biomarker can be used for the guidance of medical therapy. Most of the mediators de-
scribed above, involved in the pathophysiologic pathway from obesity to atherosclerosis, 
have been evaluated for their applicability as a biomarkers of CHD. Because of their 
involvement in the pathophysiology of CHD, these mediators are likely to have incre-
mental value for CHD risk prediction beyond established cardiovascular risk factors 
and risk prediction models. In this section, several mediators will be more extensively 
discussed. For each of these mediators a description is given of how it influences insulin 
resistance and atherosclerosis and its performance in CHD risk prediction.
Adipocytokines
Adiponectin
Adiponectin is a protein produced by mature adipocytes. It has important favorable 
effects on insulin sensitivity, as well as on the atherosclerotic process.50 Adiponectin 
ameliorates insulin sensitivity by stimulation of glucose uptake, oxidation of FFAs in 
skeletal muscle and by reduction of glucose output by the liver. This reduces the level of 
high-energy substrates for oxidative stress that would otherwise boost inflammation. 
The extensive anti-inflammatory actions of adiponectin take place on several steps of 
the (inflammatory) atherosclerotic cascade.51 They, for instance, interfere with NF-κB 
signaling and inhibit TNF-α release after oxidative modification of LDL in the arterial 
wall, leading to impaired monocyte activation and reduced expression of endothelial 
adhesion molecules.52 Moreover, adiponectin reduces foam cell formation, promotes the 
production of NO and contributes to arterial vasodilation.53 
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Adiponectin has a negative association with obesity and DM, meaning that plasma levels 
of adiponectin decrease with increasing visceral adipose tissue mass, as well as with in-
creasing insulin resistance.50 This occurs in response to increased levels of TNF-α and a 
raised proinflammatory state accompanying obesity and atherosclerosis.51 Adiponectin 
is, therefore, hypothesized as a marker of the MetS and inflammation. This is confirmed 
by the observed lower levels of adiponectin in patients with DM and CHD, and by the 
finding that reduced levels of adiponectin predict the development of DM.54 With regard 
to CHD, the Health Professionals Follow-up Study (HPFS) in men found that a higher 
level of adiponectin after 6 years of follow-up was significantly associated with a lower 
risk of myocardial infarction.55 By contrast, the British Women’s Heart and Health Study 
(BWHHS), with a follow-up of 4 years, could not reproduce this relationship in women.56 
In BWHHS, adiponectin was associated with cardiovascular risk factors, but there was 
no association with CHD. In addition, the British Regional Heart Study (BRHS) found 
no association between adiponectin and CHD in men after 16 years of follow-up.57 This 
study also encompassed a meta-analysis on the association of adiponectin and CHD 
in seven prospective studies, inclusiding the previously mentioned studies. The meta-
analysis comprised 4,267 participants, of whom 1,313 experienced CHD after a mean 
follow-up of 9.7 years. The estimated odds ratio for CHD for the upper tertile of adipo-
nectin compared with the lower tertile was 0.84 (95% CI: 0.70-1.01). Prospective data in 
the DM population are scarce. In a substudy of the HPFS in 745 men with DM type 2, 
after an average follow-up of 5 years, 89 subjects experienced an incident CHD event.58 
Higher levels of adiponectin were not predictive of CHD after multivariate adjustment 
for high-density lipoprotein. In conclusion, notwithstanding that adiponectin improves 
insulin sensitivity and has important anti-inflammatory actions, its association with 
CHD is not undisputed.
Leptin
Leptin is an adipocytokine chiefly produced by mature adipocytes. There are six dif-
ferent isoforms of the leptin receptor (LEPR) derived from the LEPR gene by alternate 
splicing.59 The only long isoform of the LEPR is LEPRb, which is highly expressed in the 
hypothalamus. The first function linked to Leptin is control of body weight by its regu-
lation of appetite, food intake and energy expenditure via these LEPRb receptors in the 
hypothalamus.60 Leptin directly modulates pancreatic β-cell function and inhibits insu-
lin secretion.61 In addition, it also protects these β-cells against oxidative stress. Insulin, 
in turn, stimulates leptin secretion.62 Therefore, leptin is closely related with obesity and 
DM. However, in obese individuals, endogenous leptin is unable to reduce body weight, 
despite its increased levels from increased adipose tissue mass. This unresponsiveness is 
ascribed to leptin resistance.63
Leptin plays a complex ambivalent role in inflammation and atherosclerosis, anti-in-
flammatory as well as proinflammatory.63 Thereby, a theory of ‘selective’ leptin resistance 
is embraced, which does not attenuate all of its actions. Leptin has direct effects on 
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immune cells, endothelial cells and platelets via its receptors.23, 63 The effects of leptin 
on immune cells are necessary for the initiation of an inflammatory response.64 This is 
acknowledged by the fact that patients with leptin deficiency show immunodeficiency. 
In addition, activated leptin receptors on endothelial cells directly influence vascular 
tone and endothelial function.63 Leptin enhances endothelial function by upregulat-
ing NO levels. and at higher levels might even induce NO-dependent vasorelaxation. 
Conversely, increased leptin levels, as seen in obese subjects, are associated with im-
paired NO-dependent coronary vasorelaxation.65 The effects of leptin on inflammation 
are confirmed by the correlation of leptin levels with oxidative stress, levels of C-reactive 
protein (CRP) and expression of adhesion molecules.63 Furthermore, the leptin recep-
tors on platelets trigger platelet aggregation. Of note, the presence of leptin resistance 
provides relative protection against leptin-induced platelet aggregation in obese subjects 
by receptor desensitization.23
The above-described associations of leptin with body weight and inflammation are veri-
fied in clinical studies. In fact, patients with obesity, DM and CHD exhibit increased 
levels of leptin.66 Moreover, leptin was demonstrated to independently predict the de-
velopment of DM in men, but not in women.67 The association of leptin with CHD is 
investigated by several studies and systematically reviewed in 2009 by Sattar et al.68 
The two largest population based studies are the West of Scotland Coronary Prevention 
Study (WOSCOPS) and the BRHS. In the WOSCOPS study, elevated leptin levels pre-
dicted acute cardiovascular events after 5 years follow-up.69 However, in the BRHS leptin 
was not associated with CHD, although leptin was associated with baseline cardiovascu-
lar risk factors and circulating inflammation markers.68 The results of the studies were 
analyzed in a systematic review, which contained the WOSCOPS, BRHS and five other 
prospective studies, including 1,335 patients who developed CHD during the mean 
follow-up of 10 years, and 3,407 control subjects.68 The combined adjusted risk ratio 
between the upper tertile and lower tertile of leptin was not significant (1.44; 95% CI: 
0.95-2.16). 
In patients with DM type 2, an independent association between leptin and subclini-
cal atherosclerosis has been demonstrated by its association with the coronary calcium 
score (CCS), whereas its association with CHD is controversial.66, 70, 71 In summary, leptin 
proves to be a marker of obesity associated with DM, but its function as a marker of 
inflammation is dubious. Accordingly, at present, there is no proof that leptin can ac-
curately be used for assessment of CHD risk. 
Markers of inflammation
C-reactive protein
CRP is a sensitive and dynamic systemic marker of inflammation produced by the liver. 
Consequently, production of CRP directly increases in response to a variety of systemic 
events such as infection or tissue damage throughout the body. Besides this, mildly ele-
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vated CRP levels are seen in subjects with abdominal obesity and DM.9 This is caused by 
IL-6 released from macrophages in the visceral adipose tissue and subendothelial space, 
which stimulates CRP secretion from the liver. CRP contributes to insulin resistance by 
attenuating insulin signaling.72 Accordingly, many studies have confirmed that elevated 
CRP levels are predictive of the development of insulin resistance, DM and the MetS.73 
With regard to CHD, there is a great body of evidence that has established the relation-
ship between CRP and CHD as shown in prospective studies in the general population 
studies as well as in patients with DM and MetS.73, 74 Nevertheless, it remains to be elu-
cidated whether CRP is really involved in the causal pathway of atherosclerosis or a 
non-specific bystander.75 The presence of CRP in the atherosclerotic plaque is an ar-
gument for its role in atherogenesis.76 Moreover, some mechanisms are described by 
which CRP promotes atherosclerosis: CRP reduces eNOS, mediates the negative effects 
of oxidized LDL on endothelial cells such as expression of adhesion molecules, is in-
volved in the activation of the complement cascade and promotes foam cell formation.77 
On the other hand, some studies did not observe a difference in atherosclerotic lesion 
area or lesion severity in the presence of high CRP levels, compared with low levels or 
absence of CRP.78, 79 In order to further clarify whether CRP has a causal association 
with CHD, several genetic epidemiological studies have been performed.80 These stud-
ies used a Mendelian randomization, which assumes that individuals with a variation 
in the CRP gene have a substantial change in CRP concentration, which proportionally 
relates to their cardiovascular risk. A genome-wide association study published in 2009 
demonstrated that, despite the fact that several genetic loci were associated with changes 
in CRP concentration, these changes were not associated with CHD risk.80
The association of CRP with CHD is extensively assessed in a recent meta-analysis by 
the Emerging Risk factors Collaboration.81 This meta-analysis included 54 studies with 
a total of 160,309 subjects and 10,451 CHD end points. The risk ratios (RR) for CHD, 
adjusted for conventional risk factors was 1.37 (95% CI: 1.27-1.48) per one standard de-
viation (SD) higher log CRP concentration. This demonstrated the predictive value of 
CRP for CHD and raised the question of whether CRP improves CHD risk prediction. 
In the Reykjavik study, CRP was predictive for CHD with an odds ratio of 1.45 (95% 
CI: 1.25-1.68) for subjects in the highest tertile compared with subjects in the lower ter-
tile of CRP.82 Nevertheless, the authors concluded that CRP is a moderate predictor for 
CHD. Other studies have demonstrated that the addition of CRP to traditional cardio-
vascular risk factors improved accuracy for prediction of cardiovascular disease (CVD; 
defined as CHD and stroke) by reclassification of 30-50% of the patients.83, 84 Finally, 
the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating 
Rosuvastin (JUPITER) trial prospectively investigated the effect of lowering CRP levels 
on CVD events.85 For this purpose, 17,802 men and women with low LDL (<3.4 mmol/l) 
and elevated high-sensitivity CRP (>2.0 mmol/l) were randomly assigned to either 20 
mg daily rosuvastatin or placebo. The use of rosuvastatin after a mean follow-up of 1.9 
years resulted in a reduction in LDL levels of 50% and high-senstivity CRP levels of 37%, 
and was associated with a significantly reduced HR for CVD of 0.56 (95% CI: 0.46-0.69) 
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compared with the placebo group.
In addition, in the diabetic population, compared with other biomarkers, the value of 
CRP for the prediction of CHD is more extensively evaluated. Studies in the diabetic 
population showed that the relationship of CRP with CHD in this subgroup might be 
less obvious. In a substudy of the HPFS a total of 746 men with DM type 2 were enrolled, 
of which 103 patients had an incident CVD event after a mean follow-up of 5 years.74 
The individuals in the highest CRP quartile had a significantly increased RR for CVD 
events, after adjustment for baseline risk factors, of 2.62 (95% CI: 1.29-5.32). Conversely, 
in the Strong Heart Study (SHS), which comprised of 2,735 participants with CRP ≤10 
mg/l, half were diagnosed with DM and 343 participants suffered from a CVD event 
during a median follow-up of 6.2 years.86 Although CRP after multivariate adjustment 
was significantly associated with CVD events in the overall study population, in females 
and in the nondiabetic subgroup, no significant association was observed between CRP 
and CVD events in males and in the diabetic subgroup.
In conclusion, despite the fact that CRP is most likely not involved in the causal pathway 
of CHD, CRP is a good marker of CHD in the general population. To this end, CRP has 
great potential to be clinically used clinically on a large scale, due to it low cost, non-
invasive assessment and its broad availability. Moreover, the JUPITER trial indicated 
that the combined lowering of LDL and CRP levels reduced CVD risk. The application 
of CRP for CHD risk discrimination among individuals with DM needs further study.
Interleukin-6
IL-6 is a cytokine mainly produced by adipose tissue, but also by monocytes, macro-
phages and skeletal muscle.87 One of it functions is the regulation of the proliferation 
and differentiation of hematopoietic cells. IL-6 is proinflammatory and inhibits the se-
cretion of adiponectin.88 When secreted by adipose tissue, it can directly enter the liver 
through the portal vein. There, IL-6 induces the secretion of CRP, especially during 
an acute-phase response to inflammation or tissue injury.89 Furthermore, in the liver, 
it contributes to insulin resistance by impairment of insulin signaling, which leads to 
decreased levels of glycogen synthase and decreased glucose uptake.36 By contrast, in 
skeletal muscle IL-6 is secreted in response to exercise and increases glucose uptake.90
In addition to its role in the systemic acute-phase response, IL-6 regulates local inflam-
mation at sites of tissue injury via its direct effects on immune cells.91 Atherosclerosis is 
enhanced by promotion of the expression of adhesion molecules and stimulating foam 
cell formation. Furthermore, increased levels of IL-6 contribute to a prothrombotic state 
through increased platelet counts.23 
IL-6 levels should be interpreted with care; IL-6 has a short half-life and relatively great-
er within-person variability compared with CRP or other CVD risk factors.92 Several 
prospective studies have established that, similar as CRP, IL-6 levels are increased in 
subjects with obesity or DM and that raised IL-6 levels are predictive for the develop-
ment of DM.93 Large prospective general population studies such as the Reykjavik study, 
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BRHS, and WOSCOPS have recognized the predictive value of IL-6 levels for CHD.92, 
94 By contrast, in the HPFS in men and the Nurses’ Health Study (NHS) in women, 
IL-6 was not predictive for CHD after multivariate adjustment for baseline risk fac-
tors.95 This was further investigated by Danesh et al. in a meta-analysis of 17 relevant 
studies, including the previously mentioned studies.92 This meta-analysis, published in 
2008, comprised a total of 24,768 individuals of whom 5,730 suffered from a CHD event 
after an average follow-up of 6 years. The combined multivariate adjusted odds ratio for 
CHD per 1 SD increase in baseline IL-6 levels was 1.26 (95% CI: 1.19-1.35). Whether IL-6 
improved risk prediction was not further addressed. However, in the ARIC study, for 
instance, IL-6 levels did not improve the baseline CVD risk model.96
Two substantial studies in patients with DM type 2 did not found an association between 
IL-6 and progression of CCS. One study was a substudy of the Veterans Affairs Diabetes 
Trial (VADT), with a mean follow-up of 4.6 years and was comprised of 197 patients.97 
The other study, with a follow-up of 2.5 years, comprised of 398 patients.98 A substudy of 
the Estrogen and Thromboembolism Risk (ESTHER) study assessed the predictive value 
of IL-6 levels for CVD events in 1,072 participants with DM.99 After 5 years follow-up, 
84 patients had a CVD event. Patients in the upper tertile of IL-6 levels, compared with 
patients in the lower tertile, had an increased risk of CVD events and a multivariate ad-
justed hazard ratio of 1.90 (95% CI: 1.06-3.40). Similarly to the general population, IL-6 
levels did not improve risk prediction beyond baseline risk factors.
In brief, IL-6 might not be an ideal marker because its short half-life and greater within-
person variability than other markers. Although IL-6 levels predict the development of 
DM and CVD, current studies have not demonstrated an incremental predictive value 
for CVD beyond established CVD risk factors.
Tumor necrosis factor-α
TNF-α is a pro-inflammatory cytokine that is involved in the innate immune system.100 
It is released by monocytes, macrophages, adipose tissue and endothelial cells through-
out the acute-phase response to inflammation and tissue injury. To this end, receptors 
of TNF-α are expressed on most cell types, except erythrocytes, and upon stimulation 
lead to activation of NF-κB.101 Activated NF-κB modulates the inflammatory response 
by increase in gene expression.100 Furthermore, TNF-α increases the concentration of 
FFAs and insulin resistance, which leads to increases in serum triglycerides and glucose. 
During the acute phase response when TNF-α levels are raised, this mechanism provides 
extra substrates for the increased metabolic needs of cells involved in the inflamma-
tory response.102 However, subjects with chronic inflammatory disease or obesity also 
have increased TNF-α levels, which promote the development of insulin resistance and 
atherosclerosis.
TNF-α causes insulin resistance by several mechanisms. For instance, in order to raise 
serum triglycerides, TNF-α counteracts insulin’s antilipolytic action by inhibition of 
early insulin signaling.103 As a result, lipolysis produces FFAs for triglyceride synthesis. 
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This mechanism demonstrates that TNF-α directly inhibits insulin signaling and by 
its action raises the plasma concentration of FFAs, which also inhibits insulin signal-
ing.103, 104 Moreover, TNF-α increases insulin resistance through decreasing adiponectin 
levels and increasing leptin levels.105 In fact, it was demonstrated that supplementation 
of TNF-α to healthy individuals reduced insulin sensitivity.106
TNF-α plays an important role in the atherosclerotic process. Notably, it activates NF-
κB, which in turn can increase the production TNF-α.107 ROS formation is stimulated by 
TNF-α in endothelial cells and also through the increase in FFAs and glucose.100 On the 
other hand, TNF-α reduces NO bioavailability by acting on several steps of NO synthe-
sis. Namely, by reduction of NO expression, NO activity, NO substrate availability and 
accumulation of asymmetric dimethylarginine.107, 108 Furthermore, increased scaveng-
ing of ROS further lowers the NO concentration. This results in a weakened inhibition 
of ICAM-1 and VCAM-1 expression by NO, whereas TNF-α supports its expression.100 
Thus, TNF-α leads to increased oxidative stress and reduced NO bioavailability, and 
thereby impairs endothelial function. This sets the stage for atherosclerosis, since en-
dothelial dysfunction and increased serum triglycerides facilitate infiltration of LDL 
particles into the intima of the arterial wall. Finally, in response to oxidatively modified 
LDL in the intima, TNF-α is locally released and enhances foam cell formation. These 
cells increase inflammation by the the secretion of TNF-α, among others.109 
In clinical studies evaluating the predictive value TNF-α for CHD, TNF-α was mea-
sured by its plasma concentration as well as by levels of the type 1 (sTNFR-1) or type 
2 (sTNFR-2) TNF-α soluble receptors. Of note, in these studies TNF-α and its soluble 
receptor plasma concentrations were higher in patients with DM and MetS.110, 111 In the 
Cytokines Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) 
study, including 184 patients with myocardial infarction and 45 controls, sTNFR-1 was 
an independent predictor of death after 406 days of follow-up.112 Another study com-
prised of 167 patients with CHD found no association between TNF-α and the number 
of coronary lesions.111 In 2003, the Aging and Body Composition (Health ABC) study 
reported on the predictive value of TNF-α for the 188 identified cases of CHD among 
2,225 elderly individuals after 3.6 years follow-up.113 The adjusted RR for CHD per SD 
log (TNF-α) was 1.22 (95% CI: 1.22-1.43). Thereafter, in 2004 the HPFS and NHS as-
sessed this association in separate analysis for men and women.95 In men, including 
529 controls and 265 cases of CHD after follow-up of 6 years, plasma concentrations of 
sTNFR-1 and sTNFR-2 were not associated with CHD events. By contrast, in women, 
comprising of 469 controls and 239 cases of CHD after 8 years of follow-up, sTNFR-1 
and sTNFR-2 levels were univariately associated with CHD events, but not when mul-
tivariate adjusted.
In summary, TNF-α induces DM and CHD through its proinflammatory actions, which 
provoke insulin resistance and endothelial dysfunction. At present, the predictive value 
of TNF-α for CHD is not exactly known due to a limited number of studies; however, 




Chemokines are a large family of cytokines that are involved in the attraction and mi-
gration of immune cells from the blood into the vessel wall at sites of inflammation 
or injury.114 Chemokines and their receptors are located in vascular cells such as en-
dothelial cells, vascular smooth muscle cells, platelets and immune cells.115 They are 
extensively involved in the atherosclerotic process. This is demonstrated in studies with 
transgenic mice, in which the deficiency of a chemokine or its receptor proved to reduce 
atherosclerotic lesions and even stabilize vulnerable plaque.116 For instance, deficiency 
of MCP-1, also known as CCL2, or its receptor CCR2 decreased atherosclerosis and 
macrophage infiltration.117, 118 As mentioned previously, inflammation and endothelial 
dysfunction causes the expression of cell adhesion molecules. These molecules promote 
the expression of chemokines on endothelial cells and smooth muscle cells, which facili-
tate monocyte arrest and migration into the vessel wall.16 Consequently, monocytes and 
macrophages accumulate in the arterial wall and augment atherosclerosis. Furthermore, 
the expression of several chemokines is upregulated in atherosclerotic lesions, where it 
enhance plaque progression.114 They can also activate platelets, which store large number 
of chemokines, which are released upon activation.16 Lastly, activation of macrophages 
by chemokines might induce ROS and foam cell formation. 
Measurement of chemokines is difficult, since they have a short half-life and several have 
concentrations below the test detection limits.114 The étude Prospective sur l’Infarctus 
du Moyarde (PRIME) study assessed the predictive value of four different chemo-
kines: regulated on activation normal T-cell expressed and secreted (RANTES/CCL5), 
interferon-γ-inducible protein-10 (IP-10/CXCL10), MCP-1, and eotaxin-1 (CCL11).119 
This was performed as a nested case-control study in men, including 621 CHD cases 
and 1,242 controls, after a follow-up of 10 years. In this study, subjects with diabetes 
(4.4 and 1.9% of cases and controls, respectively) had similar levels of chemokines com-
pared with the nondiabetic subjects. Moreover, there was no association between the 
chemokines and CHD. Whether MCP-1 is involved in the pathophysiology of CHD was 
investigated in the European Prospective Investigation into Cancer in Norfolk (EPIC-
Norfolk) study.120 This study, comprising of 1,138 patients with an incident CHD events 
after 6 years of follow-up, did not find an association between either genetic variants of 
MCP-1 or serum MCP-1 levels and CHD events. Finally, chemokines play an important 
role in atherosclerosis via local recruitment of immune cells and in plaque progression. 
The measurement of chemokines is challenging and just one chemokine is not represen-
tive for all their actions, because they function independently.114 At present, prospective 
population-based studies have not shown that chemokines can predict CHD events. 
Lipoprotein-associated phospholipase A2
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme produced by circu-
lating monocytes, T lymphocytes and mast cells, which circulates in the blood mainly 
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bound to LDL.121 This enzyme hydrolyzes phospholipids, predominantly LDL, in the 
arterial wall, which generates proinflammatory mediators such as oxidized LDL. As 
described previously, this is an important step in atherosclerosis, enhancing local in-
flammation by facilitating the attraction of monocytes, impairment of endothelial 
function and apoptosis in smooth muscle cells and macrophages. Therefore, Lp-PLA2 is 
regarded as a marker of inflammation.122 Lp-PLA2 levels can be measured as Lp-PLA2 
mass or Lp-PLA2 activity with a good correlation. However, Lp-PLA2 mass is used in 
most studies and, therefore, preferred.123 
The relationship of Lp-PLA2 and subclinical atherosclerosis is assessed by several stud-
ies, which have displayed conflicting results. In the 1,820 participants of the Rotterdam 
study, Lp-PLA2 activity was not associated with extracoronary atherosclerosis.124 By 
contrast, among patients with type 2 DM in the substudy of VADT, Lp-PLA2 mass was 
a significant predictor of progression of CCS.97 In another study, the Coronary Artery 
Calcification in Type 1 Diabetes (CACTI) study, the association between both LP-PLA2 
mass and activity with CCS progression after a mean follow-up of 2.6 years were assessed 
in a population comprised of 506 patients with DM type 1 and 591 subjects without 
diabetes.125 This study demonstrated that in the complete study population LP-PLA2 
activity, but not LP-PLA2 mass, independently predicts CCS progression. Conversely, 
in the subgroup of patients with DM type 1, Lp-PLA2 activity was not different between 
subjects with or without CCS progression. 
The predictive value Lp-PLA2 mass and activity for CHD was evaluated by Thompson et 
al. in 2010 as part of a broad meta-analysis assessing CVD end-points.123 Twelve studies 
were included for the association between Lp-PLA2 mass and CHD event, resulting in a 
total of 40,291 subjects and 4,361 cases. The combined adjusted RR for CHD per increase 
of 1 SD Lp-PLA2 mass was 1.11 (95% CI: 1.07-1.16). Analysis of Lp-PLA2 activity demon-
strated a similar RR, making Lp-PLA2 a potential predictive marker to identify patients 
at high risk for CVD. However, this was not confirmed in the multibiomarker project 
Monica Risk, Genetics, Archiving and Monograph (MORGAM), where Lp-PLA2 mass 
and activity were not identified as an independent predictor of CVD.126 Regarding pa-
tients with DM, the HPFS and NHS, comprised of 1,517 patients with DM type 2, of 
whom 324 experienced CHD after 10 years of follow-up, demonstrated that Lp-PLA2 was 
independently and significantly associated with incident CHD.127 Altogether, Lp-PLA2 
shows a promising association with CHD in both the general population and in patients 
with DM, although the evidence in the DM subpopulation is limited. Further studies 
are necessary to investigate whether Lp-PLA2 contributes to CHD risk stratification.
Novel biomarkers
Tumor necrosis factor-like weak inducer of apoptosis
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) belongs to the TNF 
superfamily, which function as transmembrane proteins as well as soluble molecules, 
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and has a regulatory function in inflammation and immune responses.128 It is present at 
high levels in a variety of tissues and organs, for instance in the heart, liver, vasculature 
and adipose tissue. TWEAK acts on a single receptor, namely fibroblast growth factor-
inducible 14 (Fn14). Resting tissue levels of Fn14 are low, but become rapidly upregulated 
during injury or inflammation and thereby sensitize the actions of TWEAK. Most actions 
of TWEAK are proinflammatory, although anti-inflammatory actions that attenuate the 
innate immune response have been described. TWEAK inhibits adipogenesis in human 
preadipocytes and reduces mRNA expression of adiponectin.129 It can activate NF-κB 
through the canonical pathway, similar to TNF-α, but also through noncanonical mech-
anisms, which give rise to a prolonged activation of NF-κB.130 Activated NF-κB impairs 
insulin signaling and increases insulin resistance. Furthermore, TWEAK contributes 
to atherosclerosis by stimulating the expression of ICAM-1, MCP-1 and chemokines in 
endothelial cells and the expression of proinflammatory chemokines via the activation 
of NF-κB in the atherosclerotic plaque.128
Soluble TWEAK (sTWEAK) can be measured in the plasma. At present, studies on sT-
WEAK are scarce. Reduced concentrations of sTWEAK were found in the presence of 
DM and atherosclerosis.128 Furthermore, a few studies have demonstrated that sTWEAK 
has predictive value for CVD in patients with chronic kidney disease.131
Pentraxin 3
Pentraxin 3 (PTX3) was first identified in various tissues as a cytokine-inducible mol-
ecule.132 It belongs to the superfamily of pentraxins involved in the humoral arm of the 
innate immune system. PTX3 is a long pentraxin which has, as compared with the short 
pentraxins such as CRP, an additional N-terminal. PTX3 is a pattern-recognition mol-
ecule that binds selected pathogens, such as microorganisms, and in response modulates 
complement activation, opsonization and glycosylation-dependent inflammation. It is 
expressed by dendritic cells, endothelial cells, monocytes, macrophages, fibroblasts and 
adipocytes, among others. These cells produce PTX3 locally upon stimulation by lipo-
polysaccharide, IL-1, TNF-α and oxidized LDL.133 Blood levels of PTX3 rapidly increase 
in the presence of inflammation and have demonstrated a good correspondence with 
disease severity.132
Recently, it has been demonstrated that, although PTX3 levels decrease with obesity, 
gene expression of PTX3 in visceral adipose tissue is higher in overweight and obese 
subjects.134 Furthermore, PTX3 had a negative correlation with insulin secretion in re-
sponse to glucose. With regards to atherosclerosis, one study found that PTX3 blood 
levels were not related to CVD risk factors, but its blood levels were significantly in-
creased in patients with unstable angina pectoris compared with controls.135 In addition, 
a prospective study in elderly patients found that PTX3 was associated with CVD mor-
tality and all-cause mortality, but not with CVD events defined as angina pectoris, 




The identification of CHD in individuals with obesity and DM is often delayed, caus-
ing a increased risk for cardiovascular events and a worse prognosis. Consequently, a 
biomarker of CHD is required to improve the early identification of CHD in these pa-
tients beyond established cardiovascular risk factors. For this purpose, many mediators 
involved in the pathophysiological pathway from obesity to atherosclerosis have been 
investigated for their applicability as biomarkers of CHD. This review discussed a select 
group of these mediators.
In the general population, some of these mediators have shown a good predictive 
value for CHD, but their incremental value for CHD risk prediction beyond estab-
lished cardiovascular risk factors needs to be validated. In the subgroup of individuals 
with ‘cardiovascular MetS’, implicating an increased CHD risk, associations between 
these mediators and CHD have been less extensively investigated and remain unclear. 
Moreover, mediators with a good predictive value for CHD in the general population were 
not consistently associated with CHD in this subpopulation. This highlights the need 
for futher research. New knowledge about the pathophysiology of CHD and new imag-
ing techniques might provide opportunities for the recognition of CHD. Consequently, 
potential biomarkers have to be further evaluated for their predictive value for CHD. 
Future perspective
The aim of future investigation should be to improve the identification of high-risk 
individuals who will experience a CHD event. To this end, new insights in the patho-
physiology of CHD and new techniques might provide opportunities for the recognition 
of CHD. Furthermore, new screening strategies could be developed and further evalu-
ated for their incremental value in the prediction of CHD and feasibility with regard to 
cost-effectiveness. For this purpose, currently used risk models including established 
CHD risk factors could be expanded with one or more validated biomarkers, or even 
with measurement of subclinical atherosclerosis (carotid intima media thickness, vas-
cular stiffness or CCS). Nevertheless, further research remains necessary to identify 
and evaluate new biomarkers. Novel biomarkers should be validated for their predictive 
value of CHD and additional value to CHD risk prediction in the general population 
and other subgroups. This is of great importance, because novel biomarkers might not 
only improve the identification of individuals at increased CHD risk, but also provide 
new targets for pharmaceutical therapies. For example, new medical therapies are cur-
rently being investigated that target phospholipase A2 enzymes and thereby reduce 
Lp-PLA2.122 First results with these drugs of the Integrated Biomarkers and Imaging 
Study-2 trial in patients with confirmed CHD found a reduction of necrotic core, but 





•	 There is a need for a biomarker of CHD to improve the identification of CHD in indi-
viduals with ‘cardiovascular metabolic syndrome’ beyond established cardiovascular 
risk factors
•	 Mediators involved in the pathophysiology of CHD induced by obesity are potential 
biomarkers of CHD 
Obesity, inflammation, DM and CHD 
•	 The interplay between obesity, inflammation, DM and CHD is complex and involves a 
great variety of mediators, signal transduction pathways and mechanisms.
Increasing adipose tissue mass contribute to inflammation
•	 Increased adipose tissue has an altered secretion of adipokines, cytokines and FFAs.
•	 Proinflammatiory mediators are increased, whereas anti-inflammatory mediators are 
decreased.
Oxidative stress, reduced bioavailability of NO and insulin resistance
•	 Proinflammatory mediators increase oxidative stress and reduce the bioavailability of 
NO, contributing to inflammation and insulin resistance.
•	 Insulin resistance in turn increases oxidative stress and reduces bioavailability of NO.
DM type 2 and MetS
•	 Increased insulin resistance resulting from raised proinflammatory mediators pro-
motes the development of DM type 2.
•	 Proinflammatory mediators and insulin resistance cause dyslipidemia and impaired 
vasodilation, which promote the establishment of MetS.
CHD
•	 The proinflammatory milieu induces the expression of cell adhesion molecules on 
endothelial cells and the subsequent attraction and diapedesis of monocytes.
•	 The infiltration of LDL in the intima of the arterial wall and its oxidative modification 
is a key step in the development of atherosclerosis. Increasing LDL levels in the intima 
cause foam cell formation.
•	 Local inflammation is further enhanced by foam cells through the expression of re-
ceptors and secretion of cytokines and chemokines that attract more immune cells 
into the atherosclerotic plaque. 
Biomarkers
Biomarkers of CHD should improve CHD risk prediction beyond established risk 
factors.
Adipokines
•	 Adiponectin has anti-inflammatory properties, as opposed to leptin, which seems pro-
inflammatory in obese subjects.
•	 Adiponectin and leptin are associated with DM and CHD. However, in meta-analysis, 




•	 CRP, IL-6 and Lp-PLA2 are predictive for CHD and further studies are necessary to 
assess the incremental predictive value of these markers.
•	 Only a few studies report on TNF-α and CHD; the largest study did not find an as-
sociation between TNF-α and CHD events.
•	 Chemokines were not shown to be predictive for incident CHD in population-based 
studies. 
Novel biomarkers 
•	 TWEAK and Pentraxin 3 are promising novel biomarkers of CHD. Their association 
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Function and anatomy: 
SPECT-MPI and MSCT coronary angiography






For the diagnosis of coronary artery disease (CAD), non-invasive cardiac imaging is in-
dispensable. Myocardial perfusion imaging (MPI) by single photon emission computed 
tomography (SPECT) investigates the pathophysiological consequences of luminal ob-
structive CAD, while multislice computed tomography coronary angiography (CTA) 
indicates  the presence, extent and location of coronary atherosclerosis. The integration 
of CTA and SPECT data may provide important information, which may be useful for 
patient management. In this manuscript the value of both techniques will be described. 
In addition, the feasibility and potential value of combined anatomic and functional 




Coronary artery disease (CAD) is still one the most prevalent healthcare problems in the 
industrialised world. Cardiovascular imaging plays an important role in the diagnosis 
of CAD. In the last decades several non-invasive functional imaging techniques, such 
as single photon emission computed tomography (SPECT), magnetic resonance imag-
ing and contrast echocardiography have become readily available. SPECT myocardial 
perfusion imaging (MPI) in particular is generally widely used and a well-established 
non-invasive tool for the diagnosis of ischaemic coronary disease. Reflecting the patho-
physiological consequences of luminal obstructive CAD, this technique has been used 
for more than 30 years and has proven to be highly accurate.1, 2
In recent years, non-invasive assessment of cardiac anatomy has also become possible 
with the introduction of multislice computed tomography coronary angiography (CTA), 
which allows for detection of significant CAD with a high diagnostic accuracy com-
pared to conventional invasive coronary angiography.3, 4 Comparative studies between 
SPECT and CTA have shown that a significant stenosis detected on CTA, results in a 
perfusion abnormality on SPECT in only approximately 50% of patients, conversely a 
normal SPECT was unable to rule out the presence of significant CAD or atherosclerosis 
in general.5, 6 CTA and SPECT thus provide complementary information regarding the 
presence and haemodynamic effects of CAD. As a result the focus of non-invasive im-
aging has shifted towards combined assessment of both anatomy and function. In this 
review we will briefly describe the technique and clinical applications of SPECT and 
CTA, and we will describe the usefulness and the advances in combined anatomic and 
functional imaging.
Myocardial perfusion imaging by SPECT
The technique
The underlying principle of this technique is that under conditions of stress, territories 
supplied by diseased coronary arteries receive less blood flow than normal myocardium. 
A cardiac specific radiopharmaceutical (Technetium-99 m or Thallium-201) is adminis-
tered, while the heart rate is raised (exercise or dobutamine) to induce myocardial stress 
or during maximal vasodilatation by adenosine or dipyridamole infusion. SPECT is a 
nuclear tomographic imaging technique using gamma rays, which are emitted by the in-
jected radiopharmaceutical. SPECT imaging is performed by using a gamma camera to 
acquire 2-dimensional images from multiple angles. A computer is used to apply a tomo-
graphic reconstruction algorithm to the multiple projections, yielding a 3-dimensional 
dataset. This dataset may then be manipulated to show thin slices along any chosen 
axis of the body. To acquire SPECT images, the gamma camera is rotated around the 
patient. Projections are acquired at defined points during the rotation, typically every 
3–6 degrees. In most cases, a full 360 degree rotation is used to obtain an optimal recon-
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struction. The time taken to obtain each projection is also variable, but 15–20 seconds 
is typical. This results in a total scan time of 15–20 minutes. SPECT imaging performed 
after stress reveals the distribution of the radiopharmaceutical, and therefore the relative 
blood flow to the different regions of the myocardium. Diagnosis is made by comparing 
stress images to a set of images obtained at rest. The site, extent and depth of these abnor-
malities are assessed. Homogeneous myocardial uptake of the tracer indicates normal 
myocardium and perfusion. Absence of the tracer means clinically significant infarc-
tion or coronary stenosis. A defect at stress images that normalises in the rest images 
indicates an inducible perfusion abnormality, and generally corresponds to a significant 
coronary stenosis. A defect both at stress and rest images (a fixed defect) indicates an 
area with loss of viable myocardium, for instance myocardial infarction. With SPECT, 
it is possible to obtain cardiac gated acquisitions. Triggered by the electrocardiogram 
(ECG) to obtain differential information about the heart in various parts of its cycle, gat-
ed myocardial SPECT can be used to obtain quantitative information about myocardial 
perfusion, thickness, and contractility of the myocardium during various parts of the 
cardiac cycle. It also allows calculation of left ventricular ejection fraction, stroke vol-
ume, and cardiac output. In addition, distinction between true perfusion abnormalities 
and true artefacts is possible. Regions with true perfusion defects that are non-reversible 
will contract abnormally, while those associated with attenuation artefacts would dem-
onstrate normal motion and thickening.
Clinical application
In clinical practice MPI-SPECT is commonly used for the following indications:
1: diagnosis of suspected CAD in patients with an intermediate risk of CAD
2: risk stratification in patients with suspected and proven CAD
3: risk assessment before non-cardiac surgery
4: detection and quantification of viability/hibernating myocardium
5: assessment of functional significance in patients with proven multivessel CAD
6: assessment of intervention effect
For the diagnosis of CAD the extent and severity of an abnormal study is commonly 
used for the separation of patients into high and low risk for subsequent cardiac events. 
Patients with a low risk scan can be treated with medical therapy and unnecessary 
further testing and medical costs can be avoided.7 On the other hand, patients with 
extensive and severe myocardial ischaemia have worse prognosis and are referred for 
invasive coronary angiography and may benefit from intervention.8, 9
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Computed tomography coronary angiography
The technique
Currently CTA scans are typically performed using a 64-detector row computed tomog-
raphy scanner. After infusion of an iodinated contrast agent, patients are scanned during 
an inspiratory breath hold to counter acquisition problems arising from cardiac motion 
during breathing. To avoid coronary motion artefacts, acquired images are linked to the 
ECG in order to retrospectively select good quality images from a “motion free” phase 
of the cardiac cycle, typically end diastolic. Because of the need for end diastolic images 
of every level of the heart, and because of the limited coverage of the 64-detector row 
CTA scanner in the craniocaudal direction, acquisition of data is performed during 
multiple heartbeats. After acquisition, a dataset of the full heart is reconstructed with 
information obtained during the end diastolic phases of several heartbeats. Before the 
CTA scan patient’s heart rate and blood pressure are generally monitored to determine 
the need for heart rate reduction. In the absence of contraindications patients with heart 
Figure 1. SPECT-MPI of a 59 year old south-Asian male with diabetes, hypertension and hypercholesterolae-
mia referred for screening of silent myocardial ischaemia. There is normal uptake of the tracer in the entire 
myocardium, without reversibility or persistent defect. ECG-gated images showed no wall motion abnormali-




rate’s exceeding 65 beats per minute are typically administered oral or intravenous beta 
blocking medication in order to reduce heart rate and improve image quality.
Several developments have occurred since the introduction of 64- detector row scan-
ners. Dual-source scanners employing two X-ray tubes have been developed to increase 
temporal resolution resulting in improved image quality and less dependency on heart 
rate control.10 A further improvement has been the introduction of prospective ECG gat-
ing which allows for acquisition of images during a small predetermined “motion free” 
part of the cardiac phase, which substantially lowers radiation dose to approximately 
1.1-3.0 mSv.11 Finally, entire cardiac coverage in one heart beat can be obtained by the 
recently introduced 320-slice detector row CTA system.12 This decreases artefacts from 
the merging of data from different heartbeats and decreases radiation dose when used 
in combination with prospective ECG triggering.
CTA allows for non-invasive assessment of the coronary artery tree and is used for the 
detection of coronary artery stenosis. In contrast to invasive coronary angiography 
which only visualises contrast in the lumen, CTA is able to image the vessel wall thereby 
directly detecting coronary atherosclerosis. A differentiation can be made between nor-
mal coronary arteries showing no signs of atherosclerosis, non-significant CAD with 
<50% luminal narrowing and significant CAD with ≥50% luminal narrowing.
Clinical application
Although CTA is still a relatively new cardiovascular imaging modality, its value in 
the assessment of patients presenting with suspected CAD is beginning to emerge. The 
diagnostic accuracy of CTA has been studied extensively. In early single centre studies 
an average weighted sensitivity of 97.5 (95% confidence interval 96-99) and specificity of 
91 (95% confidence interval 87.5-95) have been observed for the detection of significant 
CAD compared to invasive coronary angiography.13 More recently several prospective 
multicentre studies have been published showing similar sensitivities and specificities.3, 4 
Importantly, CTA has an especially high negative predictive value, and as a result the 
technique is increasingly used as a gatekeeper for further diagnostic testing. In addi-
tion, data are emerging that early identification of CAD with CTA may be useful for 
risk stratification. Since the first publications on the prognostic value of CTA in 2007, 
a number of studies have been published providing further insight into the potential 
value of non-invasive anatomic imaging for risk stratification.14, 15 These studies have 
shown that patients with a significant stenosis on CTA have worse outcome as compared 
to patients without significant CAD. An annualised event rate for the occurrence of all 
cause mortality and myocardial infarction ranging between approximately 1% and 5% 
has been observed in patients with significant CAD compared to approximately 0% to 
2% in patients without significant CAD.
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Combined anatomic and functional imaging
The combination of anatomic and functional imaging has the potential to improve 
patient management by providing complementary information for diagnosis of CAD. 
Assessment of the presence of coronary stenosis on CTA and its haemodynamic con-
sequences as assessed by SPECT may improve decision making regarding referral to 
invasive coronary angiography and potentially revascularisation. In addition, it has been 
shown that CTA and SPECT provide complementary prognostic information; thus com-
bined assessment may potentially improve risk stratification.16
Combination of CTA and SPECT data can be acquired using different approaches. 
Besides separate or side-by-side analysis of datasets (Figures 1 and 2), CTA and SPECT 
scan data can be retrospectively fused using image integration software.17 By integration 
of the datasets, perfusion defects may be more accurately allocated to the corresponding 
arteries and lesions. In a study by Gaemperli et al, the accuracy of cardiac image fusion 
was determined.18 An example of this is shown in Figures 3 and 4. The authors concluded 
that in almost one third of patients, fusion of CTA and SPECT provided additional di-
agnostic information compared to side-by-side analysis of SPECT and CTA, especially 
in functionally relevant lesions in distal segments and diagonal branches and in vessels 
with extensive disease or calcifications. In addition to retrospective fusion of datasets, 
Figure 2. CTA in the same patient as Figure 1, shows diffuse coronary atherosclerosis. Panel A shows a 3D 
image of the heart. Panel B: Right coronary artery (RCA), proximal in the RCA - There is a non-calcified 
plaque (black arrow) and the mid RCA shows a mixed plaque (white arrow). Panel C: Left descending artery 
(LAD), with a non-calcified plaque in the left main (black arrow) with significant stenosis. Furthermore, 
there is a long mixed plaque from the proximal LAD till mid LAD (white arrows) with significant stenosis. 
Finally, there is a non-calcified plaque (black arrow) in the mid LAD. Panel D: Left circumflex artery (LCx) 
and the marginal obtusus (MO) branch, showing again the significant stenosis of the LM (black arrow). The 
patient was referred for invasive angiography, confirming the suspicion of significant three-vessel disease and 
significant left main stenosis. The patient underwent uneventful coronary artery bypass grafting.
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CTA and SPECT data can also be integrated by use of dedicated hybrid SPECT/CTA 
scanners.19 Hybrid SPECT-CT imaging first application was for the apparent reduction 
in tracer uptake in the anterior wall of the heart due to breast attenuation or in the 
inferior wall of the heart due to “diaphragmatic” attenuation, which can lead to diag-
nostic challenges. An example of this application is shown in Figures 5 and 6. Since the 
enormous progression of image quality of the coronary arteries from the CT scanners, 
hybrid SPECT- CT imaging can nowadays not only be used for attenuation correction 
but for “real” image fusion of the coronary arteries and myocardial perfusion of the 
left ventricle. It is unclear if the integration of CTA and SPECT using a hybrid SPECT-
CTA scanner provides improved diagnostic imaging compared to retrospective fusion 
of separately obtained SPECT and CTA datasets. The use of a SPECT-CTA scanner may 
Figure 3. (A) Stress and rest perfusion polar maps of SPECT-MPI 
study show mixed basal anterolateral defect and reversible infero-
apical perfusion  defect (arrowheads). (B and D) Fused SPECT/CT 
images reveal total occlusion of ramus descending artery (LAD) 
and subtotal occlusion of first diagonal branch (DA1), which are 
confirmed by conventional coronary angiography (C). Anterolateral 
perfusion defect is caused by lesion of partially calcified small inter-
mediary branch (IM); however, this vessel is not well visualised by 
conventional angiography. 
Figure 4. Perfusion polar maps at stress (dobutamine stress) and rest show reversible anteroseptal perfusion 
defect. (B and C) 64-slice MSCT-angiography revealed myocardial bridging (MB) of mid LAD of 0.2-cm 
length and calcified plaque at origin of first diagonal branch (DA). (D) Fused 3D SPECT/CT images could 
allocate reversible perfusion defect to DA, whereas MB seemed to be haemodynamically insignificant. 
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however be advantageous from a logistic point of view as patients can be scanned during 
a single session in a single room.
Although, the combination of SPECT and CTA using stand alone SPECT and CTA, or 
by use of a hybrid scanner may provide complementary information for diagnosis and 
Figure 5. SPECT-MPI imaging of a 57-year old male with hypertension, hypercholesterolaemia and atypical 
chest pain. Panel A: Short-axis, vertical long-axis and horizontal long-axis view and polar map, without 
attenuation correction. Left rest, right stress images, showing a persistent defect of the inferior wall. Panel B: 
same patient and views with attenuation correction, showing no defect of the inferior wall.
Figure 6. SPECT-MPI imaging of a 66-year old female with obesity, diabetes and chest pain one week before 
presentation. Panel A: Short-axis, vertical long-axis and horizontal long-axis view and polar map, without 
attenuation correction. Left rest, right stress images, showing a partial reversible defect of the inferior wall. 
Panel B: same patient and views with attenuation correction, showing the same reversible defect as Panel A.
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risk stratification, it is questionable if information regarding anatomy and function is 
necessary in all patients referred for diagnostic imaging. In patients with a normal CTA 
(no evidence of coronary atherosclerosis) the likelihood of a perfusion abnormality is 
very low, and the survival rate is very high, suggesting that no further imaging is neces-
sary in this subgroup. Furthermore as both CTA and SPECT are associated with ionising 
radiation and as most centers do not have access to a hybrid scanner, combined imaging 
may result in increased radiation burden and logistical problems. As a result, sequential 
imaging may be a more viable alternative approach. A flow chart advocating such a strat-
egy has been recently published.20 Using CTA as an initial imaging technique to rule out 
the presence of CAD, patients with a normal CTA can be safely discharged and do not 
require further testing. In patients with non-obstructive CAD (<50%) medical therapy 
and aggressive risk factor modification may be indicated. Patients with a significant or 
borderline lesion or patients with an unequivocal CTA may be referred for SPECT imag-
ing to determine the haemodynamic effects on myocardial perfusion and to determine 
if revascularisation is indicated. Finally, patients with severe CAD detected on CTA may 
be directly referred to invasive coronary angiography. Such an approach may result in 
an overall reduction in mean radiation dose as was shown recently by Pazhenkottil et 
al.21 Compared to combined CTA and SPECT imaging in all patients, an individualised 
three tiered approach of CTA followed by stress only SPECT followed by rest SPECT 
only, if the preceding scan was abnormal, resulted in an approximately 40% reduction 
in average radiation dose.
Conclusion
Although, the first results of hybrid imaging using SPECT and CTA seems to provide 
additional clinical value compared to either technique alone or side-by-side analysis, 
more data are necessary to answer the following issues: What is the impact on treatment 
strategy and outcome? What is the radiation exposure to the patient? Is hybrid SPECT-
CTA imaging cost-effective? Can the rapid changes in CTA technology and ultrafast 
MPI-SPECT be integrated in SPECT- CT machines? Although new low-dose CTA ac-
quisition protocols with prospective ECG triggering and stress only SPECT MPI seems 
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Arterial stiffness may potentially be used as a screening tool to identify asymptomatic 
patients with diabetes with abnormal myocardial perfusion. The purpose of this study 
was therefore to determine the association between arterial stiffness, measured in term 
of pulse wave velocity (PWV) and augmentation index (AIx), and abnormal myocardial 
perfusion imaging (MPI) in asymptomatic patients with diabetes. 
Prospectively, 160 asymptomatic patients with diabetes (mean age 51 years, 87 men) 
underwent MPI with adenosine stress. The summed stress score (SSS) was determined 
in each patient according to a 17-segment and five-point score. Abnormal MPI (SSS ≥3) 
was classified as moderate (SSS 3-7) or severe (SSS ≥8) MPI defects. Using applanation 
tonometry, the carotid-femoral PWV and the radial AIx corrected to 75 beats per min-
ute were determined noninvasively. 
MPI was abnormal in 61 patients (38%), with severe MPI defects in 22 patients (14 %). 
Mean PWV increased with deteriorating MPI from 8.4 ± 2.2 m/s in normal MPI to 9.0 ± 
2.2 m/s in moderate MPI defects (p = 0.11) and to 11.1 ± 2.5 m/s in severe MPI defects (p 
<0.01). Likewise, mean AIx increased from 18.4 ± 13.4 % to 19.4 ± 10.7 % (p = 0.66) and 
towards 25.4 ± 9.0 % (p = 0.03). After adjustment for age and other risk factors, PWV 
remained a significant predictor of severe MPI defects (p = 0.01, OR 1.50, 95 % CI: 1.11-
2.00), whereas AIx lost significance (p = 0.20). 
Arterial stiffness measured by PWV is associated with severe MPI defects in asymptom-




It is considered that the global prevalence of diabetes will approximately double in the 
next two decades.1 Diabetes is associated with a marked increase in the incidence of 
cardiovascular morbidity and mortality, mainly attributable to coronary artery disease 
(CAD). Moreover, the presence and progression of CAD in diabetic patients is often 
asymptomatic, leading to more extensive disease at the time of diagnosis.1, 2 Since a de-
layed diagnosis of CAD considerably worsens the prognosis, early recognition of CAD 
could lead to more effectively targeted intervention and reduce morbidity and mortality 
in this population. Myocardial perfusion imaging (MPI) with SPECT is most com-
monly applied to identify patients with CAD, and can accurately identify patients at 
increased cardiovascular risk.1-4 However, based on recent data, a wide ranging routine 
MPI screening strategy of all asymptomatic patients with diabetes would appear to be 
ineffective.5 Accordingly, a selective “prescreening” strategy using an initial test for the 
identification of patients with a higher likelihood of abnormal MPI, followed by referral 
of only these patients to MPI may be preferred. Noninvasive assessment of arterial stiff-
ness could represent a promising tool for this purpose. In several studies, a relationship 
between arterial stiffness and cardiovascular disease has been observed.6-8 Assessment 
of arterial stiffness by means of pulse wave velocity (PWV) or pulse wave analysis (PWA) 
for augmentation index (AIx), may therefore have the potential to serve as a marker of 
abnormal MPI. Although PWV and AIx have been extensively studied in the general 
population,9-13 fewer data are available concerning their relationship with CAD in as-
ymptomatic patients with diabetes. 
The aim of the current study was to prospectively assess the relationship between the 
noninvasive measures of arterial stiffness (PWV and AIx) with the presence and extent 




Prospectively, 160 consecutive asymptomatic patients with diabetes were recruited from 
a routine outpatient clinic. Patients were referred to the cardiology outpatient clinic for 
risk assessment and cardiovascular screening. Anginal symptoms were ruled out us-
ing a self-completed questionnaire for encountered chest pain.14 The American Diabetes 
association (ADA) criteria were used to identify diabetes and for further stratification 
into type 1 or type 2 diabetes.14, 15 Patients were considered as having type 1 diabetes if 
laboratory analysis demonstrated autoantibodies to islet cells, insulin and glutamic acid 
decarboxylase or low levels of plasma c-peptide. Otherwise, patients were considered 
to have type 2 diabetes. Medical history and demographics were obtained. All patients 
underwent physical examination, and blood and urine laboratory testing. MPI was 
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performed as part of clinical work-up to determine presence and extent of myocardial 
perfusion defects. Additional measurements of PWV and AIx were used to assess arte-
rial stiffness. 
Cardiovascular risk factors
Cardiovascular risk factors were defined according to the following criteria: positive 
family history for CAD (presence of CAD in first-degree family members, male <55 
years and/or female <65 years), smoking (current smoking or smoking in the last 2 
years), hypertension (blood pressure >140/90 mmHg or treatment with antihypertensive 
medication), body mass index, hypercholesterolemia (total cholesterol level >5.0 mmol/L 
or use of cholesterol-lowering medication), and microalbuminuria (urine albumin/cre-
atinine ratio ≥3.5 mg/mmol).2 Plasma hemoglobin A1c (HbA1c) was determined as a 
measure of glycemic control.
SPECT myocardial perfusion imaging
SPECT data acquisition
ECG-gated adenosine 99mTc sestamibi (99mTc MIBI) SPECT MPI was performed using 
a 2-day protocol, comprising stress imaging on the first day and a rest scan on the second 
day.2, 16 Antihypertensive treatment with beta-adrenergic blocking agents or calcium an-
tagonists was stopped and patients were instructed to abstain from caffeine-containing 
products 24 h prior to the stress test. Vasodilator stress was induced by intravenous 
infusion of adenosine 140 µg/kg per minute for 6 min, with simultaneous hand-grip ex-
ercise. 99mTc MIBI (500MBq) was injected intravenously after the third minute. Blood 
pressure and a 12-lead ECG were recorded throughout the adenosine infusion. 
Images were acquired 2 h after injection of the radiopharmaceutical using a triple-head 
SPECT gamma camera (GCA 9300/HG; Toshiba, Tokyo, Japan) with low-energy, high-
resolution collimators. Images were acquired using a circular 360˚ orbit, 60 projections 
and 40 s per projection, in compliance with the American Society of Nuclear Cardiology 
(ASNC) imaging guidelines. Images were processed to obtain the short-axis, vertical 
long-axis, and horizontal long-axis sections, as well as polar map formats, normalized 
to maximal myocardial activity.2, 16 Patient motion was reviewed by examining the raw 
cine images. No attenuation or scatter correction was used.
SPECT data analysis
For semiquantitative visual interpretation, the myocardium was divided into 17 seg-
ments according to ASNC guidelines.2, 16 Tracer uptake in each segment was evaluated 
in consensus by two expert observers blinded to patient’s clinical characteristics and test 
results, using a five-point scoring system ranging from 0 (normal uptake) to 4 (absent 
uptake). The summed stress score (SSS) was determined as the sum of the 17 segmental 
scores of the stress images. MPI was considered normal for SSS <3. In case of abnor-
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mal MPI, SSS in the range 3-7 were considered to represent moderate MPI defects, and 
SSS ≥8 to represent severe MPI defects.17 Finally, regional wall motion on gated SPECT 
images was evaluated to allow differentiation between true MPI abnormalities and dia-
phragmatic or breast attenuation artifacts.
Assessment of arterial stiffness
Measurements were derived and analyzed noninvasively by applanation tonometry us-
ing a SphygmoCor system (Atcor Medical, Sydney, Australia). All measurements were 
performed in the morning in a quiet, temperature-controlled clinical research labora-
tory by a specially trained technologist blinded to the patient’s clinical characteristics 
and test results. The patients were instructed to omit their morning medication and con-
tinue fasting until after the test. Assessment of PWV and PWA commenced following 
a 10-min rest in supine position, after a state of constant heart rate and blood pressure 
had been reached.
Pulse wave velocity
The pulse waves were recorded at the common carotid artery and the femoral artery 
by sequential tonometry with simultaneous electrocardiographic gating. Pulse transit 
time was determined as the average of ten consecutive beats. The distance between the 
two sites was measured. Aortic PWV (m/s) was defined as the distance between the two 
recording sites traveled by the pulse wave, divided by the transit time. Using system soft-
ware, aortic PWV was determined semiautomatically. The validation and reproducibility 
of this semiautomatic method have been previously published.17, 18 Measurements were 
performed three times in each patient and averaged to obtain the mean aortic PWV. 
Pulse wave analysis
The peripheral pressure waveforms were recorded from the radial artery at the wrist with 
a hand-held high-fidelity tonometer (Millar Instruments, Houston, USA) and calibrated 
by peripheral blood pressures at the brachial artery.7, 19 The corresponding central aortic 
pressure waveform was generated by a validated generalized transfer function. The cen-
tral aortic pressure waveform was analyzed to identify the first shoulder of the pressure 
wave, representing the incident wave, attributable to left ventricular ejection. The merg-
ing point of the incident and the reflected wave (the inflection point) was then identified 
on the generated aortic pressure waveform. The absolute augmented pressure was the 
maximum systolic pressure minus the pressure at the inflection point. Subsequently, 
the AIx was defined as the absolute augmented pressure divided by the pulse pressure 
and expressed as a percentage.7, 8 Finally, the AIx was normalized to a heart rate of 75 
bpm (AIx@75). In each patient, three consecutive waveform recordings were averaged 




Continuous variables were expressed as means ± standard deviation and categorical 
variables as numbers (percentages). First, associations of PWV and AIx@75 with base-
line clinical risk factors were assessed using Pearson’s correlation coefficient (r) or the 
Spearman’s rank correlation coefficient (rs) in case of dichotomous variables. Second, dif-
ferences in the mean PWV and AIx@75 for each group of MPI results were evaluated with 
the independent T-test. Thereafter, with univariate logistic regression analysis potential 
predictors of severe MPI defects were identified. Subsequently, all potential predictors 
were analyzed in a multivariate logistic regression model to identify the independent 
predictors of severe MPI defects. Additionally, patients were categorized according to 
PWV quartiles and for each quartile the prevalence of severe MPI defects was obtained. 
Subsequently, global chi-square analysis was used to determine the incremental pre-
dictive value of PWV over baseline characteristics. Thereafter, using receiver operating 
characteristic (ROC) curve analysis two cut-off values were chosen for PWV; one for the 
detection of severe MPI defects with optimal sensitivity and specificity and the other 
for the exclusion of severe MPI defects with optimal sensitivity and negative predictive 
value. All statistical analyses were performed using SPSS software (version 16.0, SPSS 





The study population comprised of 160 asymptomatic diabetic patients. Their baseline 
characteristics are provided in Table 1. 
Table 1 Baseline characteristics of the study population of 160 diabetic patients
SPECT myocardial perfusion imaging
The overall mean SSS was 3.1 ± 4.1 (range 0-21). Abnormal MPI (SSS ≥3) was observed 
in 60 patients (38 %), including moderate MPI defects (SSS 3-7) in 38 patients (24 %) and 
severe MPI defects (SSS ≥8) in 22 patients (14 %).
Clinical factors Mean ± SD or number (%)
Age (years) 51 ± 12
Men 87 (54%)
Type 2 diabetes 91 (57%)
Diabetes duration (years) 15 ± 13
Insulin use 125 (78%)
Family history of CAD 75 (47%)
Smoking 42 (26%)
Body mass index (kg/m²) 28 ± 6
HbA1c (%) 8.2 ± 1.7
Hypertension 92 (58%)
Use of antihypertensive medication 76 (48%)
ACE-inhibitor use 43 (27%)
Beta-blocker use 19 (12%)
Systolic blood pressure (mmHg) 133 ± 16
Diastolic blood pressure (mmHg) 80 ± 9
Hypercholesterolemia 107 (67%)
Cholesterol lowering medication 73 (46%)
Total cholesterol (mmol/L) 4.8 ± 1.1
Micro-albuminuria 39 (24%)
Aspirin use 31 (19%)
Abbreviations: ACE: angiotensin converting enzyme; CAD: coronary artery disease; 





The overall mean PWV was 8.9 ± 2.4 m/s. PWV was associated with age ( r= 0.62, p 
<0.01), type 2 diabetes (rs = 0.23, p <0.01), diabetes duration (r = 0.30, p <0.01), body 
mass index (r = 0.22, p <0.01), hypertension (rs = 0.43, p <0.01), and microalbuminuria 
(r = 0.29, p <0.01). As shown in Figure 1a, mean PWV was only slightly lower in patients 
with normal MPI than in patients with moderate MPI defects (8.4 ± 2.2 m/s and 9.0 ± 2.2 
m/s, respectively, p = 0.11). However, the mean PWV was significantly higher in patients 
with severe MPI defects (11.1 ± 2.5 m/s, p <0.01).
Association between pulse wave analysis and myocardial perfusion
The mean AIx was 21.1 ± 12.3 % in the total population. Normalization for a heart rate 
of 75 bpm resulted in an overall mean AIx@75 of 19.6 ± 12.4 %. A significant associa-
tion was observed between AIx@75 and the following risk factors: age (r = 0.47, p <0.01), 
male gender (rs = -0.43, p <0.01), type 2 diabetes (rs = 0.30, p <0.01), hypercholesterolemia 
(rs = 0.17, p <0.03), and microalbuminuria (r = 0.26, p <0.01).
After stratification of mean AIx@75 values according to SPECT MPI results, a trend 
similar to that for PWV was observed. Likewise, mean AIx@75 was slightly higher in 
patients with moderate MPI defects than in those with normal MPI (19.4 ± 10.7 % and 
18.4 ± 13.4 %, respectively, p = 0.66) and was significantly higher in patients with severe 






































































Figure 1. Relationship between parameters of vascular stiffness and the extent of MPI defects as assessed 
by SPECT MPI. A: Mean aortic PWV was higher in patients with abnormal MPI. The highest PWV was 




Predictors of severe myocardial perfusion defects
As illustrated in Table 2, age, gender, smoking, HbA1c, microalbuminuria and both 
PWV and AIx@75 were identified as potential predictors of severe MPI defects in a 
univariate logistic regression model. Of note, after adjustment for age, gender, smoking, 
HbA1c, and microalbuminuria, the PWV remained a significant predictor of severe MPI 
defects (p = 0.01), whereas the AIx@75 was no longer significant. 
As demonstrated in Figure 2, the prevalence of severe MPI defects gradually increased 
with increasing PWV quartile. Importantly, in none of the patients in the lowest PWV 
quartile were severe MPI defects present. Also, only a relatively small proportion of 
patients (5 %) in the second PWV quartile had severe MPI defects. In contrast, the preva-
lence of severe MPI defects was 20 % in the third PWV quartile, and was 30 % in the 
fourth quartile. Moreover, the addition of PWV to a model with baseline clinical risk 
factors age, gender and smoking for the prediction of severe MPI defects showed a sig-
nificantly improved predictive value of PWV (Figure 3).
ROC curve analysis for the detection of severe MPI defects showed the highest sensitiv-
ity and specificity (77 % and 75 %, respectively) with a PWV cut-off value of 9.8 m/s. 
An optimal sensitivity of 91 % with an associated negative predictive value of 98% for 
the exclusion of severe MPI defects was found using a cut-off value of 9.2 m/s for PWV 
(Figure 4). 
Table 2 Predictors of severe MPI defects (SSS ≥8) on SPECT
Abbreviations: AIx@75: Augmentation index normalized for the heart rate of 75 bpm; CAD: coronary artery 
disease; HbA1c: plasma hemoglobin A1c; MPI: myocardial perfusion imaging; PWV: Pulse wave velocity.
Clinical characteristic Exp β (95 % CI) p-value Exp β (95 % CI) p-value
Age (years) 1.09 (1.04-1.14) <0.01 1.06 (0.98-1.14) 0.16
Male gender 3.30 (1.15-9.45) 0.03 6.35 (1.47-27.41) 0.01
Type 2 diabetes 1.47 (0.55-3.90) 0.44
Diabetes duration (years) 1.02 (0.99-1.06) 0.15
Family history of CAD 1.16 (0.47-2.85) 0.75
Smoking 3.80 (1.48-9.77) 0.01 5.74 (1.35-24.46) 0.02
Body mass index (kg/m²) 0.99 (0.91-1.07) 0.77
HbA1c (%) 1.28 (1.00-1.65) 0.05 1.52 (1.03-2.25) 0.03
Hypertension 1.98 (0.73-5.41) 0.18
Hypercholesterolemia 1.65 (0.57-4.79) 0.36
Micro-albuminuria 3.86 (1.52-9.81) 0.01 1.05 (0.26-4.27) 0.95
PWV (m/s) 1.49 (1.22-1.81) <0.01 1.49 (1.11-2.00) 0.01
AIx@75 (%) 1.06 (1.01-1.11) 0.02 1.05 (0.97-1.14) 0.20
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Figure 2 Prevalence of patients with severe MPI 
defects per PWV quartile. The prevalence of severe 
MPI defects increased with increasing PWV. Of note, 
the prevalence of severe MPI defects chiefly increased 
in the third and fourth PWV quartile.
Figure 3 Incremental predictive value of PWV for 
the detection of severe MPI defects as shown by an 
increase in the value of global chi-square. Addition 
of PWV to a model with baseline clinical risk factors 
age, gender, and smoking provided a significantly 
improved predictive value.
Figure 4 Detection of severe MPI defects on SPECT by PWV. A: ROC curve analysis for the detection of severe 
MPI defects yielded an optimal sensitivity and specificity of 77% and 75%, respectively, with a PWV cut-off 
value of 9.8 m/s. B: In contrast, optimization for the exclusion of severe MPI defects resulted in a cut-off value 




In the present study of asymptomatic patients with diabetes, arterial stiffness as assessed 
by PWV and AIx was greater in the presence of severe MPI defects. PWV was indepen-
dently associated with severe MPI defects, whereas AIx was no longer significant after 
correction for other cardiovascular risk factors and PWV. Addition of PWV to a model 
of baseline clinical risk factors showed significant incremental value for the prediction 
of severe MPI defects. Furthermore, ROC curve analysis revealed a moderate to good 
sensitivity of 77 % and a specificity of 75 % for the detection of severe MPI defects, with 
a PWV cut-off value of 9.8 m/s. Conversely, changing the cut-off value to 9.2 m/s resulted 
in a high sensitivity of 91 % and negative predictive value of 98 % for the exclusion of 
severe MPI defects. Accordingly, the current results indicate that noninvasive evaluation 
of arterial stiffness may be a practical tool for prescreening asymptomatic patients with 
diabetes for differentiation into a higher and lower likelihood of abnormal MPI. 
Arterial stiffness and relationship to CAD
In the general population the relationship between arterial stiffness and the presence of 
CAD has been confirmed in a considerable number of studies. Arterial stiffness mea-
sured as PWV or AIx not only is directly associated with the presence and severity 
of CAD on invasive coronary imaging,10 but also has incremental prognostic value for 
predicting cardiovascular events.9, 11-13 A recent meta-analysis (15,877 subjects, 17 stud-
ies, average follow-up of 7.7 years) has shown that the risk of cardiovascular events is 
increased twofold in patients with increased PWV.20 Moreover, the predictive ability 
of PWV was shown to be even higher in patients with elevated baseline cardiovascular 
risk, supporting a role for PWV in high-risk populations, such as patients with diabetes. 
A few studies have specifically evaluated arterial stiffness in patients with diabetes. 
Cruickshank et al. evaluated the prognostic value of PWV for all-cause and cardio-
vascular mortality in 397 patients with diabetes with or without CAD. During a mean 
follow-up of 10.7 years, aortic PWV was an independent predictor for all-cause and car-
diovascular mortality.21 Additionally, Hatsuda et al. found in 595 patients with diabetes 
that PWV was significantly increased in 70 patients with established CAD.22 Finally, 
Fukui et al. investigated 208 consecutive patients with type 2 diabetes and reported that 
AIx was significantly higher in 47 patients with previously confirmed CAD.23 These 
observations indicate that markers of arterial stiffness may indeed be associated with 
CAD in patients with diabetes. 
However, to our knowledge this is the first study in which PWV and AIx have been 
applied in asymptomatic patients with diabetes to prospectively identify the presence 
of CAD, defined by the presence of (severe) MPI defects. Although both PWV and AIx 
were higher in patients with severe MPI defects, only PWV was shown to be an inde-
pendent predictor of severe MPI defects. These observations are in agreement with the 
previous literature, as more discrepant results have also been reported in the general 
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population using AIx as compared to PWV.24, 25
Possibly, the more variable results with AIx may be explained by underlying method-
ological differences. Carotid-femoral PWV is a direct measure of arterial stiffness as 
determined by the intrinsic stress/strain relationship of the arterial wall and mean arte-
rial pressure. Therefore PWV is considered as the ‘gold-standard’. 6-8 In contrast, AIx 
is an indirect measurement, derived from peripherally recorded pressure waveforms. 
Using a generalized transfer function, the corresponding central arterial waveform 
is generated, from which AIx is determined. Therefore, AIx is influenced by multiple 
factors such as PWV, heart rate, diastolic blood pressure, peripheral circulation and en-
dothelial function.7, 8 Furthermore, its discriminatory value may be less in the elderly,24, 
25 and the use of the generalized transfer function may also be inappropriate in certain 
populations. 24-27 In fact, Hope et al. recently evaluated the validity of this method in 
patients with diabetes and found that estimation of central pressures was prone to sub-
stantially greater error in this population.26 Similar differences in accuracy have also 
been reported in relation to gender, indicating that AIx might be a less representative 
marker of arterial stiffness than PWV.24, 25 Conceivably, the weaker association between 
AIx and CAD as compared to PWV may therefore be explained by the fact that our 
study was performed in patients with diabetes while also including a high percentage of 
female patients. 
Clinical implications and perspectives
At present, screening of asymptomatic patients with diabetes for CAD remains contro-
versial. The majority of available data are based on CAD detection using SPECT MPI.3, 4 
In the present study, the prevalence of abnormal MPI was 38%. In contrast, the recent 
DIAD trial demonstrated a much lower rate of abnormal MPI with only few patients 
having severe MPI defects.5, 28 To a large extent, this discrepancy may be explained by 
differences in baseline characteristics of the enrolled patients. Importantly, cardiac event 
rates were low in the DIAD study and not significantly reduced by a MPI-based screen-
ing strategy. Nevertheless, in the small group of patients with abnormal MPI, a step-wise 
increase in event rates was observed with increasing MPI abnormality. Of note, hard 
event rates were 2% in patients with normal scans but were 12% in patients with at 
least moderately abnormal MPI scans. In contrast to the general asymptomatic diabetic 
population, these high-risk patients may benefit from screening, as also suggested by 
the bypass angioplasty revascularization investigation BARI 2 diabetes trial.29, 30 In this 
trial no survival benefit was shown in patients undergoing early coronary revascular-
ization as compared to intensive medical treatment. However, among high risk patients 
selected for coronary artery bypass grafting, prompt revascularization was associated 
with a lower rate of major cardiovascular than medical therapy. Accordingly, these ob-
servations indicate that while routine screening for abnormal MPI may not be effective 
in asymptomatic patients with diabetes, selective screening strategies are warranted to 
identify the small but high-risk subgroup within this population. In this regard, our 
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current study may provide valuable data for the design of such strategies. Assessment of 
arterial stiffness by means of PWV was shown to accurately identify patients with a high 
risk of severe MPI defects. Accordingly, further screening in patients with elevated PWV 
may be recommended. On the other hand, when using a slightly lower cut-off value, 
PWV was also shown to have a high negative predictive value, indicating that PWV can 
accurately rule out severe MPI defects. Therefore, further evaluation in patients with a 
negative PWV study may be safely omitted. 
Due to its low costs and noninvasive nature, PWV may be a practical first-line tool to 
differentiate patients with a higher and lower likelihood of having abnormal MPI. A 
number of limitations must be acknowledged in the current study. Some of the observed 
MPI defects may be attributed to artifact attenuation. However, regional wall motion on 
gated SPECT images was analyzed for optimal differentiation between true MPI defects 
and attenuation artifacts. Evidently, larger prospective studies are needed to demon-
strate the effectiveness of this strategy in terms of costs and outcome. 
Conclusions
Arterial stiffness as noninvasively assessed by PWV is related to severely abnormal myo-
cardial perfusion in asymptomatic patients with diabetes. Accordingly, PWV could be 
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Left ventricular (LV) diastolic dysfunction and increased arterial stiffness are com-
mon in patients with diabetes mellitus (DM). However, the relation between these two 
pathophysiological factors remains unclear. The aim of this study was to investigate the 
relationship between LV diastolic function and arterial stiffness as assessed with ap-
planation tonometry.
In 142 asymptomatic patients with DM (mean age 48 years, 75 (53 %) men, 72 (51 %) 
patients with type 2 DM) LV diastolic function was assessed with echocardiography. 
Arterial stiffness was evaluated measuring the aortic pulse wave velocity (PWV) where-
as wave reflection was assessed measuring central systolic blood pressure (cSBP), central 
pulse pressure (cPP), and augmentation index (AIx) with applanation tonometry. 
Mean E/A ratio, E’ and E/E’ ratio were 1.1 ± 0.3, 8.1 ± 2.3 cm/s and 9.2 ± 3.3, respectively. 
Mean PWV, mean cSBP, median cPP and mean AIx were 7.9 ± 2.4 m/s, 122 ± 17 mmHg, 
40 [35-51] mmHg and 17.9 ± 12.1 %, respectively. PWV was independently associated 
with LV diastolic dysfunction grade (β = 0.76, p = 0.03). In contrast, measures of wave 
reflection, cPP , cSBP and AIx were independently related with E/A ratio, but not with 
the LV diastolic dysfunction grade.
Parameters of arterial stiffness and wave reflection are associated with echocardiograph-
ic indices of LV diastolic function in asymptomatic patients with DM. Therapies that 
prevent progression of arterial stiffness and reduce late-systolic pressure overload may 




Patients with diabetes mellitus (DM) have a two- to fourfold higher risk of cardiovascular 
events than nondiabetic patients.1 Endothelial dysfunction, micro- and macrovascular 
remodeling, increased deposition of collagen and advanced glycation end products are 
well known pathophysiologic mechanisms that lead to accelerated arterial and myo-
cardial stiffness in diabetic patients.2 Left ventricular (LV) diastolic dysfunction is one 
of the first consequences of increased myocardial stiffness, contributes to 50 % of the 
incidence of heart failure with preserved LV ejection fraction and is associated with poor 
outcome.3-5 In addition, increased arterial stiffness has been associated with LV diastolic 
dysfunction and is an independent predictor of cardiovascular events.6, 7 Therefore, early 
detection of LV diastolic dysfunction and increased arterial stiffness in patients with 
DM may help to identify the patients at increased risk for cardiovascular events and al-
low for early initiation of preventive therapeutic strategies.
So far, evaluation of the relation between LV diastolic function and arterial stiffness in 
patients with DM has provided conflicting results.8-10 Whereas LV diastolic function 
is consistently assessed by standardized parameters obtained with echocardiography 
according to current recommendations of the American Society of Echocardiography 
(ASE) and European Association of Echocardiography (EAE),11 there is no uniformity 
in the noninvasive assessment of arterial stiffness. Based upon the methodology used to 
evaluate arterial stiffness, the results of previous studies investigating the relation be-
tween LV diastolic function and arterial stiffness may significantly vary.8-10 Applanation 
tonometry may be the preferred technique since it provides the aortic pulse wave velocity 
(PWV), considered the gold standard measure of arterial stiffness and is an established 
end-point of target-organ damage in patients with hypertension.12-14 Thus, the aim of the 
current study was to investigate the relation between LV diastolic function measured 
with echocardiography and tissue Doppler imaging and arterial stiffness assessed with 
applanation tonometry in asymptomatic patients with DM. 
Methods
Patient population
The patient population was derived from an ongoing registry including asymptomatic 
patients with DM. DM was diagnosed and classified according the American Diabetes 
Association criteria.15 Patients with demonstrable auto-antibodies to islet cells, insulin 
and glutamic acid decarboxylase or low levels of plasma c-peptide in laboratory analy-
sis were considered as having type 1 DM. Otherwise, patients were considered to have 
type 2 DM. Comprehensive evaluation of asymptomatic DM patients was routinely per-
formed at the outpatient clinic of the Leiden University Medical Center.16 This evaluation 
included a cardiovascular risk assessment performed at the cardiology outpatient clinic 
consisting of structured clinical history, physical examination and blood and urine 
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laboratory testing. LV function and dimensions and valvular function were assessed 
with transthoracic echocardiography. Noninvasive assessment of arterial stiffness was 
performed with applanation tonometry. Clinical and echocardiographic data were pro-
spectively collected in the departmental cardiology information system (EPD-Vision®) 
and echocardiographic database and were retrospectively analyzed. 
Asymptomatic status was confirmed with a self-completed questionnaire on chest pain.17 
Patients with significant coronary artery disease, impaired systolic function defined as 
LV ejection fraction (LVEF) <50 % and moderate and severe valvular heart dysfunction 
were excluded.
The independent associations between parameters of LV diastolic function and indices 
of arterial stiffness by applanation tonometry were assessed.
Cardiovascular risk factors evaluation
Overweight defined by a body mass index (BMI) ≥25 kg/m2, family history of coronary 
artery disease (in first degree family members; male <55 years and/or female <65 years), 
smoking status (current smoking or smoking in the last 2 years), hypertension (blood 
pressure >140/90 mmHg or use of antihypertensive medication) and hypercholesterol-
emia (total cholesterol level >5.0 mmol/L or use of cholesterol lowering medication) were 
recorded as cardiovascular risk factors. In addition, diabetes related risk factors were 
defined by DM duration in years, levels of hemoglobin A1c, renal dysfunction based on 
glomerular filtration rate and presence of microalbuminuria (urine albumin/creatinine 
ratio ≥3.5 mg/mmol).
Echocardiography
Two-dimensional transthoracic echocardiography was performed in all patients using 
a commercially available system (Vivid 7 and E9, General-Electric Vingmed, Horton, 
Norway). ECG-gated images were obtained at rest in the left lateral decubitus position 
using 3.5-MHz and M5S transducers in the parasternal, apical and subcostal views. 
Standard M-mode and two-dimensional, color, continuous and pulsed wave Doppler 
images were acquired during breath hold and saved in cine-loop format. The obtained 
images were analyzed offline, using dedicated software (EchoPac version 110.0.0 
General-Electric Vingmed).
LV end-systolic volume (LVESV), end-diastolic volume (LVEDV) and LVEF were as-
sessed using the biplane Simpson method in the apical 4- and 2-chamber views.18 LV 
systolic dysfunction was defined as LVEF <50 %. In addition, left atrial (LA) volume 
was determined with the biplane Simpson method in the apical 4- and 2-chamber views 
according to the ASE and the EAE guidelines.18 The LA volume index was calculated by 
dividing the LA volume by the body surface area. Enlarged left atrium was defined by a 
LA volume index ≥34 mL/m2.11
LV diastolic function assessment included the measurement of peak velocities of the 
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early (E) and late (A) mitral inflow and the deceleration time (DT) of the E-wave at the 
apical 4-chamber view, using the pulsed wave Doppler. The E/A ratio was calculated. 
Isovolumic relaxation time was measured from pulsed wave Doppler spectral recordings 
obtained in the apical 5-chamber view placing the sample volume between the aortic 
valve and the anterior mitral leaflet. Furthermore, systolic and diastolic pulmonary vein 
velocities (PVs and PVd) were measured from pulsed wave Doppler recordings at the 
right superior pulmonary vein in the apical 4-chamber view. Thereafter, the pulmonary 
vein PVs/PVd ratio was calculated. Additionally, high frame rate tissue Doppler imag-
ing data were obtained in the apical 4-chamber view and the early peak mitral annular 
velocity (E’) at the lateral and septal mitral annulus were measured offline. The mean 
E’ value was obtained by averaging these measurements. Subsequently, the E/E’ ratio 
was calculated.11 Finally, patients were classified in grades of LV diastolic dysfunction, 
according criteria derived from the ASE guidelines.11 Patients with E’ ≥9 cm/s and LA 
volume ≤34 mL/m2 were defined as having a normal diastolic function. In the remain-
ing patients, mild diastolic dysfunction (grade I) was defined as E/A ratio <0.8, DT >200 
ms and E/E’ ratio ≤8; moderate diastolic dysfunction (grade II) as E/A ratio 0.8-1.5, DT 
between 160-200 ms and E/E’ ratio between 9 and 12 and severe diastolic dysfunction 
(grade III) as E/A ratio ≥2, DT <160 ms and E/E’ ratio ≥13.11
Applanation tonometry
All patients underwent noninvasive evaluation of arterial stiffness with applanation to-
nometry using a SphygmoCor system (SphygmoCor, Atcor Medical, Sydney, Australia) 
with a hand-held high fidelity tonometer (Millar Instruments, Houston, TX, USA). 
Measurements were performed by a specially trained technologist, blinded to patient’s 
clinical characteristics and echocardiographic results, under standardized conditions 
(during the morning in a quiet, temperature-controlled clinical research laboratory). 
Patients were instructed to abstain from their morning medication and remain fasting 
until the end of the test. Measurements were performed after 10-minute rest in supine 
position, when a state of constant heart rate and blood pressure was reached. 
Pulse wave velocity
Aortic pulse wave velocity (PWV) was determined with arterial tonometry of the carotid 
and femoral arteries with simultaneous ECG-gating.6, 19 The aortic PWV was defined 
as the distance traveled by the pulse wave, between recording sites on the carotid and 
femoral artery, divided by transit time (averaged from 10 consecutive beats) and was 
determined semi-automatically as previously described.6, 19 To correct for measurement 
variability, three consecutive beats were measured and the average was calculated. The 





Central systolic blood pressure (cSBP), central pulse pressure (cPP) and augmenta-
tion index (AIx), measures of wave reflection, were derived from pulse wave analysis. 
Peripheral pressure wave forms were recorded on the radial artery at the level of the 
wrist and calibrated by peripheral blood pressures measured at the brachial artery with a 
cuff-sphygmomanometer. Central aortic pressure waveforms were generated from these 
recorded pressure waveforms with a validated generalized transfer function and used to 
calculate cSBP, cPP and AIx (Figure 1).12, 19
cSBP was defined as the peak pressure of the aortic pressure waveform (Figure 1). cPP 
was calculated as the difference between central systolic and diastolic pressure (Figure 
1). The aortic pressure waveform is formed by the forward pressure wave of ventricular 
contraction and a backward pressure wave from reflection on the peripheral arterial 
system.12 With increasing arterial stiffness, the reflected wave shifts from diastole to 
systole and increases systolic blood pressure, which is identified on the central aortic 
pressure waveform by the merging point of the initial forward wave and the reflected 
wave (Figure 1). The AIx was defined and calculated as the percentage that the reflected 
wave contributes to the pulse pressure (maximum systolic pressure minus pressure at the 
merging point). Thereafter, AIx was normalized to a heart rate of 75 beats/min.12, 21 AIx 
was measured on 3 consecutive recordings and the average was calculated. Reference 
values were derived from a substudy of the Anglo-Cardiff Collaborative Trial (ACCT) 
on vascular aging, including 559 healthy subjects (258 men and 301 women) in the age 
category of 40 and 49 years.22 In this study, the observed mean cSBP, CPP and AIx in 
men were 113 ± 9 mmHg, 34 ± 6 mmHg and 19 ± 10 % and in women 109 ± 11 mmHg, 


























































Figure 1 Central aortic pressure waveform of an individual with normal arterial stiffness (a) and an indi-
vidual with increased arterial stiffness (b). Central systolic blood pressure was defined as the peak pressure of 
the central aortic pressure waveform. Central pulse pressure (cPP) was calculated as the pressure difference of 
the aortic pressure waveform. The augmentation index is calculated as the percentage pressure augmentation 
from the reflected wave (ΔP) to the cPP.
*: merging point of incident wave and reflected wave, ΔP: pressure augmentation from the reflected wave, A: 




Normal distributed continuous variables were expressed as mean ± standard deviation, 
non-normal distributed variables as median (25th and 75th percentiles), and categorical 
variables as numbers (percentages). The Pearson’s and Spearman’s correlation coeffi-
cients were used to assess univariate associations between the indices of arterial stiffness 
and wave reflection and baseline clinical variables and echocardiographic parameters of 
LV diastolic function. 
Multivariate linear regression analyses were performed to assess independent rela-
tions between the indices of arterial stiffness and wave reflection and parameters of LV 
diastolic function. These associations were assessed for each LV diastolic function echo-
cardiographic parameter and corrected for age, gender, type and duration of DM, heart 
rate and BMI. All statistical analyses were performed using SPSS software (version 16.0, 




A total of 142 asymptomatic patients with DM were evaluated. The baseline clinical 
variables are presented in Table 1. The mean age was 48 ± 11 years and 75 (53 %) were 
men. Fifty-one percent of patients had DM type 2. The mean DM duration was 15 ± 12 
years and mean BMI was 28 ± 6 kg/m2. Sixty-eight (48 %) patients had hypertension. 
Echocardiography
The mean LVEF and LA volume index were normal, 65 ± 9 % and 16 ± 4 mL/m2, respec-
tively (Table 2). The mean E/A ratio, E’ and E/E’ ratio were 1.1 ± 0.3, 8.1 ± 2.3 cm/s and 
9.2 ± 3.3, respectively. In 15 patients an increased left ventricular filling pressure was 
identified by E/E’ ratio ≥13. Normal LV diastolic filling pattern, mild (grade I) and mod-
erate (grade II) diastolic dysfunction were observed in 72 (51 %), 54 (38 %) and 16 (11 %) 
patients, respectively. Grade III diastolic dysfunction was not recorded in any patient. 
Clinical variables n=142
Age (years) 48 ± 11
Male gender, n (%) 75 (53%)
DM type 2, n (%) 72 (51%)
DM duration (years) 15 ± 12
Hemoglobin A1c (%) 7.9 ± 1.5
BMI (kg/m2) 28 ± 6
Family history of CAD, n (%) 52 (37%)
Smoking, n (%) 35 (25%)
Diastolic blood pressure (mmHg) 80 ± 9
Systolic blood pressure (mmHg) 131 ± 16
Heart rate (beats/min) 70 ± 10
Hypertension, n (%) 68 (48%)
Hypercholesterolemia, n (%) 102 (72%)
Glomerular filtration ratio (mL/min/1.73m2) 92 ± 21
Microalbuminuria ≥3.5 mg/mmol, n (%) 21 (15%)
Table 1 Baseline clinical variables




Arterial stiffness assessed with applanation tonometry
The mean PWV was 7.9 ± 2.4 m/s, similar as the reference value established in a healthy 
study population (Table 2).20 The mean cSBP and median cPP were both slightly in-
creased (122 ± 17 mmHg and 40 [35-51] mmHg, respectively). However, the mean AIx 
was within the normal range (17.9 ± 12.1 %).22
Variable n=142
Echocardiographic parameters
LVEDV (mL) 114 ± 29
LVESV (mL) 41 ± 16
LVEF (%) 65 ± 9
LA volume index (mL/m2) 16 ± 4
E (cm/s) 70 ± 16
A (cm/s) 65 ± 18
E/A ratio 1.1 ± 0.3
DT (ms) 226 ± 68
Isovolumic relaxation time (ms) 84 ± 12
E’ (cm/s) 8.1 ± 2.3
E/E’ ratio 9.2 ± 3.3
PVs (cm/s) 50 ± 11
PVd (cm/s) 42 ± 10
PVs/PVd ratio 1.2 ± 0.3
Indices of arterial stiffness
PWV (m/s) 7.9 ± 2.4
cSBP (mmHg) 122 ± 17
cPP (mmHg)* 40 [35, 51]
AIx (%) 17.9 ± 12.1
Table 2 Echocardiographic parameters of left ventricular function and indices of arterial 
stiffness measured with applanation tonometry
Abbreviations: A: peak transmitral late diastolic inflow velocity, AIx: augmentation 
index, cPP: central pulse pressure, cSBP: central systolic blood pressure, DT: decelera-
tion time of the E-wave velocity, E: peak transmitral early diastolic inflow velocity, E’: 
peak early mitral annular velocity averaged from measurement in septal and lateral 
mitral annulus, LA volume index: left atrial volume index, LVEDV: left ventricular 
end-diastolic volume, LVEF: left ventricular ejection fraction, LVESV: left ventricular 
end-systolic volume, PVd: diastolic pulmonary vein velocity, PVs: systolic pulmonary 
vein velocity, PWV: pulse wave velocity.
*expressed as median (25th and 75th percentiles).
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Clinical and echocardiographic correlates of arterial stiffness 
Table 3 presents the univariate correlation coefficients between indices of arterial stiff-
ness and wave reflection and baseline clinical variables as well as echocardiographic 
parameters of LV diastolic function. Age was significantly correlated with all indices of 
arterial stiffness and wave reflection, whereas male gender was only significantly related 
with AIx. Hypertension and systolic blood pressure were significantly related with all 
indices of arterial stiffness and wave reflection. In contrast, other well-known cardio-
vascular risk factors or specific diabetes-related variables were not consistently related 
with indices of arterial stiffness or wave reflection. Importantly, echocardiographic pa-
rameters of LV diastolic function were significantly associated with all indices of arterial 
stiffness and wave reflection. Similarly, LV diastolic dysfunction grade was significantly 
associated with all indices of arterial stiffness and wave reflection.
Independent associations between LV diastolic function and arterial stiffness
Independent significant associations between echocardiographic parameters of LV dia-
stolic function and arterial indices were identified with multivariate linear regression 
 PWV cSBP cPP AIx
Age (years) 0.34** 0.36** 0.45** 0.43**
Male gender -0.05 -0.07 -0.07 -0.47**
DM type 2 0.11 0.23** 0.11 0.24**
DM duration (years) 0.24** 0.07 0.15 0.07
BMI (kg/m2) 0.17* 0.19* 0.07 0.22**
Heart rate (beats/min) 0.17* 0.03* -0.15 0.24**
Systolic blood pressure (mmHg) 0.22** 0.47** 0.31** 0.26**
Hypertension 0.39** 0.39** 0.31** 0.29**
Hypercholesterolemia 0.15 0.12 0.17* 0.22**
Microalbuminuria 0.25** 0.23** 0.13 0.14
E/A ratio -0.35** -0.44** -0.39** -0.52**
E’ (cm/s) 0.32** -0.40** -0.38** -0.44**
E/E’ ratio 0.26** 0.30** 0.29** 0.31**
LV diastolic dysfunction 0.38** 0.37** 0.32** 0.29**
Abbreviations: A: peak transmitral late diastolic inflow velocity, AIx: augmentation index, BMI: body mass 
index, cPP: central pulse pressure, cSBP: central systolic blood pressure, DM: diabetes mellitus, E: peak trans-
mitral early diastolic inflow velocity, E’: peak early mitral annular velocity averaged from measurement in 
septal and lateral mitral annulus, PWV: pulse wave velocity.
* p-value <0.05, ** p-value <0.01
Table 3 Correlation coefficients between indices of arterial stiffness and baseline clinical variables as well as 
parameters of LV diastolic function
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analysis (Table 4). The multivariate linear regression models were corrected for age, gen-
der, DM type 2, DM duration, body mass index and heart rate. PWV was independently 
associated with LV diastolic dysfunction grade and tended to be significantly correlated 
with E/A ratio. In contrast, cPP was significantly correlated with E/A ratio but not with 
LV diastolic dysfunction grade. Furthermore, cSBP and AIx were associated with E/A 
ratio and E’.
Discussion
The present evaluation demonstrated the independent associations between arterial 
stiffness and wave reflection parameters and LV diastolic function indices in asymp-
tomatic patients with DM. PWV, a parameter of arterial stiffness, was independently 
associated with LV diastolic dysfunction grade, whereas cPP, cSBP and AIx, parameters 
of wave reflection, were significantly associated with E/A ratio. cSBP and AIx were also 
independently correlated with E’. 
 Dependent variable  Independent variable β 95% CI p-value
PWV
   E/A ratio -1.36 -2.86 to 0.14 0.07
   E’ -0.13 -0.36 to 0.09 0.25
   E/E’ ratio 0.04 -0.10 to 0.18 0.56
   LV diastolic dysfunction 0.76 0.05 to 1.46 0.03
cSBP
   E/A ratio -18.30 -28.91 to -7.68 0.001
   E’ -2.10 -3.74 to -0.47 0.01
   E/E’ ratio 0.86 -0.14 to 1.85 0.09
   LV diastolic dysfunction 4.05 -0.99 to 9.08 0.11
cPP
   E/A ratio -9.93 -17.78 to -2.07 0.01
   E’ -1.08 -2.28 to 0.12 0.08
   E/E’ ratio 0.56 -0.16 to 1.29 0.13
   LV diastolic dysfunction 2.40 -1.27 to 6.07 0.20
AIx
   E/A ratio -10.38 -16.62 to -4.15 0.001
   E’ -1.05 -2.01 to -0.08 0.03
   E/E’ ratio 0.04 -0.54 to 0.63 0.88
   LV diastolic dysfunction -0.79 -3.75 to 2.19 0.60
Table 4 Associations between echocardiographic parameters of LV diastolic function and indices of arterial 
stiffness.
Multivariate linear regression analysis with adjustment for age, gender, diabetes mellitus (DM) type 2, DM 
duration, body mass index and heart rate.
Abbreviations: A: peak transmitral late diastolic inflow velocity, AIx: augmentation index, cPP: central pulse 
pressure, cSBP: central systolic blood pressure, E: peak transmitral early diastolic inflow velocity, E’: peak 




LV diastolic dysfunction and arterial stiffness in asymptomatic DM patients
In patients with DM, endothelial dysfunction, increased extracellular deposition of 
collagen and advanced glycation end products, and activation of the renin-angiotensin-
aldosterone system and cytokines lead to increased arterial and myocardial stiffness.2 
Increased arterial stiffness has been reported in asymptomatic DM patients with LV 
diastolic dysfunction and preserved LVEF.10, 23 In addition, arterial stiffness and LV di-
astolic dysfunction are considered important pathophysiologic determinants of overt 
heart failure development and coronary heart disease events in patients with DM.24, 25 
In a population-based study including 1,760 DM patients, the presence of LV diastolic 
dysfunction and increased LV filling pressures (increased E/E’ ratio) was independently 
associated with the subsequent development of heart failure.24 In addition, data from 
The Cardiff Diabetes Database, including 2,911 patients with type 2 DM showed that 
peripheral pulse pressure was the best predictor of coronary heart disease events.25 This 
evidence suggests that parameters of LV diastolic function and arterial stiffness can be 
used as markers of cardiovascular disease for the identification of patients with DM 
at increased risk of cardiovascular events. Progressive arterial stiffening causes an ac-
celerated systolic return of the arterial wave reflection from the peripheral arterial tree, 
leading to increased systolic blood pressure and reduced coronary perfusion.26 These 
changes result in an increased systolic workload and mismatch in the myocardial sup-
ply/oxygen demand ratio, which cause LV diastolic dysfunction and at a later stage 
systolic dysfunction. However, the association between arterial stiffness and LV diastolic 
dysfunction in DM patients remains debated. 
In 49 patients with new onset type 2 DM, Loimaala et al. measured arterial stiffness with 
whole body impedance cardiography and LV diastolic function with conventional echo-
cardiography and tissue Doppler imaging.27 PWV was only independently associated 
with E’. Furthermore, in 42 patients with DM, Eren and coworkers demonstrated signifi-
cant correlations between aortic distensibility measured with M-mode echocardiography 
and E/A ratio, isovolumic relaxation time and DT.28 Using magnetic resonance imaging, 
van der Meer et al. demonstrated a significant correlation between aortic distensibility 
and LV diastolic function in asymptomatic patients with type 2 DM.23 The use of dif-
ferent techniques to evaluate arterial stiffness may have led to inconsistent correlations 
with several parameters of LV diastolic function.
 Assessment of arterial stiffness with applanation tonometry and correlates of 
LV diastolic dysfunction
Applanation tonometry is a validated and reproducible method for the noninvasive 
assessment of arterial stiffness.19, 29 The friendly use and low costs are some of the advan-
tages of this method. PWV measured at the carotid and femoral arteries is considered 
the gold standard measure of arterial stiffness.12
Recently, Sharman et al. evaluated wave reflection parameters (AIx and cPP) with ap-
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planation tonometry in 172 patients with type 2 DM.10 cPP was independently associated 
with E/E’ ratio and A as assessed with echocardiography. However, PWV was not evalu-
ated. As previously described, wave reflection parameters (such as cPP and AIx) and 
arterial stiffness parameters (such as PWV) may reflect different aspects of arterial prop-
erties and, therefore, may correlate differently with LV diastolic function parameters. 
Indeed, wave reflection parameters have demonstrated to be less affected by the aging 
process as compared to parameters of arterial stiffness.30 In addition, previous studies 
have reported stronger associations between PWV and LV diastolic function as com-
pared to parameters of wave reflection.31, 32 The present evaluation confirms previous 
results by demonstrating independent associations between LV diastolic dysfunction 
and PWV and between E/A ratio and several indices of wave reflection. The indices 
derived by pulse wave analysis, cSBP, cPP and AIx, depend on the reflected wave and 
are also determined by LVEF. 12 This dependency of wave reflection parameters on LV 
function might explain their independent association with E/A ratio.
Limitations
Some limitations need to be mentioned. The cross-sectional design precluded the detec-
tion of a cause-effect relation between LV diastolic dysfunction and arterial stiffness. To 
confirm the causal link between these two entities, longitudinal studies are needed. The 
prevalence of LV diastolic dysfunction was relatively low in the present patient popula-
tion including only asymptomatic DM patients. The present results may not apply to 
cohorts of patients with more advanced disease.
Conclusions
Indices of arterial stiffness and wave reflection are independently associated with echo-
cardiographic parameters of LV diastolic function in asymptomatic patients with DM. 
PWV, parameter of arterial stiffness, was independently associated with LV diastolic 
dysfunction grade, whereas cPP, cSBP and AIx, parameters of wave reflection, were 
significantly associated with E/A ratio. Therapies that prevent progression of arterial 
stiffness and reduce late-systolic pressure overload may reduce the prevalence of LV 
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Changes in multidirectional LV strain in  
asymptomatic patients with type 2 diabetes mellitus: 
a 2-year follow-up study
Cornelis J. Roos, Arthur J. Scholte, Aantje V. Kharagjitsingh, Jeroen J. Bax, 
Victoria Delgado. 





Asymptomatic patients with diabetes mellitus (DM) and normal left ventricular (LV) 
ejection fraction (EF) may have LV dysfunction as assessed with speckle tracking 
echocardiography. Whether this subtle LV dysfunction may progress or not over time 
remains unknown. The present evaluation assessed changes in LV function with two-
dimensional (2D) speckle tracking analysis in asymptomatic clinically stable patients 
with type 2 DM and normal LVEF after 2-year follow-up. 
A total of 112 asymptomatic patients with type 2 DM and normal LVEF (53 ± 10 years, 
59 % men) were evaluated. Patients remained clinically stable between baseline and 
follow-up echocardiography. Conventional and 2D speckle tracking echocardiographic 
measurements were performed. Circumferential (CS) and longitudinal strain (LS) were 
measured to assess systolic function and strain rate during isovolumic relaxation time 
(SR IVR) and peak transmitral early diastolic inflow strain rate (SR E) to asses diastolic 
function. 
After 2-year follow-up, a significant increase in the LV mass index and significant 
decrease in the E/A ratio were observed. Left ventricular ejection fraction remained un-
changed (59 % to 60 %, p = 0.4). In contrast, 2D speckle tracking analysis demonstrated 
a significant impairment in CS (-19.7 ± 4.0 % to -18.9 ± 3.8 %, p <0.001), LS (-17.2 ± 2.3 
% to -16.9 ± 2.7 %, p = 0.022) and SR E (1.02 ± 0.28 S-1 to 0.94 ± 0.25 S-1, p <0.001). After 
adjusting for changes in LV mass index, only changes in CS and SR E remained signifi-
cant (p <0.001 and p = 0.013, respectively).
Asymptomatic patients with type 2 DM and normal LVEF may show mild progression 
of subclinical LV dysfunction assessed with 2D speckle tracking echocardiography. The 




Diabetes mellitus (DM) is an independent risk factor for the development of heart failure 
(HF).1, 2 In addition, HF patients with DM have more severe disease and worse prognosis 
than patients without DM.3 The increased prevalence of coronary artery disease (CAD) 
and hypertension in patients with DM contribute to the increased incidence of HF.4, 5 
Furthermore, diabetic cardiomyopathy has been proposed as a primary myocardial dis-
ease in DM patients without significant epicardial CAD, hypertension or valvular heart 
disease. This entity is characterized by microvascular disease, altered myocardial metab-
olism and increased myocardial fibrosis, that lead to gradual decline in left ventricular 
(LV) function with impairment in LV relaxation first, and then, followed by systolic dys-
function may progress over time to congestive HF.6, 7 Therefore, before presenting with 
overt HF symptoms, diabetic patients may have long-standing subclinical myocardial 
dysfunction. Interestingly, whether progression of subclinical LV dysfunction towards 
overt HF symptoms occurs in DM patients is unknown. At present, there is a lack of 
longitudinal evaluations concerning the presence and development of structural and 
functional myocardial abnormalities in patients with DM.
Two-dimensional (2D) speckle tracking echocardiography has demonstrated that type 
2 DM patients without cardiovascular complications and with preserved LV ejection 
fraction (EF) may exhibit LV systolic and diastolic dysfunction.8 Further progression in 
LV dysfunction in asymptomatic clinically stable patients with type 2 DM has not been 
evaluated with this imaging technique. Therefore, the aim was to assess changes in LV 
function with 2D speckle tracking echocardiography in asymptomatic clinically stable 
patients with type 2 DM and normal LVEF.
Methods
Patient population
The population consisted of 112 asymptomatic patients with type 2 DM and complete 
clinical and echocardiographic follow-up at 2 years. This subgroup of patients was select-
ed from an original cohort of patients previously described.9 In brief, the original cohort 
included type 2 DM patients who were referred for cardiovascular risk assessment as 
part of regular patient care. All patients underwent a structured interview, physical ex-
amination, blood and urine laboratory testing and 2D transthoracic echocardiography. 
Type 2 DM was diagnosed according to the American Diabetes Association criteria in 
the absence of demonstrable auto-antibodies to islet cells, insulin and glutamic acid 
decarboxylase or low plasma C-peptide levels.10 All patients were free of cardiovascular 
complaints as confirmed with the Rose questionnaire on chest pain.11 Exclusion criteria 
were: angina or angina-equivalent symptoms, known CAD (defined as previous acute 
coronary syndrome, percutaneous or surgical coronary revascularization or angio-
graphically documented coronary stenosis of ≥50 % luminal diameter), cardiomyopathy, 
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significant valvular heart disease, congenital heart disease, and heart rhythm other than 
sinus rhythm or conduction abnormalities. 
In the present evaluation, consecutive patients with repeat echocardiography at 2-year 
follow-up, who remained clinically stable during the follow-up, were included. Patients 
who presented with major adverse cardiovascular events (acute coronary syndrome, 
myocardial infarction or coronary revascularization and cardiac surgery) during the 
follow-up were excluded. From the original 234 asymptomatic patients with type 2 
diabetes mellitus, 121 patients had repeat echocardiogram at 2-year follow-up. Nine pa-
tients were excluded: 8 patients because of cardiovascular events and one because of 
inadequate image quality to ensure reliable speckle tracking analysis. 
Clinical, demographic, and echocardiographic data were prospectively collected in the 
departmental electronic patient dossier information system (EPD-vision®; Leiden, The 
Netherlands) and retrospectively analyzed.
Echocardiography
Patients underwent 2D transthoracic echocardiography at baseline and at 2-year follow-
up using a commercially available system (Vivid 7 and E9, General-Electric Vingmed, 
Horton, Norway) equipped with 3.5-MHz and M5S transducers. ECG-gated images 
were obtained in the parasternal, apical and subcostal views with the patient lying in 
the left lateral decubitus position. Standard M-mode, 2D, color, pulsed and continuous 
wave Doppler images were recorded during breath hold and saved in cine-loop format. 
Analyses of the images were performed offline with dedicated software (EchoPac version 
112.0.1 General-Electric Vingmed).
Left ventricular end-diastolic volume (LVEDV) and LV end-systolic volume (LVESV) 
were measured from the apical four- and two-chamber views and calculated using the 
Simpson’s biplane method.12 Thereafter, LVEF was calculated as [(LVEDV-LVESV)/
LVEDV] x 100. LV mass was measured at end-diastole on M-mode recordings obtained 
in the parasternal long-axis view and calculated with the Devereux formula.13 The in-
tra- and interobserver reproducibility for the measurement of LV mass, assessed in 20 
randomly selected patients, was 1.4 ± 13.2 g/m2 and -1.2 ± 8.4 g/m2, respectively. In addi-
tion, left atrial (LA) volume was calculated according to the ellipsoid method from three 
LA diameters measured in the apical four-chamber and parasternal long-axis views.12 
LV and LA dimensions were normalized for body surface area (BSA).
Parameters of LV diastolic function were determined from transmitral inflow veloci-
ties using pulsed wave Doppler recordings in the apical four-chamber view.14 Early (E) 
and late (A) peak mitral inflow velocity of LV filling and deceleration time (DT) of the 
E-wave were measured and the E/A ratio was calculated. Isovolumic relaxation time 
(IVRT) was measured from pulsed wave Doppler spectral recordings obtained in the 
apical five-chamber view. Systolic and diastolic pulmonary vein flow velocities (PVs and 
PVd) were measured from pulsed wave Doppler recordings at the right superior pulmo-
nary vein in the apical four-chamber view and the pulmonary vein PVs/PVd ratio was 
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calculated. Furthermore, peak mitral annular velocity (E’) was measured using tissue 
Doppler imaging in the apical four-chamber view. E’ was measured at the septal and 
lateral mitral annulus and the mean E’ was calculated. Subsequently, the E/E’ ratio was 
derived.15
The diastolic dysfunction grade was determined according to the criteria proposed by 
the European Association of Echocardiography:14 1. normal diastolic function when E’ 
≥9 cm/s and LA volume ≤34 mL/m2, 2. mild diastolic dysfunction (grade I) when E/A 
ratio <0.8, DT >200 ms and E/E’ ratio ≤8, 3. moderate diastolic dysfunction (grade II) 
when E/A ratio 0.8-1.5, DT between 160-200 ms and E/E’ ratio between 9 and 12 and 4. 
severe diastolic dysfunction (grade III) when E/A ratio ≥2, DT <160 ms and E/E’ ratio 
≥13.14 
2D Speckle tracking echocardiography
LV function was further assessed with 2D speckle tracking echocardiography us-
ing semi-automated software (EchoPac version 112.0.1 General-Electric Vingmed). 
2D speckle tracking allows for angle-independent quantification of myocardial tissue 
deformation (strain) and the rate of deformation (strain rate) by analyzing frame to 
frame the movement of ‘speckles’ (myocardial acoustic markers) throughout the cardiac 
cycle.16 2D speckle tracking analysis was performed offline in standard grey-scale 2D 
images with a frame rate of at least 40 frames per minute. LV systolic function was as-
sessed by measuring LV systolic circumferential and longitudinal strain. As previously 
described, circumferential strain (CS) evaluates the myocardial shortening along the 
curvature of the left ventricle in the short-axis view, whereas longitudinal strain (LS) 
assesses the magnitude of myocardial shortening in the longitudinal direction in the 
apical LV views.17, 18 Furthermore, LV diastolic function was assessed measuring longi-
tudinal strain rate during the IVRT (SR IVR) and at the peak early mitral inflow velocity 
(SR E) at the apical long-axis views.19 These variables were measured as surrogates of LV 
pressure decay during the IVRT and LV relaxation, respectively.
Global LV circumferential peak systolic strain was measured using the LV short-axis 
view at the papillary muscle level. The endocardial border was manually traced on a 
single end-systolic frame. Subsequently, the software automatically generated a region of 
interest, which was manually adjusted to include the entire myocardial wall (Figure 1). 
Next, the software automatically divided the region of interest in six equal segments 
and indicated the tracking quality for each segment. If necessary, the region of interest 
was adjusted to improve tracking quality. Afterwards, the software provided strain and 
strain rate curves for the six myocardial segments (Figure 1). In addition, a ‘global’ curve 
was provided, representing the average strain, from which global LV circumferential 
peak systolic strain was derived.
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Figure 1 Assessment of left ventricular myocardial strain (A, B) and strain rate (C) using 2D speckle tracking 
analysis. The upper left corner of each panel shows the region of interest including the entire myocardium. 
Regional strain curves are presented by the software as the colored lines (A, B) and a global strain curve (A 
and B) or strain rate curve (C) as the white dotted line. Circumferential strain (A) was measured from the LV 
short axis view. Longitudinal strain (B) was measured from the three standard apical views (apical long axis, 
two-chamber, and four-chamber view, respectively) and the average was calculated. Strain rate (C) during 
isovolumic relaxation time (calculated by adding the IVRT to the aortic valve closure time which is indicated 
by the vertical green dotted line in the strain rate curve) and at peak early diastolic inflow velocity (defined 
as the first peak in global longitudinal strain after aortic valve closure time) were measured from the three 
standard apical views and the average was calculated. 
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Global LV longitudinal peak systolic strain was measured using the same method in the 
three standard apical views: the apical long-axis, two-chamber, and four-chamber views, 
respectively. The average global LV longitudinal peak systolic strain from the three api-
cal views was calculated.
In addition, the longitudinal strain rate curves were used to assess SR IVR and SR E 
(Figure 1). SR IVR was defined as longitudinal strain rate during IVRT (calculated by 
adding the IVRT to the aortic valve closure time). SR E was defined as the first peak in 
global longitudinal strain rate after aortic valve closure. SR IVR and SR E were measured 
in the apical long-axis, two-, and four-chamber views and the average of these measure-
ments was calculated.
Intra- and interobserver variabilities have been previously reported for global CS (1.2 ± 
1.0 % and 2.3 ± 2.4 %) and for average global LS (1.2 ± 0.5 % and 0.9 ± 1.0 %).8
Statistical analysis
Continuous data are presented as mean ± standard deviation when normally distributed 
(as assessed with the Kolmogorov-Smirnov test) and as median (25th and 75th percen-
tiles) when non-normally distributed. Categorical data are presented as frequencies and 
percentages.
Changes in conventional echocardiographic parameters at follow-up were determined 
using the paired t-test, Wilcoxon signed rank test and Friedman’s test for repeated 
measurements, as appropriate. Changes in 2D speckle tracking strain parameters were 
evaluated with linear mixed models and adjusted for changes in the LV mass index dur-
ing follow-up. A p-value of <0.05 was considered statistically significant. All statistical 





Baseline clinical, demographic and echocardiographic characteristics
A total of 112 patients (mean age 53 ± 10 years, 66 (59%) men) were evaluated. By defini-
tion, all patients remained clinically stable and free of cardiovascular complaints during 
a median follow-up of 2.5 (2.3-2.8) years. The clinical characteristics of the patients are 
summarized in Table 1. Mean DM duration was almost 10 years and mean hemoglobin 
A1c was 7.6 ± 1.6 %. In addition, 72 (64 %) patients had hypertension (defined as blood 
pressure >140/90 or use of antihypertensive medication).
Echocardiographic parameters are presented in Table 2. Patients showed normal LV 
systolic function, based on the measurement of LVEF (59 ± 6 %) and LV volumes (mean 
indexed LVEDV and LVESV were 47 ± 9 mL/m2 and 19 ± 5 mL/m2, respectively).12 
Likewise, mean LV mass index and LA volume index were within normal range, 88 ± 18 
g/m2 and 18 ± 5 mL/m2, respectively. In contrast, mean E/A ratio and E’ were decreased 
and mean E/E’ ratio was increased.14 Classification in grades of LV diastolic dysfunc-
tion showed that 28 % of patients had normal LV diastolic filling pattern, 41 % had mild 
(grade I) and 31 % had moderate (grade II) diastolic dysfunction. 
When LV systolic and diastolic functions were assessed with 2D speckle tracking echo-
cardiography, patients showed impaired global LV CS and LS (Table 3).8 In addition, LV 
diastolic dysfunction was confirmed with a reduced SR E, but normal SR IVR.8, 20
Changes in conventional and 2D speckle tracking echocardiographic data at 
follow-up
At follow-up, conventional echocardiography demonstrated no significant changes in 
LV systolic function (Table 2). Indexed LV volumes and LVEF remained unchanged. 
Interestingly, LV mass index significantly increased (from 88 ± 18 g/m2 to 95 ± 18 g/m2, p 
<0.01). In terms of LV diastolic function, the E/A ratio significantly decreased (from 1.04 
± 0.29 to 0.95 ± 0.28, p <0.01), indicating a decline in LV diastolic function. In contrast, 
mean E’, E/E’ ratio and LA volume index did not significantly change.
Changes in LV function as assessed with 2D speckle tracking echocardiography 
demonstrated deterioration in global LV systolic function (Table 3). Due to technical 
limitations, follow-up LV LS could not be assessed in one patient and LV CS analysis was 
not feasible in three patients. Global CS and global LS significantly impaired at follow-up 
(from -19.7 ± 4.0 % to -18.9 ± 3.8 %, p <0.001, and from -17.2 ± 2.3 % to -16.9 ± 2.7 %, p = 
0.022, respectively). In addition, there was a progressive decline in LV diastolic function 
and particularly of LV relaxation with an impairment in SR E (from 1.02 ± 0.28 S-1 to 0.94 
± 0.25 S-1, p <0.001). In contrast, SR IVR remained unchanged. When these changes were 
corrected for changes in LV mass index, changes in global LS were no longer significant 
(p = 0.051), whereas changes in CS and SR E remained significant (p <0.001 and p = 




Age (years) 53 ± 10
Male gender, n (%) 66 (59%)
Diabetes duration (months) 115 ± 90
Hemoglobin A1c (%) 7.6 ± 1.6
Diabetes treatment, n (%)
   Diet only 3 (3%)
   Oral glucose lowering agent 65 (58%)
   Insulin 23 (21%)
   Insulin and oral agent 21 (19%)
Body mass index (kg/m2) 29 ± 5
Body surface area (m2) 2.0 ± 0.2
Family history CAD, n (%) 60 (54%)
Smoking, n (%) 20 (18%)
Hypertension, n (%) 72 (64%)
Hypercholesterolemia, n (%) 88 (79%)
Total cholesterol (mmol/L) 4.9 ± 1.2
Triglycerides (mmol/L) 1.7 (1.2-2.6)
Creatinine (μmol/L) 78 ± 21
Glomerular filtration rate (mL/min/1.73m2) 87 (75-106)
Urinary albumine/creatinine ratio (μg/μmol) 2.0 (0.9-7.0)
Microalbuminuria ≥3.5 μg/μmol 34 (30%)
Medication, n (%)
   Aspirin 21 (19%)
   Angiotensin-converting enzyme inhibitor 38 (34%)
   Angiotensin receptor antagonists 28 (25%)
   Statins 61 (55%)
Table 1 Baseline clinical, demographic characteristics.
Abbreviations: CAD: coronary artery disease.
Family history of CAD was defined as a history of CAD in first degree family member before the age of 55 
years in males or before 65 years in females. Hypertension was defined as systolic blood pressure ≥140 mmHg 
or diastolic blood pressure ≥90 mmHg or use of antihypertensive medication. Hypercholesterolemia was de-
fined as a total cholesterol ≥5 mmol/L or statin use. Glomerular filtration rate (GFR) was calculated with the 
Modification of Diet in Renal Disease (MDRD) study equation. Patients were considered to have a normal 




2D speckle tracking parameters Baseline Follow-up p-value p-value*
Global circumferential strain (%) -19.7 ± 4.0 -18.9 ± 3.8 <0.001 <0.001
Global longitudinal strain (%) -17.2 ± 2.3 -16.9 ± 2.7 0.022 0.051
Average SR IVR (S-1) 0.39 ± 0.21 0.38 ± 0.21 0.651 0.949
Average SR E ( S-1) 1.02 ± 0.28 0.94 ± 0.25 <0.001 0.013
Table 3 Changes in left ventricular function as measured with 2D speckle tracking at follow-up.
*p-value: adjusted for changes in LV mass index.
Abbreviations: SR E: strain rate at peak transmitral early diastolic inflow velocity, SR IVR: strain rate during 
isovolumetric relaxation time.
Echocardiographic parameters Baseline Follow-up p-value
LVEDV (mL/m2) 47 ± 9 48 ± 10 0.5
LVESV (mL/m2) 19 ± 5 20 ± 6 0.8
LVEF (%) 59 ± 6 60 ± 7 0.4
LV mass indexed by BSA (g/m2) 88 ± 18 95 ± 18 <0.01
LA volume indexed by BSA (mL/m2) 18 ± 5 18 ± 5 0.9
E (cm/s) 69 ± 15 69 ± 17 0.9
A (cm/s) 70 ± 18 75 ± 18 <0.01
E/A ratio 1.04 ± 0.29 0.95 ± 0.28 <0.01
DT (ms) 203 ± 36 217 ± 41 <0.01
IVRT (ms) 74 ± 10 74 ± 10 0.9
PVs (cm/s) 49 ± 12 48 ± 17 0.6
PVd (cm/s) 39 ± 10 37 ± 12 0.2
PVs/PVd ratio 1.31 ± 0.28 1.34 ± 0.31 0.5
E’ (cm/s) 6.6 ± 2.1 6.6 ± 1.9 0.9
E/E’ ratio 11.4 ± 5.1 11.3 ± 4.6 0.9
LV diastolic dysfunction 0.4
   Normal function, n (%) 28% 25%
   Mild diastolic dysfunction, n (%) 41% 40%
   Moderate diastolic dysfunction, n (%) 31% 35%
Abbreviations: A: peak transmitral late diastolic inflow velocity, BSA: body surface area, DT: decelera-
tion time of E, E: peak transmitral early diastolic inflow velocity, E’: peak early mitral annular velocity, 
IVRT: isovolumic relaxation time, LA: left atrium, LV: left ventricle, LVEDV: left ventricular end-diastolic 
volume, LVEF: left ventricular ejection fraction, LVESV: left ventricular end-systolic volume.




The present evaluation demonstrated a mild decline in LV function as assessed with 
2D speckle tracking echocardiography in asymptomatic patients with type 2 DM and 
normal LVEF after a median follow-up of 2.5 years. At follow-up, deterioration of LV 
systolic function was shown by a significant decrease in CS and LS, whereas a decline 
in LV diastolic function was indicated by a significant decrease in SR E. Furthermore, a 
significant increase in LV mass was observed. Conversely, these changes in LV function 
were not detected by conventional echocardiography. 
Increased prevalence of LV dysfunction in asymptomatic patients with DM
Contemporary population-based studies have shown that the incidence of congestive 
HF in patients with DM has increased by 3-15 times in the last years.6, 21 Nichols et al. re-
ported a 2.5-fold higher incidence of congestive HF in 8,231 DM patients compared with 
8,845 non-DM patients who were followed-up for 5.5 years (30.9 vs. 12.4 cases per 1,000 
person-years, p <0.001).21 The presence of CAD, renal dysfunction and hypertension 
are strong contributors to the increased incidence of congestive HF in DM patients.21, 22 
However, DM patients may remain asymptomatic for long time and early detection of 
changes in cardiac structure and function due to primary myocardial disease, hyper-
tension or asymptomatic CAD may help to identify the patients with an increased risk 
for developing congestive HF. A wide range of prevalence of subclinical LV diastolic 
dysfunction has been reported in asymptomatic patients with DM ranging from 23 to 
75 %.6, 23 In a cohort of 1,760 asymptomatic DM patients, From et al. demonstrated that 
the prevalence of subclinical LV diastolic dysfunction, defined by an E/E’ ratio >15, was 
23 %.6 During 5-years follow-up, DM patients with LV diastolic dysfunction doubled the 
cumulative probability of incident congestive HF of DM patients without LV diastolic 
dysfunction (36.9 % vs. 16.8 %, p <0.001). The presence of LV diastolic dysfunction was 
independently associated with incident congestive HF after correcting for age, CAD, 
hypertension, LVEF, body mass index, LA volume, LV mass and E-wave deceleration 
time.6 These findings underscore the need of sensitive diagnostic tools that permit early 
detection of subclinical LV dysfunction. 
Prevalence of LV dysfunction assessed with speckle tracking echocardiography 
in asymptomatic DM patients
Conventional echocardiography is traditionally used to quantify LV systolic function by 
means of LVEF and diastolic function through assessment of mitral valve inflow velocity 
pattern and measurement of the E/A ratio and E-wave deceleration time.12, 14 However, 
LVEF is an insensitive parameter to detect subtle LV dysfunction.24, 25 In addition, the 
E/A ratio and E-wave deceleration time depend on preload conditions, LV relaxation and 
LV compliance, and cannot differentiate normal diastolic function from grade II diastol-
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ic dysfunction without Valsalva manoeuvres. Accordingly, current recommendations 
include also the measurement of tissue Doppler imaging parameters such as the E’ and 
the E/E’ ratio, known markers of LV relaxation and LV filling pressures, respectively.14
More recently, 2D speckle tracking echocardiography has allowed the detection of sub-
clinical myocardial dysfunction by measuring multidirectional LV strain and strain 
rate. This modality overcomes important limitations of conventional echocardiography 
and tissue Doppler imaging. The assessment of LV strain and strain rate is a more sen-
sitive marker of LV dysfunction and has a better reproducibility compared to LVEF.8 
In patients with DM and preserved LVEF, 2D speckle tracking echocardiography has 
demonstrated the presence of subtle LV systolic dysfunction.8, 26 For example, the study 
by Nakai and coworkers showed that patients with type 2 DM and normal LVEF had 
impaired LV CS and LS when compared with healthy controls (LV CS: -22.6 % in type 2 
DM patients vs. -24.4 % in controls, p <0.005; and LV LS: -17.6 % in type 2 DM patients 
vs. -20.8 % in controls, p <0.001).26 However, studies evaluating changes in LV mechanics 
over time in type 2 DM patients who remain asymptomatic are sparse. 
Progression of subclinical LV dysfunction
At present, only a few studies have investigated changes of LV dysfunction over time in 
patients with DM.27 In 27 type 2 DM patients, Vintila et al. showed progression of sub-
clinical LV dysfunction after 5-years follow-up by a significant reduction in longitudinal 
velocities measured with TDI echocardiography (mean longitudinal systolic velocity 4.9 
cm/s vs. 5.6 cm/s, p = 0.001).28 The present evaluation confirms and extends previous 
observations by measuring 2D speckle tracking echocardiography derived LV systolic 
and diastolic parameters. Asymptomatic patients with type 2 DM showed subclinical 
LV systolic and diastolic dysfunction as reflected by impaired CS and LS, and reduced 
SR E. More important, after 2-year follow-up and despite remaining clinically stable 
and asymptomatic, these patients showed progression of subclinical LV dysfunction 
with further impairment in CS and LS, and decline in SR E together with an increase 
in LV mass. In contrast, conventional echocardiographic measurements did not show 
significant changes in LV systolic and diastolic function. Therefore, 2D speckle tracking 
echocardiography may be a promising tool for identification and monitoring of sub-
clinical LV dysfunction in patients with DM. Early identification of type 2 DM patients 
with subclinical LV dysfunction allows initiation of therapeutic strategies to prevent 
progression to HF and improve prognosis. Moreover, the current study demonstrated 
mild progression of subclinical LV dysfunction after 2-year follow-up, which supports 
the importance of regular echocardiographic surveillance of these patients.
Limitations
Some limitations should be acknowledged. First, the present evaluation is retrospec-
tive, includes a relatively small cohort of asymptomatic type 2 DM patients and some 
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patients had additional cardiovascular risk factors, such as hypertension or hypercho-
lesterolemia, which may contribute to development and progression of LV dysfunction. 
However, as type 2 DM often is part of a clustering of cardiovascular risk factors, the 
current population is a better representation of the daily clinical practice. Second, to 
avoid the influence of myocardial ischemia on LV function, only patients who were clini-
cally stable were included in the study. Exercise test was not systematically performed 
to exclude significant coronary stenosis. However, patients who presented with angina 
complaints or acute coronary syndromes during follow-up were excluded. Third, previ-
ous studies have demonstrated that strain and strain rate increase from base to apex, 
and therefore, heterogeneity in regional strain peaks was not further evaluated in the 
present study.29 Fourth, N-terminal pro brain natriuretic peptide (NT-proBNP) was not 
systematically assessed. Finally, the prognostic implications of these mild changes in 
LV function were not evaluated. Additional prospective studies are needed in order to 
elucidate whether systematic echocardiographic surveillance should be recommended 
in order to improve the risk stratification of this subpopulation.
Conclusions
 
Asymptomatic patients with type 2 DM and normal LVEF may show mild progression 
of subclinical LV dysfunction assessed with 2D speckle tracking echocardiography. The 
prognostic implications of these mild changes in LV function and recommendations on 
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The association between atherosclerosis in the descending thoracic aorta (DTA) vi-
sualized on computed tomography coronary angiography (CTA) and coronary artery 
disease (CAD) has not been extensively explored. Therefore, a comprehensive analysis of 
DTA atherosclerosis on CTA was performed and the association of DTA atherosclerosis 
with CAD was evaluated in patients with suspected CAD.
A total of 344 patients (54 ± 12 years, 54 % men) with suspected CAD underwent CTA. 
CTA were classified based on CAD severity in no signs of atherosclerosis or minor wall-
irregularities <30 %, non-significant CAD 30-50 %, or significant CAD ≥ 50 % stenosis. 
The DTA was divided in segments according the posterior intercostal arteries. Per seg-
ment the presence of atherosclerotic plaque (defined as ≥2 mm wall thickness) was 
determined and maximal wall thickness was measured. Plaque composition was scored 
as non-calcified or mixed and the percentage of DTA segments with atherosclerosis was 
calculated.
Significant CAD was present in 152 (44 %) patients and 278 (81 %) had DTA athero-
sclerotic plaque. DTA maximal wall thickness and percentage of DTA segments with 
atherosclerosis were 2.7 ± 1 mm and 49 ± 36 %. The presence, severity and extent of DTA 
atherosclerosis significantly increased with increasing CAD severity. Multivariate logis-
tic regression analysis corrected for age and other risk factors demonstrated independent 
associations of DTA plaque (OR 6.56, 95 % CI 1.78-24.19, p = 0.005) and maximal DTA 
wall thickness (OR 2.00, 95 % CI 1.28-3.12, p = 0.002) with significant CAD.
The presence and severity of DTA atherosclerosis were independently related with sig-




Multi-slice computed tomography coronary angiography (CTA) is a well-established 
modality for the evaluation of coronary artery disease (CAD) 1, 2 and also permits visu-
alization of the descending thoracic aorta (DTA). Interestingly, atherosclerosis in the 
DTA, a marker of diffuse atherosclerotic cardiovascular disease, is frequently observed.3, 
4 In addition, various imaging techniques have demonstrated the association between 
DTA atherosclerosis, CAD and cardiovascular events.3, 5-10 The advantage of CTA for 
assessing DTA atherosclerosis is the complementary information that can be derived 
from the available CTA images. Various parameters can be derived from CTA to ad-
dress DTA atherosclerosis, including DTA calcification, atherosclerotic plaque and wall 
thickness. Although a number of studies have confirmed the independent association 
between DTA calcification on CTA and CAD,7, 9-12 other CTA derived parameters of 
DTA atherosclerosis have not been used extensively for this purpose.
Hence, the aim of the present study was to (1) perform a comprehensive evaluation of 
the presence, extent, severity and composition of DTA atherosclerosis on CTA and (2) 
to assess associations between DTA atherosclerosis and CAD.
Patients and methods
Patients
The cohort comprised 344 patients with suspected CAD evaluated in the Leiden 
University Medical Center in the period between February 2005 and December 2009. All 
patients underwent CTA to assess the presence of significant CAD. Contra-indications 
for CTA included renal failure (glomerular filtration rate <30 mL/min), known hy-
persensitivity to iodine containing contrast or pregnancy. Inclusion criteria were an 
interpretable CTA with diagnostic image quality for the evaluation of CAD and the 
display of the complete DTA on the CTA scan (entire DTA visualized on the axial CTA 
images and at least 5 or more DTA segments present on the CTA scan).
Clinical data, including demographics, symptoms and CTA results were collected in the 
departmental electronic patient file (EPD vision version 8.3.3.6; Leiden, The Netherlands) 
and retrospectively analyzed. The Institutional Review Board of the Leiden University 
Medical Center approved this retrospective evaluation of clinically collected data, and 
waived the need for written informed consent.
Cardiovascular risk factors included hypertension (defined as systolic blood pressure 
≥140 mmHg, diastolic pressure ≥90 mmHg or use of antihypertensive medication), 
hypercholesterolemia (defined as serum total cholesterol ≥230 mg/dL or use lipid lower-
ing therapy), diabetes mellitus (defined as fasting plasma glucose level ≥126 mg/dL, use 
of oral glucose lowering medication or insulin), obesity (body mass index >30 kg/m2), 
smoking status, positive family history for CAD (presence of CAD in first-degree family 
member at <65 years in women and <55 years in men).
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The presence and severity of CAD were assessed on CTA. Furthermore, a comprehensive 
analysis of the DTA was performed on the CTA scan, to assess the presence, severity, 
extent and composition of DTA atherosclerosis. 
CTA data acquisition
Patients were scanned on a 64-detector row helical scanner (Aquilion 64, Toshiba 
Medical Systems, Otawara, Japan) or 320-detector row volumetric scanner (Aquilion 
ONE, Toshiba Medical Systems, Otawara Japan). Additional scan parameters for the 
64-detector row scanner were collimation 64 x 0.5 mm, gantry rotation time 400 ms, 
tube voltage 120-135 kV and tube current 300-350 mA as adjusted to body mass index.2 
For the 320-row scanner collimation was 320 x 0.5 mm, gantry rotation time 350 ms, 
tube voltage 100-135 kV and tube current 400-580 mA as adjusted to body mass index.1 
One hour prior to the scan, blood pressure and heart rate were measured and beta-
blockers (50-100 mg metoprolol, orally) were administered to patients with a heart 
rate ≥65 beats/min without contraindication for beta-blocking agents. First, a non-en-
hanced calcium scan was performed with slice thickness of 3.0 mm. Thereafter, CTA 
was performed with simultaneous recording of the electrocardiogram for retrospective 
(64-detector row scanner) or prospective (320-detector row scanner) gating of the data. 
An amount of 60-110 mL non-ionic contrast medium (Iomeron 400, Bracco, Milan, 
Italy) was administered in the antecubital vein with a flow rate 5-6 mL/s, followed by a 
saline flush. The scan was triggered with automated peak enhancement detection with 
the region of interest located in the left ventricle. Data acquisition was completed within 
a single breath hold of approximately 10 s. A data set at 75 % of the R-R interval was then 
automatically reconstructed with a slice thickness of 0.5 mm and reconstruction inter-
val of 0.3 mm for the 64-detector row scanner and 0.5 mm and 0.25 mm, respectively, 
for the 320-detector row scanner. In case of motion artifacts, additional reconstructions 
of different time points in the R-R interval were reconstructed.
The estimated mean radiation dose for the 64-row CTA and 320-row CTA in our centre 
have been previously described as 18.1 ± 5.9 mSv and 7.1 ± 1.7 mSv, respectively.13
CTA data analysis
Post-processing and evaluation of the CTA scans were performed on a remote work 
station with dedicated CTA analysis software (Vitrea 2 or Vitrea FX 1.0, Vital Images, 
Minnetonka, MN, USA). For each patient, the Agatston coronary calcium score was 
measured on the calcium scan. Thereafter, the CTA reconstruction with the best image 




Computed tomography coronary angiography scans were evaluated by two experienced 
observers, including one interventional cardiologist. Discrepancies between observers 
were resolved by a consensus decision during a joint reading. The coronary artery sys-
tem was divided into 17 segments according the modified American Heart Association 
classification.14
First, the quality of the scan was classified as good, reasonable, moderate or poor, based 
on scan noise, motion artifacts and contrast filling of the coronary arteries. 
Per segment, the presence of atherosclerotic plaque and severity of luminal stenosis were 
determined from the axial images and verified by the interpretation of curved multipla-
nar reconstruction in at least 2 orthogonal planes. Atherosclerotic plaque was defined 
as a structure >1 mm2 within and/or adjacent to the coronary artery lumen that could 
clearly be distinguished from the coronary artery lumen and surrounding tissue.15 For 
each segment, the severity of luminal stenosis was visually scored as follows: 1. no signs 
of atherosclerosis or minor wall irregularities (<30 % stenosis), 2. non-significant CAD 
(30-50 % stenosis) and 3. significant CAD (≥50 % stenosis).16 In patients with a per-
cutaneous coronary intervention (PCI), stented coronary segments were considered as 
having significant CAD.
A CTA was considered non-interpretable if the presence and severity of CAD could not 
be determined due to poor image quality (non-diagnostic image quality of CTA for the 
evaluation of CAD). 
On a patient basis, patients were stratified according to the most severe stenosis as 
follows: 1. no signs of atherosclerosis or minor wall irregularities (<30 % stenosis), 2. 
non-significant CAD (30-50 % stenosis) and 3. significant CAD (≥50 % stenosis).16
Analysis of DTA atherosclerosis
In addition to the coronary arteries, the CTA scan also permits visualization of the DTA. 
In order to visualize the entire heart, the preset scan range of the CTA reaches from 
the tracheal bifurcation to beneath the diaphragm. Hence, the DTA is imaged over the 
course from beneath the aortic arch to the abdominal aorta.
Assessment of atherosclerosis in the DTA was performed on the axial images by two 
experienced observers, blinded to patient’s clinical characteristics and CTA results 
(presence and severity of CAD). 
First, the Agatston calcium score of the DTA was determined on a non-contrast en-
hanced scan. Thereafter, the DTA was anatomically divided based on the posterior 
intercostal arteries in 5-8 segments per scan as shown in Figure 1. In each segment, 
the site of maximal wall thickness was measured perpendicularly to the center of the 
aorta. The presence of atherosclerotic plaque was defined as a wall thickness ≥2 mm in 
at least one DTA segment.3 Per patient plaque composition was scored as no plaque, non-
calcified plaque (only low-density plaque) or calcified plaque (containing high-density 
plaque) (Figures 1 c, d). Finally, the extent of atherosclerosis was determined by the 
percentage of segments with atherosclerotic plaque.
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The intra- and inter-observer variability of the measurements of DTA atherosclerosis 
were determined by repeated analysis of 20 randomly selected patients more than 4 
weeks apart, by the same observer, and by the assessment of DTA atherosclerosis in the 
same patient by a second independent observer. 
Statistical analysis
Continuous variables with normal distribution, as assessed with the Kolmogorov-
Smirnov test, are presented as mean ± standard deviation and non-normal distributed 
continuous variables as median (25th and 75th percentiles). Categorical variables are 
presented as frequencies and percentages. Comparisons between groups of continu-
ous variables were performed with the Student t-test, one-way analysis of variance and 
Kruskal-Wallis test, as appropriate. Categorical variables were compared with the Chi 
square test. 
Correlates of significant CAD amongst clinical and demographic characteristics and 
DTA atherosclerosis variables were identified with univariate logistic regression analy-
Figure 1. Evaluation of atherosclerosis in the descending thoracic aorta (DTA) on a CTA scan. Panel A dem-
onstrates how the descending thoracic aorta was anatomically divided in segments, based on the posterior 
intercostal arteries (red horizontal lines). Panels B, C and D are axial images at the sight of maximal wall 
thickness of the corresponding DTA segments 2, 4 and 6, respectively. Panel B shows a normal DTA wall 
without atherosclerosis. Panel C depicts atherosclerotic plaque with calcification (indicated with arrow) and 
maximal wall thickness of 7.3 mm. Panel D shows atherosclerotic plaque with wall thickness of 3.3 mm.
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sis. Subsequently, independent associations of the correlates with significant CAD were 
evaluated with multivariate logistic regression analysis. For logistic regression analyses, 
non-normal distributed continuous variables were log-transformed to obtain a normal 
distribution. Odds ratio (OR) and 95 % confidence intervals (CI) were derived from 
logistic regression analysis. 
Intra- and inter-observer variability of the measurements of DTA atherosclerosis were 
evaluated with the intraclass correlation (ICC) coefficient for continuous variables and 
Cohen’s Kappa statistics for categorical variables. The ICC coefficient of good agreement 
was defined as >0.72. Kappa values of agreement between 0.40-0.75 were defined as 
moderate and >0.75 as good.
For all statistical tests p <0.05 was considered significant. All statistical analyses were 




Patient’s clinical and demographic characteristics
The cohort consisted of 344 patients who underwent CTA for suspected CAD. The mean 
age of the patients was 54 ± 12 years and 186 (54 %) were men. The clinical and de-
mographic characteristics of all patients and of the patients with versus without DTA 
atherosclerotic plaques are presented in Table 1. Patients with DTA atherosclerotic 
plaque were significantly older and had a higher prevalence of hypertension, hypercho-
lesterolemia and previous PCI as compared to patients without DTA atherosclerosis. 
Moreover, the coronary artery calcium score was significantly higher (39 [0-278] vs. 0 
[0-1], p <0.001) in patients with DTA atherosclerotic plaque.
Analysis of CAD and DTA atherosclerosis
Analysis of CAD identified no signs of atherosclerosis or minor wall irregularities, non-
significant CAD and significant CAD in 103 (30 %), 89 (26 %) and 152 (44 %) patients, 
respectively (Table 2). 
Results of the comprehensive analysis of DTA atherosclerosis are shown in Table 2. DTA 
calcification (DTA calcium score >0) was present in 183 (53 %) patients and the median 
DTA calcium score was 1 [0-97]. The overall mean DTA maximal wall thickness was 
All patients DTA atherosclerotic plaque
(≥2mm wall thickness)
No plaque Plaque
n=344 n=66 (19%) n=278 (81%) p-value
Age, (years) 54 ± 12 42 ± 10 57 ± 10 <0.001
Men, n (%) 186 (54%) 30 (45%) 156 (56%) 0.118
Hypertension, n (%) 158 (46%) 19 (29%) 139 (50%) 0.003
Hypercholesterolemia, n (%) 141 (41%) 19 (29%) 122 (44%) 0.034
Diabetes, n (%) 80 (23%) 16 (24%) 64 (23%) 0.758
Obesity, n (%) 73 (21%) 9 (14%) 64 (23%) 0.118
Smoking, n (%) 94 (27%) 19 (29%) 75 (27%) 0.685
Family history, n (%) 168 (49%) 32 (48%) 136 (49%) 0.896
Myocardial infarction, n (%) 43 (12%) 4 (6%) 39 (14%) 0.089
PCI, n (%) 52 (15%) 2 (3%) 50 (18%) 0.002
Coronary calcium score 10 [0-216] 0 [0-1] 39 [0-278] <0.001
Table 1. Clinical and demographic characteristics of the entire cohort and comparison between patients with 
and without DTA plaque.
Abbreviations: DTA: descending thoracic aorta, PCI: percutaneous coronary intervention.
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2.7 ± 1 mm. DTA atherosclerotic plaque was present in 278 (81 %) patients and calcified 
DTA atherosclerotic plaque in 87 (25 %) patients. In addition, the mean extent of DTA 
atherosclerosis (percentage of DTA segments with atherosclerotic plaque) was 49 ± 36 
%, respectively.
DTA atherosclerosis and CAD severity
The presence, severity and extent of DTA atherosclerosis significantly increased in 
parallel to increasing severity of CAD (Table 2). An example of a patient with DTA ath-
erosclerosis and CAD on CTA is presented in Figures 1 and 2.
The median DTA calcium score significantly increased over the patient groups of CAD 
severity, from 0 [0-2] in patients without signs of atherosclerosis or minor wall irregu-
larities to 1 [0-98] in patients with non-significant CAD and to 22 [0-513] in patients 
with significant CAD (p <0.001). Similarly, DTA maximal wall thickness significantly 
increased from 2.0 ± 0.5 mm in patients without signs of atherosclerosis or minor wall 
irregularities to 2.6 ± 0.8 mm in patients with non-significant CAD and to 3.2 ± 1.1 mm 
in patients with significant CAD (p <0.001).
The prevalence of DTA atherosclerotic plaque significantly increased from 60 (58 %) in 
patients without signs of atherosclerosis or minor wall irregularities to 69 (77 %) in pa-
tients with non-significant and to 149 (98 %) in patients with significant CAD (p <0.001). 
With respect to plaque composition, the prevalence of calcified DTA plaque significantly 
Comparisons between groups of CAD severity was performed with the one-way analysis of variance for 
continuous variables with normal distribution and with the Kruskal-Wallis test for non-normal distributed 
continuous variables. Categorical variables were compared with the Chi square test.
Abbreviations: CAD: coronary artery disease, DTA: descending thoracic aorta.
Table 2. Measurements of DTA atherosclerosis of the entire population and comparison between patients 
groups of CAD severity.
DTA variables
All patients CAD severity  
 <30 % 30-50 % ≥50 %
n=344 n=103 (30%) n=89 (26%) n=152 (44%) p-value
Calcium score 1 [0-97] 0 [0-2] 1 [0-98] 22 [0-513] <0.001
Maximal wall thickness, mm 2.7 ± 1 2.0 ± 0.5 2.6 ± 0.8 3.2 ± 1.1 <0.001
Atherosclerotic plaque, n (%) 278 (81%) 60 (58%) 69 (77%) 149 (98%) <0.001
Plaque composition     <0.001
     no plaque, n (%) 66 (19%) 43 (42%) 20 (22%) 3 (2%)  
     non-calcified, n (%) 191 (55%) 59 (57%) 47 (53%) 85 (56%)  
     calcified, n (%) 87 (25%) 1 (1%) 22 (25%) 64 (42%)  
Extent atherosclerosis,
% of segments affected
49 ± 36 24 ± 28 47 ± 38 66 ± 30 <0.001
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increased with increasing CAD severity, whereas the prevalence of non-calcified DTA 
plaque did not change. 
Finally, the extent of DTA atherosclerosis significantly increased from 24 ± 28 % in 
patients without signs of atherosclerosis or minor wall irregularities to 47 ± 38 % in 
patients with non-significant CAD and to 66 ± 30 % in patients with significant CAD 
(p <0.001).
Correlates of significant CAD
The results of univariate logistic regression analysis for the assessment of associations 
between clinical and demographic characteristics and measurements of DTA athero-
sclerosis with significant CAD are presented in Table 3. Age, male gender, hypertension, 
hypercholesterolemia and smoking were correlates of significant CAD. Moreover, all 
measurements of DTA atherosclerosis (log transformed calcium score, maximal wall 
thickness, presence of atherosclerotic plaque, plaque composition and extent of athero-
sclerosis) were correlated with significant CAD.
Figure 2. Multi planar reconstructions of the coronary arteries of the same patient in Figure 1. There is a left 
dominant coronary system with separate ostia of the LAD and LCx. The proximal segment of the LCx and 
mid segment of the LAD have mixed plaques (containing non-calcified plaque and calcified plaque) with non-
significant coronary artery disease (30-50 % luminal stenosis). 
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Independent associations between DTA atherosclerosis and significant CAD
The independent association between DTA atherosclerosis and significant CAD was 
assessed with multivariate logistic regression analysis. The multivariate model was cor-
rected for the (univariately identified) correlates of significant CAD: age, male gender, 
hypertension, hypercholesterolemia and smoking. Furthermore, DTA calcium score, 
DTA maximal wall thickness and presence of DTA plaque were entered as parameters 
of DTA atherosclerosis. After multivariate correction, DTA maximal wall thickness and 
presence of DTA plaque remained independently associated with significant CAD (OR 
2.00, 95 % CI 1.28-3.12, p = 0.002 and OR 6.56, 95 % CI 1.78-24.19, p = 0.005, respective-
ly). Of note, the association of DTA calcium score with significant CAD lost significance 
after DTA maximal wall thickness was entered into the model (Table 4).
Table 3. Univariate associations of clinical, demographic characteristics and measurements of DTA athero-
sclerosis with the presence of significant CAD.
Abbreviations: CAD: coronary artery disease, DTA: descending thoracic aorta.
 OR 95% CI p-value
Clinical, demographic characteristics
Age 1.07 1.05-1.09 <0.001
Men 1.94 1.26-3.00 0.003
Hypertension 1.95 1.26-3.01 0.003
Hypercholesterolemia 2.25 1.45-3.49 <0.001
Obesity 0.64 0.37-1.09 0.102
Smoking 2.20 1.36-3.57 0.001
Family history 0.85 0.55-1.30 0.459
Diabetes 0.84 0.51-1.40 0.515
DTA variables
Log DTA calcium score 1.89 1.55-2.31 <0.001
Maximal DTA wall thickness (mm) 3.80 2.68-5.39 <0.001
Presence of DTA plaque 24.26 7.44-79.09 <0.001
Plaque composition    
     Calcified (versus non-calcified) 1.24 1.99-6.05 <0.001
Extent atherosclerosis, % of segments affected 1.03 1.02-1.03 <0.001
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Intra- and inter-observer variability of DTA atherosclerosis analysis
The intra- and inter-observer variability of the analysis of DTA atherosclerosis showed 
good agreement between observers. The intra-observer variability of DTA maximal wall 
thickness and extent of atherosclerosis demonstrated a good intra-observer agreement, 
ICC coefficients 0.81 (0.59-0.92), p <0.001 and 0.77 (0.45-0.91), p <0.001, respectively. 
Furthermore, the agreement of the presence of DTA atherosclerotic plaque and plaque 
morphology was moderate, Kappa values 0.57, p = 0.010 and 0.57, p <0.001, respectively. 
Similarly, the inter-observer variability showed a good agreement of DTA maximal wall 
thickness and extent of DTA atherosclerosis, ICC coefficients 0.89 (0.72-0.96), p <0.001 
and 0.92 (0.81-0.97), p <0.001, respectively, and moderate agreement of the presence of 
DTA atherosclerotic plaque and plaque morphology, Kappa values 0.53, p = 0.015 and 
0.59, p <0.001, respectively.
 OR 95% CI p-value
Age 1.02 0.98-1.05 0.333
Male 2.03 1.18-3.49 0.011
Hypertension 1.11 0.64-1.91 0.704
Hypercholesterolemia 1.90 1.11-3.27 0.019
Smoking status 2.11 1.13-3.92 0.019
Log DTA calcium score 1.19 0.88-1.61 0.258
Maximal DTA wall thickness (1mm) 2.00 1.28-3.12 0.002
Presence of DTA plaque 6.56 1.78-24.19 0.005
Table 4. Independent associations (on multivariate analysis) of clinical, demographic characteristics and 
measurements of DTA atherosclerosis with the presence of significant CAD.




In the present study in patients with suspected CAD, a comprehensive analysis of DTA 
atherosclerosis on CTA was performed and independent associations of parameters of 
DTA atherosclerosis with CAD were assessed. A high prevalence of DTA atherosclerosis 
and CAD was observed in this group of patients, and the presence, severity and extent of 
DTA atherosclerosis increased in parallel to the increase in CAD severity. In addition, all 
parameters of DTA atherosclerosis were significantly correlated with significant CAD in 
univariate logistic regression analysis. After multivariate correction for other cardiovas-
cular risk factors, the presence of DTA atherosclerotic plaque and DTA maximal wall 
thickness were identified as independent correlates of significant CAD. For this reason, 
there was no association between the DTA calcium score with CAD. 
Assessment of atherosclerosis in the descending thoracic aorta
At present, aortic atherosclerosis has been evaluated using computed tomography (CT), 
magnetic resonance imaging and fluorodeoxyglucose positron-emission tomography,3, 
17, 18 but mostly with transesophageal echocardiography (TEE).5, 8, 19 DTA atherosclerosis 
on TEE is recognized as irregular intimal wall thickening with increased echogenicity 
and additionally classified in simple or complex atherosclerosis, based on plaque thick-
ness, presence of ulceration and mobile debris. In addition, CT enables the evaluation of 
DTA atherosclerosis through measurement of the Agatston calcium score, atheroscle-
rotic plaque and DTA wall thickness.3, 20, 21
Several general population studies have investigated DTA atherosclerosis and its associ-
ation with CAD. In the Stroke Prevention: Assessment of Risk in a Community (SPARC) 
study including 581 subjects, the prevalence of DTA atherosclerosis as assessed with 
TEE was 45 % and significantly associated with known CAD.5 Both the Heinz Nixdorf 
Recall study including 4,025 participants and the Multi-Ethnic Study of Atherosclerosis 
(MESA) including 6,814 participants assessed DTA calcification using non-enhanced 
CT and demonstrated independent associations with coronary calcium.9, 10 The preva-
lence of DTA calcification in the Heinz Nixdorf Recall Study was 57 % and comparable 
to the present study, whereas the median DTA calcium score was higher (6.5 [interquar-
tile range 0-59.1]). However, in the MESA study the prevalence of DTA calcification was 
only 28 %. These differences might be explained by the older age of the Heinz Nixdorf 
Recall study cohort and on the other hand, by a lower cardiovascular risk profile as in-
dicated by a lower prevalence of diabetes and smoking in the MESA study participants, 
despite the older age.
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Associations between atherosclerosis in the DTA and CAD
Only a few studies investigated whether CTA derived parameters of DTA atheroscle-
rosis were independently associated with CAD. Yamamoto et al. found in 180 patients 
with suspected CAD that DTA wall volume derived from 7 contiguous slices on en-
hanced computed tomography (CT) was associated with significant CAD (defined as 
>75% stenosis on invasive coronary angiography).22 Okuyama and colleagues evaluated 
89 patients with suspected CAD and observed that DTA atherosclerosis on CTA (calcu-
lated as the sum of DTA atherosclerosis severity grades of the upper, middle and lower 
DTA) was independently associated with significant CAD (defined as ≥50 % stenosis 
on invasive coronary angiography).21 Takasu et al. performed a comprehensive analysis 
of DTA atherosclerosis on electron beam CT, including aortic calcification as well as 
DTA wall volume, maximal wall thickness and plaque (graded from 1 to 4 based on 
lumen irregularity and wall thickness) in 25-30 mm of the midportion of the DTA in 
97 patients with suspected CAD. Independent associations were demonstrated of aortic 
calcification, DTA wall volume, maximal wall thickness, and aortic plaque with sig-
nificant CAD (defined as ≥70 % stenosis on CTA).3 Jang et al. confirmed associations 
of aortic calcification and DTA maximal wall thickness with significant CAD (defined 
as ≥50 % stenosis on invasive coronary angiography) in 104 patients who underwent 
invasive coronary angiography because of significant CAD on CTA.23 Finally, Jeltsch et 
al. assessed DTA maximal wall thickness in 30 mm of the midportion of the DTA on 
CTA in 160 patients with suspected or known CAD and did not observe an independent 
association between DTA maximal wall thickness and significant CAD (≥75 % stenosis 
on CTA), although DTA maximal wall thickness was independently associated with 
coronary atherosclerosis.20 
The findings in the current study extend the previous findings by demonstrating in-
dependent associations between DTA atherosclerosis and CAD on CTA. Whereas the 
earlier studies evaluated only a small portion of the DTA, the present study demonstrated 
the feasibility of assessing DTA atherosclerosis in the entire DTA. Moreover, a com-
prehensive analysis of DTA atherosclerosis was proposed, including the DTA Agatston 
calcium score, atherosclerotic plaque and DTA wall thickness. It was demonstrated that 
the presence, severity, extent and calcification of DTA atherosclerosis were increased 
in patients with increased severity of CAD. After multivariate adjustment, DTA ath-
erosclerotic plaque and DTA maximal wall thickness were independently associated 
with significant CAD, but the DTA Agatston calcium score was not. The differences in 
results with the previous studies might be explained by the differences in measuring 
DTA atherosclerosis, the different definitions of significant CAD, and approach of the 
multivariate analysis. Importantly, in the present study significant CAD was defined 
by ≥50 % stenosis on CTA in line with guidelines of the appropriate use for diagnostic 





General population studies like the MESA study and Heinz Nixdorf Recall study have 
already established the relationship between thoracic aortic calcification and coronary 
calcium.9, 10 Independent associations of DTA atherosclerosis with CAD indicate that 
atherosclerosis in the DTA is not limited to local vascular disease, but an expression of 
diffuse atherosclerotic cardiovascular disease. Other markers of diffuse atherosclerotic 
cardiovascular disease, such as the carotid intima media thickness, coronary calcium 
score or arterial stiffness have been confirmed as independent predictors of cardiovas-
cular events.25-27 Furthermore, the presence of arterial calcification in different vascular 
beds was demonstrated to have incremental predictive value beyond established risk 
factors for cardiovascular events and mortality.28, 29 
Therefore, the detection of DTA atherosclerosis might benefit the identification of pa-
tients at higher risk of CAD and worse prognosis. DTA atherosclerosis can easily be 
obtained from routine CT coronary angiography through the measurement of maximal 
wall thickness and atherosclerotic plaque. The prognostic value of DTA atherosclerosis 
needs further evaluation.
Limitations
Some limitations need to be addressed. First, due to the spatial resolution of CTA, dif-
ferentiation of the intima and media layers of the aortic wall is precluded. However, 
increasing aortic wall thickness most likely represents thickening of the intima layer, 
as the intima layer thickness predominantly increases with age and atherosclerosis.30 
Second, atherosclerosis in the ascending thoracic aorta and aortic arch was not evaluated 
because the ascending thoracic aorta and aortic arch were not systematically visualized 
on CTA. Third, the scan range of CTA was adjusted to the height of the heart, leading to 
a different length of DTA for the evaluation of DTA atherosclerosis. Finally, associations 
of DTA atherosclerosis with (cardiovascular) events were not assessed, because the event 
rate in the study population is low and precludes assessment of the prognostic value of 
DTA atherosclerosis. 
Conclusions
In patients with suspected CAD, DTA atherosclerosis and CAD were common on CTA 
and the presence, severity and extent of DTA atherosclerosis increased with increasing 
severity of CAD. DTA atherosclerosis measured as the presence of DTA atherosclerotic 
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Associations of Atherosclerosis in the Descending 
Thoracic Aorta on CTA with Arterial Stiffness and 
Chronic Kidney Disease in Asymptomatic Patients 
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The relation between atherosclerosis in the descending thoracic aortic (DTA), arterial 
stiffness and chronic kidney disease (CKD) in patients with diabetes mellitus (DM) re-
mains unclear. The current aim was to evaluate associations of DTA atherosclerosis with 
arterial stiffness and parameters of CKD in asymptomatic patients with DM.
A total of 213 asymptomatic patients with diabetes (mean age 52 years, 56% men) under-
went cardiovascular risk assessment including multi-slice computed tomography (for 
non-invasive coronary angiography, from which DTA atherosclerosis can be derived), 
non-invasive assessment of arterial stiffness with applanation tonometry and assessment 
of renal function. Measurements of DTA atherosclerosis included assessment of DTA 
thickening and calcium score. Arterial stiffness was determined by the carotid-femoral 
pulse wave velocity (PWV), parameters of CKD included estimated glomerular filtration 
rate (eGFR) and urinary albumin-creatinine ratio (UACR).
DTA atherosclerosis was present in 180 (84%) patients. Patients with DTA athero-
sclerosis had increased arterial stiffness, lower eGFR and higher UACR values. After 
multivariate correction, DTA calcium score was independently associated with PWV 
(β=0.18, p=0.04). Furthermore, both DTA maximal wall thickness and DTA calcium 
score were independently associated with eGFR (β=-7.37, p<0.001 and β=-1.99, p<0.003, 
respectively), but not with UACR.
The increase in arterial stiffness by atherosclerosis seemed to be mediated by arterial 
calcification, while the DTA calcium score was independently associated with arterial 
stiffness, but not DTA maximal wall thickness. Furthermore, parameters of CKD in 
patients with DM had a distinct relationship with DTA atherosclerosis: DTA atheroscle-




Patients with diabetes mellitus (DM) have an increased atherosclerotic burden, in-
creased arterial stiffness and a higher prevalence of chronic kidney disease (CKD), as 
compared to age-matched subjects without DM.1-3  Studies have shown relations between 
these factors.
Atherosclerosis is a diffuse cardiovascular disease which can affect the aorta. 
Atherosclerosis is defined by arterial wall thickening with or without calcification and 
can be assessed in the descending thoracic aorta (DTA) on computed tomography (CT) 
angiography .4, 5 
Atherosclerosis in the aorta has been related to arterial stiffness, especially by calcifica-
tion in the aorta. Several studies demonstrated that aortic calcification increases arterial 
stiffness, whereas the association of aortic wall thickening or non-calcified atheroscle-
rosis with arterial stiffness showed conflicting results.6-8  Therefore, the first aim of the 
present study was to investigate whether the association between DTA atherosclerosis 
(as derived from CT angiography) and arterial stiffness is mediated by the amount of 
calcification.
In addition, DTA atherosclerosis might enhance target end-organ damage, which  in-
cludes CKD, but limited data are currently available, particularly in patients with DM. 9 
CKD in patients with DM can be assessed by estimated glomerular filtration rate (eGFR) 
and urinary albumin-creatinine ration (UACR). An early expression of CKD in patients 
with DM is albuminuria, which over time progresses from microalbuminuria to macro-
albuminuria and eventually reduces eGFR.10 
Advancing insights in the role of atherosclerosis in the development of CKD in patients 
with DM may guide preventive treatment.
Consequently, the second aim of the present study was to assess associations of DTA 
atherosclerosis (either with or without calcification) with UACR and eGFR as markers 





Patients were included from an ongoing registry of asymptomatic patients with DM.11 
Based on the American Diabetes Association criteria12, patients were classified as having 
type 1 DM if they had demonstrable auto-antibodies to islet cells, insulin and glutamic 
acid decarboxylase or low levels of plasma c-peptide in laboratory analysis, or type 2 
DM if not. 
Comprehensive evaluation of asymptomatic patients with DM is routinely performed 
at the outpatient clinic of the Leiden University Medical Center for risk stratification.11 
The cardiovascular risk assessment included a structured clinical history, physical ex-
amination, blood and urine laboratory testing. Arterial stiffness was non-invasively 
assessed with applanation tonometry. Multi-slice CT coronary angiography (CTA) was 
performed to evaluate the presence and severity of coronary artery disease (CAD).
Clinical and demographic data were prospectively collected in the departmental cardiol-
ogy information system (EPD-Vision version 8.3.3.6; Leiden, The Netherlands) and were 
retrospectively analyzed. Asymptomatic status was confirmed with a self-completed 
questionnaire on chest pain.13 The Institutional Review Board of the Leiden University 
Medical Center approved this retrospective evaluation of clinically collected data and 
waived the need for written informed consent.
For the current evaluation, the presence, severity, extent and composition of athero-
sclerosis in the DTA were assessed from the CTA images. Patients were included in the 
analysis when the entire DTA was visualized on the axial CTA images and at least 5 or 
more DTA segments were present on the CTA. Subsequently, potential associations of 
DTA atherosclerosis with arterial stiffness and CKD were studied.
CTA data acquisition
Examinations were performed on a 64-detector row CT scanner (Aquilion 64, Toshiba 
Medical Systems, Otawara, Japan) or 320-detector row CT scanner (Aquilion ONE, 
Toshiba Medical Systems, Otawara Japan). One hour prior to the scan, heart rate and 
blood pressure were measured in order to administer beta-blockers (50 to 100 mg 
metoprolol, orally) to patients with a heart rate exceeding 65 beats/min and without 
contraindication for beta-blocking agents. First, a non-contrast calcium scan was 
performed with slice thickness of 3.0 mm. Thereafter, CTA was performed with simul-
taneous recording of the electrocardiogram for retrospective (64-detector row scanner) 
or prospective (320-detector row scanner) gating of the data. Scan acquisition param-
eters and scan protocol have been previously described.14, 15 A data set at 75 % of the 
R-R interval was automatically reconstructed with a slice thickness of 0.5 mm and re-
construction interval of 0.3 mm for the 64-detector row scanner and 0.5 mm and 0.25 
mm, respectively, for the 320-detector row scanner. Post-processing and evaluation of 
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the CTA scans were performed on a remote work station with dedicated CTA analysis 
software (Vitrea 2 or Vitrea FX 1.0, Vital Images, Minnetonka, MN, USA). 
DTA atherosclerosis
DTA atherosclerosis was assessed on the axial CTA images by an experienced observ-
er, blinded to patient’s clinical characteristics, arterial stiffness and parameters renal 
function.16 The CTA scan range was adjusted to the heart to limit patients’ radiation 
exposure. Consequently, the DTA was imaged and analyzed for atherosclerosis from 
beneath the aortic arch to the abdominal aorta. 
First, the Agatston calcium score of the DTA was determined on the non-contrast cal-
cium scan. Then, the DTA on CTA was anatomically divided based on the posterior 
intercostal arteries in 5 to 8 segments per scan as shown in Figures 1 to 3. Per segment, 
the site of maximal wall thickness was measured perpendicularly to the center of the 
aorta and evaluated for atherosclerosis (Figure 2 and 3). Any DTA atherosclerosis was 
defined to be present if the aortic wall thickness was ≥2 mm; more specifically, calcified 
DTA atherosclerosis was defined  as aortic wall thickness ≥2 mm with a high-density 
component of atherosclerosis (Figure 3).17 
Good intra- and inter-observer variability has been previously demonstrated for mea-
surement of DTA maximal wall thickness (intraclass correlation coefficients 0.81 and 
0.89) and percentage of DTA segments with atherosclerosis (intraclass correlation coef-
ficients 0.77 and 0.92), and moderate agreement for the presence of DTA atherosclerosis 
(kappa 0.57 and 0.53).16
Figure 1. Evaluation of atherosclerosis in the 
descending thoracic aorta (DTA) on CTA of a 50 
year-old man with a PWV of 7.4 m/s, eGFR of 103 
ml/min/1.73m2, and urinary albumin-creatinine 
ratio (UACR) of 0.7. Panel A shows the segments of 
the DTA by division based on the posterior inter-
costal arteries (red dotted lines). Panels B and C are 
axial images of the DTA at the site of maximal wall 
thickness of the corresponding segments 3 and 5, 




Figure 2. Evaluation of atherosclerosis in the 
descending thoracic aorta (DTA) on CTA of a 54 
year-old woman with a PWV of 10.1 m/s, eGFR of 
66 ml/min/1.73m2, and urinary albumin-creatinine 
ratio (UACR) 0.6. Panels B, C and D are the axial 
images of the DTA at the site of maximal wall 
thickness of the indicated segments, 2, 3 and 5, 
respectively. Panel B reveals no signs of atheroscle-
rosis and a maximal wall thickness of 1.8 mm. Panel 
C and D show the presence of atherosclerosis with 
a maximal wall thickness of 3.3 mm and 2.8 mm, 
respectively. 
Figure 3. Evaluation of atherosclerosis in the 
descending thoracic aorta (DTA) on CTA of a 56 
year-old woman with a PWV of 11.9 m/s, eGFR of 
67 ml/min/1.73m2, and urinary albumin-creatinine 
ratio (UACR) of 1.4. Panels B, C and D are the 
axial images of the DTA at the site of maximal wall 
thickness of the indicated segments, 2, 4 and 6, re-
spectively. Panel B and C reveal atherosclerosis with 
a maximal wall thickness of 2.9 mm and 2.6 mm, 
respectively. Panel D shows the presence of calcified 





Arterial stiffness was non-invasively assessed with applanation tonometry using a 
Sphygmocor system (SphygmoCor, Atcor Medical, Sydney, Australia) with a hand-
held high fidelity tonometer (Millar Instruments, Houston, TX, USA) 18. Patients were 
instructed to abstain from their morning medication and remain fasting until after 
the test. Measurements were performed by a trained technologist, blinded to patient’s 
clinical characteristics, under standardized conditions (during the morning in a quiet, 
temperature controlled clinical research laboratory, after the patient rested ten minutes 
in supine position and a constant heart rate and blood pressure was reached). 
First, the aortic pulse wave velocity (PWV) was calculated as the distance traveled by 
the pulse wave between the carotid and femoral artery, divided by transit time (aver-
aged from 10 consecutive beats) and was determined semi-automatically as previously 
described.19
Thereafter, pulse wave analysis was applied to obtain central aortic pressure waveforms.18 
To this end, peripheral pressure waveforms were recorded on the radial artery at the level 
of the wrist and calibrated by peripheral blood pressures measured at the brachial artery 
with a cuff-sphygmomanometer. The central aortic pressure waveforms were generated 
from the recorded pressure waveforms with a validated generalized transfer function. 
The aortic pressure waveform is composed of a forward pressure wave from ventricular 
contraction and a backward pressure wave from reflection on the peripheral arterial 
system. The central systolic blood pressure (cSBP) and central pulse pressure (cPP) were 
semi-automatically derived from the central aortic pressure waveforms. In addition, the 
augmentation index (Aix), defined as the percentage that the reflected wave contrib-
utes to the pulse pressure, was assessed and normalized to a heart rate of 75 beats per 
minute.20
Chronic kidney disease in patients with diabetes
Chronic kidney disease was assessed by albuminuria (UACR) as a marker of early CKD 
and creatinine clearance (eGFR) as a marker of more advanced CKD. The eGFR was 
calculated with the Modification of Diet in Renal Disease (MDRD) study equation.21 In 
addition, the UACR was determined from an overnight urine sample. Microalbuminuria 
was defined as UACR ≥3.5 mg/mmol.9
Statistical analysis 
Normal distribution of continuous data was checked with the Kolmogorov-Smirnov 
test. Continuous data with normal distribution are presented as mean ± standard devia-
tion and non-normally distributed data as median and interquartile range (25th and 75th 
percentiles). Categorical data are presented as frequencies and percentages. Continuous 
data were compared between patients with and without DTA atherosclerosis with the 
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Student T-test or Wilcoxon sum rank test, as appropriate. Categorical data were com-
pared using the chi-square test.
Univariate associations of the measurements of DTA atherosclerosis with indices of 
arterial stiffness and parameters of renal function were assessed by Spearman’s correla-
tion coefficients. Thereafter, multivariate linear regression analysis was used to detect 
independent associations of DTA atherosclerosis with arterial stiffness and parameters 
of renal function. Non-normally distributed continuous data were log-transformed be-
fore being introduced in the multivariate analysis. The variable of arterial stiffness that 
had the strongest correlation with the measurements of DTA atherosclerosis was used 
in multivariate analyses. The independent association between each DTA atheroscle-
rosis variable and arterial stiffness was corrected for a baseline model including age, 
gender, type 2 DM, hypertension and hypercholesterolemia. The independent asso-
ciation between each DTA atherosclerosis variable and eGFR was corrected for type 
2 DM, hypertension, hypercholesterolemia and arterial stiffness, but not for age and 
gender because the equation of eGFR already corrects for these parameters. Finally, the 
independent association between each DTA atherosclerosis variable and UACR was cor-
rected for the baseline model and arterial stiffness. 
A p value of <0.05 was considered statistically significant. All statistical analyses were 
performed using SPSS for Windows (SPSS version 20.0, Inc., Chicago, IL, USA).
Results
Patient clinical and demographic characteristics
A total of 213 asymptomatic patients with DM were included with a mean age of 52 ± 
12 years; 120 (56%) were men and 121 (57%) had type 2 DM. Clinical and demographic 
characteristics of the entire population and of the patients with versus without DTA 
atherosclerosis are summarized in Table 1. The mean DM duration was 16 ± 13 years, 
132 (62%) patients had hypertension and 44 (21%) microalbuminuria.
DTA atherosclerosis
Atherosclerosis in the DTA was demonstrated in the majority of patients (Table 2). The 
overall median DTA calcium score and mean DTA maximal wall thickness were 3 [0-
42] and 2.7 ± 0.9 mm, respectively. Any form of DTA atherosclerosis was present in 180 
(84%) patients, and calcified DTA atherosclerosis was observed in 51 (24%) patients.
Patients with versus without DTA atherosclerosis
Patients with any DTA atherosclerosis were significantly older, had more often type 2 DM 
and had a higher BMI as compared to patients without DTA atherosclerosis (Table 1). 
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Furthermore, these patients had a higher prevalence of hypertension and hypercholes-
terolemia and a higher coronary artery calcium (CAC) score (Table 1). Moreover, patients 
with DTA atherosclerosis had a significantly increased arterial stiffness, reduced eGFR 
and higher UACR (PWV 8.7±2.7 versus 6.3±1.2 m/s, p<0.01, eGFR 86±22 versus 95±21 
ml/min/1.73m2, p=0.03, and UACR 0.9 [0.5-2.9] versus 0.6 [0.3-1.5], p=0.03, respectively). 
Relation between DTA atherosclerosis and arterial stiffness
All measurements of DTA atherosclerosis were significantly related with all indices of 
arterial stiffness (correlation coefficients provided in Table 3). Amongst the indices of 
arterial stiffness, measurements of DTA atherosclerosis were strongest correlated with 
PWV. Consequently, PWV was used as marker for arterial stiffness in the multivariate 
linear regression analysis. 
After multivariate adjustment for baseline clinical variables, DTA maximal wall thick-
ness was not associated with arterial stiffness (Table 4). However, the DTA calcium score 
remained significantly associated with arterial stiffness (β=0.18, 95% confidence interval 
(CI) 0.01, 0.35, p=0.04), suggesting that the increase in arterial stiffness is independently 
related to calcified DTA atherosclerosis, and not any DTA atherosclerosis (DTA wall 
thickening).
Relation between DTA atherosclerosis and chronic kidney disease
Measurements of DTA atherosclerosis were not consistently related with all parameters 
of renal function (Table 3). Although DTA calcium score and maximal wall thickness 
were significantly correlated with creatinine, the presence of DTA atherosclerosis and 
calcified atherosclerosis were not. In addition, all measurements of DTA atherosclero-
sis were significantly correlated with eGFR and UACR, but no measurement of DTA 
atherosclerosis was correlated with microalbuminuria. Among the parameters of re-
nal function, measurements of DTA atherosclerosis showed the strongest relations with 
eGFR. 
The independent associations of DTA maximal wall thickness and calcium score with 
eGFR or UACR were evaluated in separate multivariate linear regression models (Table 
4). After multivariate correction for baseline clinical variables and arterial stiffness, 
maximal wall thickness and DTA calcium score remained significantly associated with 
eGFR (β=-7.37, 95% CI -10.93, -3.82, p<0.001, and β=-1.99, 95% CI -3.27, -0.71, p=0.003, 
respectively). In contrast, measurements of DTA atherosclerosis were not independently 
associated with UACR. Of note, arterial stiffness was significantly associated with both 
eGFR and UACR after correction for the baseline model. These findings indicate that 
DTA atherosclerosis is not related with all markers of CKD. DTA atherosclerosis was 













Age (years) 52 ± 12 37 ± 8 55 ± 10 <0.01
Male gender 120 (56%) 18 (54%) 102 (57%) 0.82
DM type 2 121 (57%) 10 (30%) 111 (62%) <0.01
DM duration (years) 16 ± 13 13 ± 10 17 ± 13 0.1
Hemoglobin A1c (%) 8.1 ± 1.6 7.8 ± 1.7 8.1 ± 1.6 0.4
Insulin use (y/n) 151 (71%) 27 (82%) 124 (69%) 0.1
Body mass index (kg/m2) 28 ± 6 25 ± 8 29 ± 10 <0.01
Smoking (y/n) 55 (26%) 6 (18%) 49 (27%) 0.3
Hypertension (y/n)* 132 (62%) 7 (21%) 125 (69%) <0.01
Antihypertensive drug use (y/n)* 100 (47%) 4 (12%) 96 (53%) <0.01
Hypercholesterolemia (y/n)* 150 (70%) 18 (54%) 132 (73%) 0.03
Statin use (y/n) 107 (50%) 10 (30%) 97 (54%) 0.01
CAC score 18 [0-203] 0 [0-0] 34 [0-287] <0.01
PWV (m/s) 8.3 ± 2.6 6.3 ± 1.2 8.7 ± 2.7 <0.01
cSBP (mmHg) 124 ± 18 112 ± 14 126 ± 18 <0.01
cPP (mmHg) 43 [36-54] 36 [30-44] 45 [38-56] <0.01
AIx (%) 19.5 ± 11.3 10.6 ± 15.3 21.1 ± 9.6 <0.01
Creatinine (μmol/L) 78 [68-90] 75 [69-82] 78 [68-91] 0.6
eGFR (ml/min/1.73m2) 88 ± 22 95 ± 21 86 ± 22 0.03
UACR 0.9 [0.5-2.5] 0.6 [0.3-1.5] 0.9 [0.5-2.9] 0.03
Microalbuminuria ≥3.5 mg/mmol,
n (%)
44 (21%) 3 (9%) 41 (23%) 0.07
Table 1 Clinical and demographic characteristics, indices of arterial stiffness and parameters of renal func-
tion of the entire population and comparison between patients with versus without DTA atherosclerosis.
Abbreviations: AIx: augmentation index, CAC: coronary artery calcium, cPP: central pulse pressure, cSBP: 
central systolic blood pressure, DM: diabetes mellitus, DTA: descending thoracic aorta, eGFR: estimated 
glomerular filtration rate, PWV: pulse wave velocity, UACR: urinary albumin-creatinine ratio.
* Hypertension was defined as systolic blood pressure ≥140 mmHg, diastolic pressure ≥90 mmHg or use of 
antihypertensive medication.
* Antihypertensive drugs; beta-blockers, angiotensin converting enzyme inhibitors, angiotensin II receptor 
antagonist and calcium antagonists.




DTA variable All patients
n=213
Calcium score 3 [0-42]
Maximal wall thickness (mm) 2.7 ± 0.9
Atherosclerosis (y/n) 180 (84%)
Calcified atherosclerosis (y/n) 51 (24%)
Table 2 DTA atherosclerosis







CAC score 0.41** 0.36** 0.36** 0.47**
Arterial stiffness
  PWV (m/s) 0.31** 0.36** 0.24** 0.39**
  cSBP (mmHg) 0.25** 0.28** 0.24** 0.34**
  cPP (mmHg) 0.30** 0.27** 0.34** 0.37**
  AIx (%) 0.24** 0.26** 0.21** 0.26**
Renal function
  Creatinine (μmol/L) 0.15* 0.04 0.08 0.25**
  eGFR (ml/min/1.73m2) -0.30** -0.16* -0.23** -0.37**
  UACR 0.25** 0.15* 0.14* 0.21**
  Microalbuminuria ≥3.5 mg/mmol(y/n) 0.09 0.12 -0.02 0.13
Table 3 Correlation coefficients of the measurements of DTA atherosclerosis with indices of arterial stiffness 
and parameters of renal 
Abbreviations: AIx: augmentation index, CAC: coronary artery calcium, cPP: central pulse pressure, cSBP: 
central systolic blood pressure, DTA: descending thoracic aorta, eGFR: estimated glomerular filtration rate, 
PWV: pulse wave velocity, UACR: urinary albumin-creatinine ratio.
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0.441 0.42 (-0.09, 0.93)
0.10
0.408 -7.37 (-10.93, -3.82)
<0.001
0.417 0.13 (-0.09, 0.34)
0.24






0.451 0.18 (0.01, 0.35)
0.04
0.370 -1.99 (-3.27, -0.71)
0.003
0.419 0.04 (-0.03, 0.11)
0.29




Table 4 Assessment of independent associations between each DTA atherosclerosis variable and arterial stiff-
ness, eGFR and UACR.
The multivariate linear regression models for the association of DTA maximal wall thickness and calcium 
score with arterial stiffness were corrected for a baseline model including age, gender, type 2 DM, hyperten-
sion and hypercholesterolemia. Multivariate models with renal function as dependent variable were adjusted 
for type 2 DM, hypertension, hypercholesterolemia and arterial stiffness, but not for age and gender because 
the equation of eGFR already corrects for age and gender. Multivariate models with diabetic nephropathy as 
dependent variable were adjusted for the baseline model and arterial stiffness. 
Abbreviations: DTA: descending thoracic aorta, eGFR: estimated glomerular filtration ratio, PWV: pulse 




The present study in asymptomatic patients with DM investigated associations of DTA 
atherosclerosis as assessed on CTA with arterial stiffness and CKD. First, this study 
demonstrated that the DTA calcium score, but not DTA maximal wall thickness, was 
independently associated with arterial stiffness suggesting that the relation between 
aortic atherosclerosis and increased arterial stiffness is mediated by calcified DTA ath-
erosclerosis and not by the presence of any DTA atherosclerosis (defined as DTA wall 
thickening).
Second, DTA atherosclerosis was associated with CKD. After multivariate correction 
for baseline risk factors and arterial stiffness, both DTA calcium score and maximal 
wall thickness were independently associated with eGFR, a marker of advanced CKD, 
whereas DTA atherosclerosis was not independently associated with UACR, a marker 
of early CKD.
Additionally, the relationship between DTA atherosclerosis and CAC score was con-
firmed in asymptomatic patients with DM. Previous general population studies have 
demonstrated that thoracic aortic calcification is determined by similar risk factors as 
coronary artery disease and that thoracic aortic calcification is related with CAC score.22, 23
DTA atherosclerosis and arterial stiffness
The presence of DTA atherosclerosis has been related to increasing arterial stiffness, spe-
cifically, different studies have shown the relation between calcified DTA atherosclerosis 
and  increased arterial stiffness.7, 8 In a community-based cohort with 193 healthy volun-
teers increasing aortic calcification (assessed by 16-slice CT) was independently associated 
with increased aortic PWV.7 An open question is whether any DTA atherosclerosis (in the 
current study expressed as increased aortic wall thickness) relates to increased arterial 
stiffness or whether the presence of calcified DTA atherosclerosis is required to result in 
increased arterial stiffness. Brandts and coworkers evaluated 15 patients with essential 
hypertension and 15 age-matched healthy volunteers with magnetic resonance imaging 
(MRI); the authors demonstrated that aortic wall thickness (derived from 10 contiguous 
slices at the height of the 8 vertebra) was significantly related with arterial stiffness, as 
assessed by aortic PWV measured on MRI.4 In contrast, Cecelja et al. evaluated 100 post-
menopausal female twins with MRI and demonstrated that  aortic PWV did not increase 
in parallel to increasing aortic atherosclerotic plaque burden, but that there was  a relation 
between aortic PWV and aortic calcium score on non-contrast CT images.6 In the present 
study, an independent association between DTA calcium score and aortic PWV was ob-
served in asymptomatic patients with DM, but the presence of any DTA atherosclerosis or 
DTA maximal wall thickness (markers of DTA atherosclerosis independent of calcium) 
were not significantly associated with PWV after multivariate correction for baseline 
clinical risk factors. These observations suggest that increased arterial stiffness is related 
to calcified DTA atherosclerosis rather than any DTA atherosclerosis.
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DTA atherosclerosis and chronic kidney disease
Chronic kidney disease in patients with diabetes can be measured by eGFR and 
UACR. These two parameters reflect different stages of CKD, with UACR preceding 
the reduction in eGFR. Previous work has addressed the associations between aortic 
atherosclerosis and eGFR or UACR. 
Concerning the relation between aortic atherosclerosis and eGFR, Desai and coworkers 
evaluated maximal thickness of atherosclerotic plaque in the aortic arch and DTA on 
transesophageal echocardiography (TEE) in 200 consecutive patients clinically referred 
for TEE.24 The thickness of atherosclerotic plaque increased in parallel to the reduc-
tion of eGFR and was independently associated with severe CKD, defined as eGFR <30 
ml/min/1.73m2. Another TEE study by Haruki et al. analyzed atherosclerotic plaque in 
the DTA in 350 consecutive patients who underwent clinically indicated 3-dimensional 
TEE.25 Patients with DTA atherosclerotic plaque had a significantly reduced eGFR. In 
addition, a Japanese study investigated the association of atherosclerosis in the coro-
nary arteries and aorta with renal function in 149 patients who underwent coronary 
angiography for suspected or known CAD and magnetic resonance imaging (MRI) of 
the aorta. The authors demonstrated that atherosclerosis in the coronary arteries was 
independently associated with reduced eGFR, whereas the association of atherosclerosis 
in the thoracic aorta with eGFR lost significance after multivariate correction.26 The cur-
rent findings are in line with and expand these previous studies and the novelty is that 
the current study used CT for imaging of aortic atherosclerosis, highlighting that non-
calcified and calcified DTA atherosclerosis are related with reduced eGFR. Moreover, the 
association of increased arterial stiffness with reduced eGFR was weakened when DTA 
atherosclerosis was entered to the multivariate model. 
Concerning the relation between aortic atherosclerosis and UACR, one study assessed 
the association of aortic atherosclerosis with UACR, while various studies investigated 
the association of carotid intima-media thickness (CIMT) with diabetic nephropathy. 
Kim et al. performed MRI in patients with type 1 DM, and atherosclerosis in the aorta 
was compared between 63 patients with macroalbuminuria (defined as urinary albumin 
excretion rate >300 mg/24 h) and 73 patients with normoalbuminuria.27 However, the 
prevalence of atherosclerosis in the thoracic aorta was only 3%  in patients with macroal-
buminuria versus 0% in patients with normoalbuminuria. A Korean population study 
assessed the association of CIMT with UACR  in 7555 participants.28 The increase in 
CIMT was independently associated with a higher UACR. However, another Korean 
study including 673 patients with type 2 DM did not observe any association between 
CIMT or carotid atherosclerotic plaque and UACR.29 Shin et al. also demonstrated that 
CIMT was not associated with microalbuminuria (defined as UACR of 30-300 mg/g) in 
218 patients with newly diagnosed type 2 DM.30 
In the present study, early CKD as indicated by UACR showed no relation with athero-
sclerosis, whereas advanced CKD as indicated by reduced eGFR, was related with DTA 
atherosclerosis. How the temporal development of aortic atherosclerosis and the differ-
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ent stages of CKD relate, needs further evaluation in longitudinal studies assessing both 
aortic atherosclerosis and CKD periodically.
Limitations
The present study has several limitations. The cross-sectional nature of the present study 
precludes assessment of causality of DTA atherosclerosis with arterial stiffness or CKD. 
The spatial resolution of CTA precludes differentiation of the intima and media layers 
of the aortic wall. Furthermore, aortic atherosclerosis was assessed on CTA images with 
the scan range adjusted to the patient’s heart to reduce radiation exposure. This excludes 
analysis of atherosclerosis in the ascending thoracic aorta, aortic arch and abdominal 
aorta.
Conclusions 
In the present study in asymptomatic patients with DM, the DTA calcium score was inde-
pendently associated with arterial stiffness, but not any DTA atherosclerosis, indicating 
that arterial calcification mediates the increase in arterial stiffness by atherosclerosis. 
Furthermore, DTA atherosclerosis was independently associated with eGFR, a marker 
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South Asians in the Western world have a high prevalence of diabetes mellitus (DM) 
and increased risk of coronary artery disease (CAD) and mortality as compared to 
Caucasians. CAD in asymptomatic South Asian patients with type 2 DM has not been 
investigated. The aim of this observational cohort-study was to investigate CAD in as-
ymptomatic South Asian patients with type 2 DM and compare with matched Caucasian 
patients. A total of 120 asymptomatic South Asian type 2 DM patients and matched 
Caucasian patients (mean age 52 years, 55% male) were derived from an ongoing registry 
of cardiovascular risk stratification in asymptomatic patients with DM. Cardiovascular 
risk assessment included multi-detector row computed tomography coronary angiog-
raphy. CAD was assessed as the coronary artery calcium (CAC) score and classified in: 
no signs of atherosclerosis or minor wall irregularities <30%, non-significant CAD 30-
50%, or significant CAD ≥50% stenosis. On a patient base, CAD was scored according to 
severity and number of vessels and segments with significant CAD. Subsequently, CAD 
was assessed per coronary artery and per segment. As compared to Caucasian patients, 
South Asian patients had a significantly higher CAC score and higher prevalence of sig-
nificant CAD (41% vs. 28%, p=0.008), involving more coronary vessels and segments. 
Significant CAD was especially more frequent in the left anterior descending coronary 
artery. In conclusion, asymptomatic South Asian patients with type 2 DM have a higher 




Several studies have demonstrated that South Asian individuals in the Western world 
have more severe CAD and higher cardiovascular mortality as compared to Caucasian 
individuals.1, 2 However, differences in CAD between asymptomatic South Asian and 
asymptomatic Caucasian patients with DM type 2 have not been investigated. Multi 
detector row computed tomography coronary angiography (coronary CTA) is a well 
validated modality for the non-invasive assessment of CAD and allows assessment of the 
CAD and plaque composition.3, 4 Therefore, the aim of the current study was to assess 
CAD in asymptomatic South Asian patients with DM type 2 with coronary CTA and to 
compare with matched asymptomatic Caucasian patients with DM type 2.
Methods
South Asian patients with DM type 2 were enrolled from an ongoing registry of cardio-
vascular risk stratification in asymptomatic patients with DM in the Leiden University 
Medical Center, the Netherlands.5 These South Asians patients are ‘Surinamese South 
Asian immigrants’ whose ancestors were recruited from North India from 1873 until 
1916 to work on plantations in Suriname.6 In 1975 around the independence of Suriname 
a large group of Surinamese South Asians settled in The Hague. Cardiovascular risk 
stratification contained a structured clinical history, physical examination, blood and 
urine laboratory testing and coronary CTA for the evaluation of CAD. South Asian 
ethnicity was established in the anamnesis.7 
South Asian patients were individually matched with asymptomatic Caucasian patients 
with DM type 2, based on age, gender, DM duration and BMI. Since South Asian individ-
uals have increased abdominal fat storage and higher insulin resistance at similar BMI 
levels, a lower obesity cut-off BMI is recommended by the World Health Organization.8 
In line with this, South Asian patients were matched to Caucasian patients with a higher 
BMI. 
Patients were diagnosed DM type 2 in the absence of demonstrable auto-antibodies to 
islet cells, insulin and glutamic acid decarboxylase or low levels of plasma C-peptide 
levels, according the American Diabetes Association criteria.9 Inclusion criteria were 
DM type 2, asymptomatic status as confirmed by the Rose questionnaire on chest pain,10 
no previous myocardial infarction, coronary revascularization or cardiac surgery, and a 
coronary CTA of diagnostic image quality for the assessment of CAD.
Clinical and demographic data were prospectively collected in the departmental cardi-
ology information system (EPD-Vision version 8.3.3.6; Leiden, The Netherlands) and 
were retrospectively analyzed. The Institutional Review Board of the Leiden University 
Medical Center approved the retrospective evaluation of clinically collected data and 
waived the need for written informed consent.
Coronary CTA was performed on a 64-detector row CT scanner (Aquilion 64, Toshiba 
Medical Systems, Otawara, Japan) or a 320-detector row CT scanner (Aquilion ONE, 
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Toshiba Medical Systems). Scan parameters of these CT scanners have been previously 
described.3, 4 
One hour before the scan, heart rate and blood pressure were measured to administer 
beta-blockers (25 to 100 mg metoprolol, orally) in patients with a heart rate ≥65 beats/
min, unless contraindicated. In addition, immediately prior to the coronary CTA scan, 
nitroglycerin 0.4 mg was administered sublingual.
The scan protocol commenced with a non-contrast scan of the heart with slice thickness 
of 3.0 mm for the coronary artery calcium (CAC) score. Subsequently, coronary CTA 
was started with the injection of non-ionic contrast media (Iomeron 400, Bracco, Milan, 
Italy) in the antecubital vein in a bolus of 60 to 110 ml with a flow rate of 5-6 mL/s (ad-
justed to patient’s weight), followed by a saline flush. Coronary CTA image acquisition 
was triggered using automated peak enhancement detection with the region of interest 
in the left ventricle. Scanning was completed during a single breath-hold of approxi-
mately 10 seconds. Data was retrospectively (64-row scanner) or prospectively (320-row 
scanner) gated by recording of the electrocardiogram during the scan. An initial data 
set was automatically reconstructed at 75% phase of the R-R interval. In case of limited 
image quality or motion artifacts, additional data sets of different phases in the R-R 
interval were reconstructed. 
Coronary CTA scans were post-processed and evaluated on a remote work station us-
ing dedicated coronary CTA analysis software (Vitrea 2 or Vitrea FX 1.0, Vital Images, 
Minnetonka, MN, USA). First, the Agatston CAC score was measured on the non-con-
trast calcium scan. Thereafter, the coronary CTA data set with the best image quality was 
selected for the evaluation of the coronary arteries. Coronary CTA scans were analysed 
by two experienced observers in consensus, blinded to patient’s clinical and demo-
graphic characteristics. The coronary artery system was divided according the modified 
American Heart Association classification into a 17-segment model.11 All segments were 
evaluated for the presence of atherosclerotic plaque, defined as a structure >1 mm2 with-
in and/or adjacent to the coronary artery lumen that could clearly be distinguished from 
the coronary artery lumen and surrounding tissue.12 For each atherosclerotic plaque the 
severity of luminal stenosis was visually determined from the axial images and curved 
multiplanar reconstructions in at least two orthogonal planes (see Figure 1). Per segment 
luminal stenosis was graded based on the most severe stenosis as follows: 1. no signs 
of atherosclerosis or minor wall irregularities <30 % stenosis, 2. non-significant CAD 
30-50 % stenosis or 3. significant CAD ≥50 % stenosis.13 In addition, the predominant 
atherosclerotic plaque composition was scored as non-calcified plaque (consisting of 
only low-density plaque), calcified plaque (consisting of only high-density plaque) or 
mixed plaque (consisting of both low- and high-density plaque). Local non-interpretable 
segments were excluded from further analysis.
Patients were stratified according to the segment with the most severe stenosis grade.13 
Significant narrowing was assessed per coronary artery and significant one-vessel, 
two-vessels and three-vessels CAD. In addition the Gensini score was calculated.14 
Subsequently, the location of CAD narrowing in proximal and distal coronary segments 
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was determined. Finally, the presence of any CAD (≥30 % stenosis) was assessed per 
coronary artery and per segment.
Continuous data were checked for normal distribution with the Kolmogorov-Smirnov 
test. Normal distributed continuous data are presented as mean ± standard deviation 
and non-normally distributed continuous data as median (25th and 75th percentiles). 
Categorical data are presented as frequencies and percentages. Comparisons of con-
tinuous data between asymptomatic South Asian and Caucasian patients with DM type 
2 were performed with the independent Student T-test, one-way analysis of variance or 
Mann-Whitney U test, as appropriate. Categorical data were compared with the chi-
square test. A p value of <0.05 was considered statistically significant. All statistical 
analyses were performed with SPSS (SPSS version 20.0, Inc., Chicago, IL, USA).
Results
A total of 120 asymptomatic South Asian patients with DM type 2 were included and in-
dividually matched with asymptomatic Caucasian patients with DM type 2. The baseline 
clinical and demographic patient characteristics are presented in Table 1. The overall 
mean age was 53±10 years, 55% were men and mean DM duration 11±8 years. Because 
South Asian patients were matched to Caucasian patients with a higher BMI, they had 
a significantly lower BMI and waist circumference. Furthermore, South Asian patients 
Figure 1 Example of coronary CTA in an asymptomatic South Asian patient with DM type 2, showing 
multivessel coronary artery disease. The left upper panel shows an axial image of the LM and proximal LAD. 
The other panels represent the multi-planar reconstructions of the indicated coronary arteries. The distal LM 
contains a mixed plaque with significant stenosis, which continues in the ostium of the LAD (indicated with 
the white arrow). The mid segment of the RCA contains a non-calcified plaque with significant stenosis (indi-
cated with the white arrow). The proximal segment of the LCx contains a calcified plaque without significant 
stenosis (indicated with the white arrow)
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had a significantly higher prevalence of peripheral artery disease (21 vs. 10 %, p=0.04). 
Other baseline clinical risk factors were similar.
Coronary CTA results and p-values for comparison are presented in Table 2. South Asian 
patients had a significantly higher presence and extent of CAC. Moreover, the presence 
of significant CAD was significantly higher: 49 (41%) versus 33 (28%) patients, p=0.008. 
The presence of significant one-, two-, and three-vessel CAD was significantly high-
er, especially the left anterior descending coronary artery (LAD) was more frequently 
affected. Also, the Gensini score was significantly higher. There was no significant dif-
ference in coronary plaque composition. 
On a vessel base, any CAD (≥30% stenosis) was significantly more frequent in the left 
main (LM) and LAD in South Asian patients, but was not different in the left circumflex 
(LCx) and right coronary artery (RCA). In addition, any CAD (≥30% stenosis) was more 
frequent in proximal coronary artery segments. On a segment base, CAD narrowing was 
significantly more frequent and severe in the LM coronary artery, the proximal and mid 









Age (years) 53 ± 10 52 ± 10 53 ± 9 0.4
Men 132 (55%) 66 (55%) 66 (55%) 1
DM duration (years) 11 ± 8 12 ± 8 11 ± 8 0.5
Body mass index (kg/m2) 29 ± 6 28 ± 5 30 ± 6 <0.01
Waist circumference (cm) 101 ± 16 98 ± 16 104 ± 14 <0.01
Hemoglobin A1c (%) 7.9 ± 1.6 7.8 ± 1.6 7.9 ± 1.6 0.6
Insulin treatment (y/n) 112 (47%) 43 (36%) 69 (58%) <0.01
DM complication (y/n)* 99 (41%) 53 (44%) 46 (38%) 0.4
Hypertension (y/n)* 161 (67%) 81 (68%) 80 (67%) 1.0
  Systolic blood pressure (mmHg) 136 ± 18 134 ± 17 138 ± 18 0.1
  Diastolic blood pressure (mmHg) 83 ± 10 83 ± 11 84 ± 10 0.5
  Antihypertensive drug use (y/n)* 137 (57%) 70 (58%) 67 (56%) 0.7
Hypercholesterolemia (y/n)* 185 (77%) 91 (76%) 94 (78%) 0.8
  Total cholesterol (mmol/L) 4.6 ± 1.1 4.4 ± 1.1 4.7 ± 1.1 0.09
  Statin use (y/n) 161 (67%) 87 (73%) 74 (62%) 0.07
Smoking (y/n) 60 (25%) 32 (27%) 28 (23%) 0.6
Stroke or transient ischemic attack 12 (5%) 7 (6%) 5 (4%) 0.5
Peripheral artery disease 31 (13%) 21 (18%) 10 (8%) 0.04
  ACE inhibitor 61 (25%) 31 (26%) 30 (25%) 0.9
  AT II antagonist 66 (28%) 29 (24%) 37 (31%) 0.2
  Beta blocker 26 (11%) 13 (11%) 13 (11%) 1
  Calcium antagonist 25 (10%) 12 (10%) 13 (11%) 0.8
  Aspirin 46 (19%) 21 (18%) 25 (21%) 0.5
Plasma creatinine (μmol/L) 78 ± 24 77 ± 29 78 ± 18 0.7
eGFR (ml/min/1.73m2)* 93 ± 28 96 ± 33 89 ± 21 0.04
Table 1 Baseline clinical and demographic characteristics of all patients and comparison between asymptom-
atic South Asian and matched Caucasian patients with DM type 2
Abbreviations: ACE: angiotensin converting enzyme, AT II: angiotensin II receptor, CAD: coronary artery 
disease, DM: diabetes mellitus, eGFR: estimated glomerular filtration rate.
* DM complication included retinopathy, nephropathy, neuropathy and peripheral vascular disease as de-
rived from the structured clinical history.
* Hypertension: systolic blood pressure ≥140 mmHg, diastolic pressure ≥90 mmHg or use of antihypertensive 
medication.
* Antihypertensive drug use included angiotensin converting enzyme inhibitors, angiotensin II receptor 
antagonist, beta-blockers and calcium antagonists.
* Hypercholesterolemia was defined as serum total cholesterol ≥5 mmol/L or use of statins.













Dominant right coronary 183 (76%) 90 (75%) 93 (78%) 0.6
Coronary artery calcium (CS ≥1) 143 (60%) 79 (66%) 64 (53%) 0.03
Total Agatston calcium artery score 16 (0-149) 26 (0-205) 3 (0-99) 0.03
Normal or wall irregularities <30% 82 (34%) 32 (27%) 50 (42%)
Non-significant CAD 30-50% 76 (32%) 39 (33%) 37 (31%)
Significant CAD ≥50% 82 (34%) 49 (41%) 33 (28%)
Gensini score 6 ± 8 8 ± 9 5 ± 7 <0.01
No. of coronary arteries narrowed 0.03
   1 44 (18%) 26 (22%) 18 (15%)
   2 24 (10%) 13 (11%) 11 (9%)
   3 14 (6%) 10 (8%) 4 (3%)
Coronary artery narrowed
   left main 3 (1%) 3 (3%) 2 (2%) 0.08
   left anterior descending 68 (28%) 42 (35%) 26 (22%) 0.02
   left circumflex 30 (13%) 18 (15%) 12 (10%) 0.2
   right 33 (14%) 19 (16%) 14 (12%) 0.3
Location of CAD narrowing
   proximal ≥30%* 128 (53%) 76 (63%) 52 (43%) <0.01
   distal ≥30%* 133 (55%) 71 (59%) 62 (52%) 0.2
   proximal ≥50% 47 (20%) 29 (24%) 18 (15%) 0.07
   distal ≥50% 68 (28%) 43 (36%) 25 (21%) 0.01
Number of segments narrowed
   ≥30% 2.7 ± 2.9 3.1 ± 3.0 2.3 ± 2.8 0.03
   30-50% 1.9 ± 2.0 2.1 ± 2.1 1.7 ± 2.0 0.1
   ≥50% 0.8 ± 1.4 1.0 ± 1.6 0.6 ± 1.2 0.03
Coronary plaque composition
   Non-calcified 1.4 ± 1.5 1.4 ± 1.8 1.5 ± 1.2 0.5
   Mixed 1.7 ± 1.9 1.8 ± 1.8 1.7 ± 1.9 0.7
   Calcified 1.0 ± 1.6 1.2 ± 1.7 0.8 ± 1.5 0.2
Table 2 Coronary artery disease as assessed with coronary CTA of all patients and comparison between 
asymptomatic South Asian and matched Caucasian patients with DM type 2.
Abbreviations: CAD: coronary artery disease, CS: calcium score.
* Proximal CAD narrowing was defined as narrowing in the left main coronary artery or in the proximal seg-
ment of the left anterior descending coronary artery, circumflex coronary artery or right coronary artery.




In the present study, asymptomatic South Asian patients with DM type 2 had a higher 
presence, severity and extent of CAD as compared to individually matched asympto-
matic Caucasian patients with DM type 2. More specifically, the presence and extent of 
CAC was higher. Significant CAD (≥50% stenosis) was significantly more frequent in 
South Asian patients, involving a higher number of coronary arteries and segments and 
particularly more frequently the LAD. 
South Asians living in an urban or Western environment are highly susceptible to de-
velop DM type 2. The age-standardized prevalence rate of DM type 2 in South Asian 
men and women in the Netherlands has been reported as high as 27.4%, approximately 
4-fold higher than Caucasian men and women.15 In the Southall and Brent study, the 
presence of DM in 1420 South Asian men was associated with a nearly 3-fold increased 
risk of CAD mortality.1 Thus, South Asian individuals have a high prevalence of DM, 
which contributes to their increased risk of CAD.
At present, only few studies investigated the presence, severity and extent of CAD in 
South Asian subjects. A recent study evaluated CAD in patients with suspected CAD 
using invasive quantitative coronary angiography, including 63 South Asian patients 
as compared to 61 Caucasian patients.2 South Asian patients had more severe CAD as 
shown by a higher mean percentage stenosis per vessel and more patients with multives-
sel CAD.
Coronary CTA showed similar CAC scores in asymptomatic subjects under the age of 50 
years, but above this age CAC scores were higher in South Asians.16 In a study by Tillin 
et al. CAC scores in the LAD of 41 South Asian patients with CAD with mean age of 61 
years were comparable to 42 Caucasian patients with mean age of 67 years.17 Moreover, 
Koulaouzidis et al. investigated CAD with coronary CTA in 101 South Asian patients 
and their age and gender matched Caucasian counterparts in London.18 South Asian pa-
tients above the age of 50 years had a significantly higher coronary artery calcium score, 
a higher mean number of segments with CAD and more multivessel CAD. 
In line with these studies, asymptomatic South Asian patients with DM type 2 in 
the present study had more severe and extensive CAD as compared to Caucasian pa-
tients. Nevertheless, only a few studies investigated the severity and extent of CAD in 
South Asians.2, 18 The novelty of the present study is the fact that CAD was evaluated in 
South Asian patients with DM type 2, who were asymptomatic. By this means, a high 
prevalence of significant CAD (≥50%) of 41% was observed. As compared to available 
literature, the prevalence of significant CAD on CTA reported in the large diabetes co-
hort (n=3370) of the CONFIRM (COronary CT Angiography EvaluatioN For Clinical 
Outcomes: An InteRnational Multicenter Registry) study was 37%.19
In patients with suspected CAD, South Asians have been demonstrated to have signifi-
cantly higher mean percentage stenosis in the proximal and distal LAD and proximal 
RCA as compared to Caucasians.2 Another study demonstrated that CAD (≥25% ste-
nosis) on coronary CTA was more frequent in all coronary arteries, with the highest 
158
CHAPTER 9
prevalence in the LAD.18 The present study extends these findings, by demonstrating 
that CAD was more frequent in proximal coronary artery segments, especially the LM 
and LAD, in asymptomatic South Asian patients. This proximal distribution of CAD has 
been associated with an increased risk for coronary events and worse outcome.20
South Asians have a higher prevalence of CAD events at a younger age. The Southall and 
Brent study evaluated CAD events in 1517 South Asians and 2049 Caucasians over 20 
years follow-up.21 South Asians had a 1.5 to 3-fold higher incidence rate of CAD events. 
Individual risk factors explained only a portion of the excess risk in South Asians. Other 
studies have demonstrated that the younger age of cardiac events in South Asian subjects 
was related with their increased cardiovascular risk profile at younger age.22,23 
In the present study, CAD was assessed in a local Dutch cohort of asymptomatic South 
Asian patients with DM type 2. Because local environment influences cardiovascular 
risk in South Asians, findings of the present study might not be generalizable to South 
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In Chapter 1, a general introduction on diabetes mellitus (DM) and the correlated in-
creased cardiovascular risk is provided. Risk stratification remains challenging and the 
current risk score models have limited applicability. New markers of coronary artery 
disease (CAD) of non-invasive cardiac imaging might improve the predictive ability of 
current risk scores and allow for the initiation of patient tailored therapeutic strategies 
for the prevention of cardiovascular events. The aim of this thesis was to determine the 
potential role of non-invasive cardiac imaging in cardiovascular risk stratification and 
management in patients with DM.
Chapter 2 reviews the pathophysiology from obesity to CAD. First, obesity induced 
mechanisms and mediators involved in the development of CAD are described and sub-
sequently several mediators are evaluated for their applicability as a biomarker for the 
identification of patients with CAD. Although some of these mediators showed a good 
predictive value for CAD, incremental value beyond established cardiovascular risk fac-
tors needs to be validated.
Chapter 3 describes non-invasive cardiac imaging of coronary artery anatomy using 
coronary computed tomography angiography (CTA) and ischemia assessment with 
single photon emission computed tomography (SPECT) myocardial perfusion imaging 
(MPI). Additionally, the feasibility and potential clinical value of combined anatomic 
and functional imaging for patient management are discussed. The results of hybrid 
imaging using coronary CTA and SPECT MPI seem to have incremental clinical value, 
as compared to either technique alone or side-by-side analysis.
Chapter 4 investigates whether arterial stiffness could be used for the identification 
of patients with DM with stress perfusion defects on SPECT MPI. In 160 DM patients 
(mean age 51 years, 54% male and 57% type 2 DM) arterial stiffness was non-inva-
sively measured with applanation tonometry as the carotid-femoral pulse wave velocity 
(PWV) and radial augmentation index (AIx). Stress myocardial perfusion defects were 
derived from SPECT MPI by evaluation of the summed stress score (SSS). Abnormal 
MPI (SSS >3) was sub-classified as moderate (SSS 3-7) or severe (SSS ≥8) MPI defects. 
Arterial stiffness increased in parallel with the severity of perfusion defects. After multi-
variate adjustment for age and other risk factors, PWV remained a significant predictor 
of severe MPI defects, but AIx was not. In conclusion, vascular stiffness as measured by 
PWV is strongly associated with severe MPI defects in DM patients. Accordingly, PWV 
could be a useful technique to identify patients with DM at elevated risk for CAD.
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Chapter 5 studies associations between indices of arterial stiffness and left ventricular 
(LV) diastolic function as assessed with echocardiography in DM patients. A total of 
142 patients (mean age 48 years, 53% male and 51% type 2 DM) underwent applanation 
tonometry and transthoracic echocardiography. Indices of arterial stiffness included 
PWV, central systolic blood pressure (cSBP), central pulse pressure (cPP) and AIx and 
parameters of LV diastolic function were E/A ratio, E’, E/E’ ratio and grade of LV dias-
tolic dysfunction. PWV was independently associated with the severity of LV diastolic 
dysfunction, whereas cPP, cSBP and AIx were independently related with E/A ratio, but 
not with the LV diastolic dysfunction grade. Thus, indices of arterial stiffness are associ-
ated with echocardiographic parameters of LV diastolic function in DM patients. These 
observations suggest that therapies reducing arterial stiffness could help to prevent the 
development of LV diastolic dysfunction.
Chapter 6 assesses the change in LV function after 2 years follow-up with conven-
tional and 2-dimensional speckle tracking echocardiography in clinically stable type 
2 DM patients. A total of 112 patients with normal LV ejection fraction were included 
(mean age 53 years, 59% male), who underwent baseline transthoracic echocardiography 
and a repeated examination after at least 2 years follow-up. Circumferential (CS) and 
longitudinal strain (LS) were measured to assess systolic function and strain rate dur-
ing isovolumetric relaxation time (SR IVR) and peak transmitral early diastolic inflow 
strain rate (SR E) to asses diastolic function. After 2 years follow-up, conventional echo-
cardiography demonstrated no differences in LV volumes and ejection fraction (EF), 
although there was a significant increase in LV mass index and decrease in E/A ratio. In 
contrast, 2D speckle tracking echocardiography showed a small significant impairment 
in CS (-19.7±4.0% to -18.9±3.8%), LS (-17.2±2.3% to -16.9±2.7 %) and SR E (1.02±0.28 S-1 
to 0.94±0.25 S-1). The changes in CS and SR E remained significant when adjusted for 
the change in LV mass index. In conclusion, type 2 DM patients and normal LV ejection 
fraction may show mild deterioration of subclinical LV function after 2 years follow-up, 
which can be detected by 2D speckle tracking echocardiography. The prognostic impli-
cations of these mild changes warrant prospective evaluation. 
Chapter 7 performs a comprehensive analysis of atherosclerosis in the descending tho-
racic aorta (DTA) on coronary CTA in patients with suspected CAD, and evaluates the 
association of DTA atherosclerosis with CAD. A total of 344 patients were included 
(mean age 54 years, 54% male) with a coronary CTA of diagnostic image quality to as-
sess CAD and complete display of the DTA. Analysis of DTA atherosclerosis included 
the DTA calcium score, maximal wall thickness and presence of atherosclerotic plaque. 
Coronary CTA were classified based on CAD severity in no signs of atherosclerosis or 
minor wall-irregularities <30%, non-significant CAD 30-50%, or significant CAD ≥50% 
stenosis. DTA atherosclerotic plaque was observed in 81% of the patients and overall 
DTA maximal wall thickness was 2.7±1 mm. The presence, severity and extent of DTA 
atherosclerosis increased in parallel to the increase in CAD severity. Moreover, after 
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multivariate correction for age and other risk factors the presence of DTA atherosclerotic 
plaque and maximal DTA wall thickness were independently associated with significant 
CAD. In conclusion, a high prevalence of DTA atherosclerosis on coronary CTA was 
observed, which was independently related with the presence of significant CAD.
Chapter 8 studies whether DTA atherosclerosis assessed on coronary CTA is associ-
ated with arterial stiffness and measures of renal function. In 213 DM patients (mean 
age 52 years, 56% male) coronary CTA, applanation tonometry and assessment of renal 
function were performed for cardiovascular risk stratification. DTA atherosclerosis was 
present in 84% patients and overall maximal wall thickness was 2.7±0.9 mm. Patients 
with DTA atherosclerosis had increased arterial stiffness (as shown by increased PWV 
and AIx) and worse renal function (as indicated by lower estimated glomerular filtra-
tion rate (eGFR) and higher urinary albumin creatinine ratio (UACR) values). After 
multivariate correction, DTA calcium score was independently associated with PWV. 
Furthermore, both DTA calcium score and DTA maximal wall thickness were inde-
pendently associated with eGFR, but not with UACR. These findings suggest that 
atherosclerosis increases arterial stiffness via arterial calcification, while the DTA cal-
cium score was independently associated with arterial stiffness, but not DTA maximal 
wall thickness. Furthermore, parameters of renal function in patients with DM had a 
distinct relationship with DTA atherosclerosis: DTA atherosclerosis was associated with 
eGFR but not with UACR.
Chapter 9 compares the presence, severity and extent of CAD in type 2 DM South 
Asian patients and matched Caucasian patients. South Asians in the Western world have 
a high prevalence of DM and an increased rate of CAD events. CAD was assessed with 
coronary CTA in 120 South Asian patients and matched Caucasian patients (mean age 
52 years, 55% male). CAD was classified based on severity (no signs of athero- sclerosis 
or minor wall irregularities <30%, non-significant CAD 30-50% or significant CAD 
≥50% stenosis) and scored on a patient base by the most severe stenosis and the number 
of vessels and segments with significant CAD. As compared to Caucasian patient, South 
Asian patients had a significantly higher prevalence of significant CAD (41% vs.28%), 
involving more coronary vessels and segments. Therefore, this chapter demonstrates 
that type 2 DM South Asian patients have a higher presence, severity and extent of CAD 
as compared to matched Caucasian patients.
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Conclusions and future perspectives
New markers of CAD might benefit availability of cardiovascular risk stratification to 
the large population of DM patients. In addition to plasma biomarkers, non-invasive 
cardiac imaging can be of use for improved cardiovascular risk assessment in DM pa-
tients. The different studies in this thesis demonstrated that arterial stiffness measured 
as carotid-femoral PWV was independently related with calcified DTA atherosclerosis, 
decreased coronary artery function and target organ damage. Measurement of arterial 
stiffness is easy to perform, non-invasive and of low cost. Therefore, arterial stiffness 
measured as PWV is suggested as a good marker of CAD and may be a first-line ap-
proach for cardiovascular risk assessment of DM patients. Further studies are needed to 
validate the incremental clinical value in DM patients, before implementation in daily 
clinical practice. 
In addition, DTA atherosclerosis on coronary CTA was independently associated with 
the presence of significant CAD and target organ damage. Further studies could com-
pare the performance of DTA atherosclerosis for the identification of DM patients 
at increased risk for significant CAD versus other markers of subclinical coronary 
atherosclerosis.
2D speckle tracking echocardiography allows assessment of subtle changes in LV func-
tion and demonstrated mild deterioration in LV function in type 2 DM patients after 2 
year follow-up. Therefore, it seems a useful modality for monitoring progression of sub-
clinical LV dysfunction in order to titrate individual medication to prevent development 
of heart failure, but further studies are clearly needed. 
Finally, South Asians patients with type 2 DM were demonstrated to have more severe 
and extensive CAD as compared to Caucasian patients. This observation suggests that 
an individual’s cardiovascular risk is also determined by ethnicity and that a low thresh-






Hoofdstuk 1 vormt een algemene inleiding op het onderwerp diabetes mellitus (DM) 
en het daarmee verbonden verhoogde risico op coronairlijden (CAD). Er is behoefte aan 
verbetering in risicostratificatie in patiënten met DM en de bestaande risicomodellen 
hebben slechts beperkte geschiktheid. Nieuwe markers van CAD verkregen met niet-
invasieve beeldvormingstechnieken van het hart, al dan niet gebruikt in combinatie met 
de bestaande risicomodellen, zouden kunnen leiden tot verbetering in risicostratificatie. 
Op basis hiervan kan het medische behandelplan voor het voorkomen van een hartin-
farct of hartstilstand per patiënt worden geoptimaliseerd. Het doel van dit onderzoek 
was om vast te stellen wat het mogelijk aandeel is van niet-invasieve beeldvorming-
stechnieken van het hart voor risicostratificatie op CAD en het optimaliseren van de 
medische behandeling in patiënten met DM.
Hoofdstuk 2 geeft een overzicht van hoe obesitas aanleiding geeft tot de ontwikkel-
ing van CAD. Allereerst worden verschillende factoren en mechanisme besproken die 
door obesitas worden gestimuleerd en betrokken zijn bij de ontwikkeling van CAD. 
Vervolgens wordt op basis van de literatuur gekeken naar de toepasbaarheid van dergeli-
jke factoren als biomarker voor het onderscheiden van personen met CAD. Enkele van 
deze factoren toonden een goede relatie met CAD. Echter, tot op heden is er geen bewijs 
dat het gebruik van dergelijke biomarkers leidt tot betere onderscheiding van patiënten 
met CAD, dan erkende risicofactoren van CAD.
Hoofdstuk 3 beschrijft niet-invasieve beeldvorming van de anatomie van de coro-
naire arteriën met computed tomography (CT) coronair angiografie (coronaire CTA) 
en ischemie (functie van de coronaire arteriën) middels myocardperfusiescintigrafie 
(MPI SPECT). Daarnaast wordt de klinische waarde bediscussieerd van gecombineerde 
beeldvorming, anatomie en functie van de coronaire arteriën, voor de behandeling 
van de patiënt. Huidige resultaten met een hybride opstelling van coronaire CTA en 
MPI SPECT tonen een klinische meerwaarde, ten opzichte van naderhand naast elkaar 
beoordeelde coronaire CTA en MPI SPECT.
Hoofdstuk 4 onderzoekt of arteriële stijfheid gebruikt kan worden voor de identificatie 
van patiënten met DM met perfusiedefecten in het myocard op de inspannings-op-
names van SPECT MPI. In 160 patiënten met DM (gemiddelde leeftijd 51 jaar, 54% 
man en 57% DM type 2) werd de arteriële stijfheid op niet-invasieve manier gemeten 
met applanatie tonometrie, als de ‘pulse wave velocity’ (PWV) tussen de arterie caro-
tis en arterie femoralis en ‘augmentatie index’ (AIx) gemeten aan de arterie radialis. 
Perfusiedefecten in het myocard werden beoordeeld op de inspannings-opnames van 
SPECT MPI met behulp van de ‘summed stress score’ (SSS). Afwijkende myocardiale 
169
CHAPTER 10
perfusie werd onderverdeeld in middelmatige (SSS 3-7) en ernstige (SSS ≥8) perfusie-
defecten. De arteriële stijfheid nam toe met toename in de ernst van perfusiedefecten. 
Na multivariate correctie voor leeftijd en andere risicofactoren bleef de PWV een onaf-
hankelijke voorspeller voor ernstige perfusiedefecten, maar de AIx niet. Hieruit werd 
geconcludeerd dat arteriële stijfheid gemeten als PWV sterk geassocieerd is met ernstige 
perfusiedefecten in patiënten met DM. Daarom, zou de PWV een bruikbare test kun-
nen zijn voor het identificeren van patiënten met DM met een verhoogd risico op CAD.
Hoofdstuk 5 bestudeert de associatie tussen arteriële stijfheid en diastolische functie 
van de linker kamer (LV) op echocardiografie in patiënten met DM. In 142 patiënten 
(gemiddelde leeftijd 48 jaar, 53% man en 51% DM type 2) werd de arteriële stijfheid 
gemeten met applanatie tonometrie en de LV diastolische functie werd bepaald van 
trans-thoracale echocardiografie. Metingen van arteriële stijfheid waren PWV, cen-
trale systolische bloeddruk (cSBP), centrale polsdruk (cPP) en AIx. Parameters van LV 
diastolische functie waren de E/A ratio, E’, E/E’ ratio en de graad van LV diastolische 
dysfunctie. De PWV had een onafhankelijke relatie met de graad van LV diastolische 
dysfunctie en de cPP, cSBP en AIx hadden een onafhankelijke relatie met de E/A ratio. De 
cPP, cSBP en AIx toonden geen associatie met de graad van LV diastolische dysfunctie. 
Hieruit werd geconcludeerd dat in patiënten met DM, metingen van arteriële stijfheid 
gerelateerd zijn aan echocardiografische parameters van LV diastolische functie. Deze 
bevindingen onderbouwen dat medische behandeling gericht op het verlagen van de ar-
teriële stijfheid het ontwikkelen van LV diastolisch dysfunctie zou kunnen voorkomen.
Hoofdstuk 6 bepaalt de verandering in LV functie na 2 jaar follow-up met conventio-
nele en 2-dimensionele ‘speckle-tracking’ echocardiografie, in klinisch stabiele patiënten 
met DM type 2. In totaal werden 112 patiënten (gemiddelde leeftijd 53 jaar, 59% man) 
met een normale LV functie geïncludeerd. Van deze patiënten was een trans-thoracaal 
echocardiogram gemaakt bij de initiële risicostratificatie en een follow-up onderzoek 
na 2 jaar. Metingen van 2D speckle tracking echocardiografie waren de circumferen-
tiële strain (CS) en longitudinale strain (LS) voor LV systolische functie en de strain 
rate gedurende de isovolumetrische relaxatietijd (SR IVR) en gedurende E (SR E) voor 
diastolische functie. Na 2 jaar follow-up toonde conventionele echocardiografie geen 
verandering in LV volumes en ejectiefractie. Wel was er een significante toename van 
de LV massa geïndexeerd voor lichaamsoppervlakte en een afname van de E/A ratio. 
Daarentegen, werd er met gebruik van 2D speckle tracking echocardiografie een ger-
inge significante afname gezien in CS (-19,7±4,0% naar -18,9±3,8%), LS (-17,2±2,3% naar 
-16,9±2,7%) en SR E (1,02±0,28 S-1 naar 0.94±0.25 S-1). De afname in CS en SR E bleven 
significant na correctie voor de verandering in LV massa geïndexeerd voor lichaamsop-
pervlakte. Op basis van deze resultaten werd geconcludeerd dat patiënten met DM type 
2 en een normale LV ejectiefractie over 2 jaar follow-up mogelijk een geringe afname van 
subklinische LV functie hebben. Dit kan aangetoond en gecontroleerd worden met 2D 
speckle tracking echocardiografie. De prognostische betekenis van deze geringe veran-
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deringen in LV functie behoeft prospectieve studie.
Hoofdstuk 7 verricht een uitgebreide beoordeling van atherosclerose in de descend-
erende thoracale aorta (DTA) op coronaire CTA in patiënten met verdenking op CAD. 
Vervolgens werd onderzocht of atherosclerose in de DTA was geassocieerd met CAD. 
In totaal werden 344 patiënten geïncludeerd (gemiddelde leeftijd 54 jaar, 54% man) met 
een coronaire CTA van diagnostische kwaliteit voor de beoordeling van CAD en de 
gehele DTA afgebeeld op de scan. Voor de beoordeling van atherosclerose in de DTA 
werd de DTA calciumscore gemeten, de DTA maximale wanddikte en de aanwezigheid 
van DTA atherosclerotische plaques. Coronaire CTA werden onderverdeeld op basis 
van de ernst van CAD in ‘geen tekenen van atherosclerose of geringe wandonregelma-
tigheden <30%’, ‘niet-significant CAD 30-50%’ of ‘significant CAD ≥50%’ vernauwing. 
Atherosclerotische plaques in de DTA werden aangetoond in 81% van de patiënten en 
de gemiddelde DTA maximale wanddikte was 2,7±1 mm. De aanwezigheid, ernst en 
uitgebreidheid van atherosclerose in de DTA nam toe met toenemende ernst van CAD. 
Voorts bleven de aanwezigheid van DTA atherosclerotische plaques en DTA maximale 
wanddikte onafhankelijke geassocieerd met de aanwezigheid van significant CAD. Deze 
studie toonde aan dat er in patiënten met verdenking op CAD een hoge prevalentie was 
van atherosclerose in de DTA op coronaire CTA, welke een onafhankelijke relatie had 
met de aanwezigheid van significant CAD.
Hoofdstuk 8 bestudeert associaties van atherosclerose in de DTA op coronaire CTA met 
arteriële stijfheid en metingen van nierfunctie. In 213 patiënten met DM (gemiddelde 
leeftijd 52 jaar, 56% man) was in het kader van risicostratificatie op CAD een coronaire 
CTA, applanatie tonometrie en nierfunctiebepaling verricht. Patiënten met atheroscle-
rose in de DTA hadden een verhoogde arteriële stijfheid en een slechtere nierfunctie. De 
DTA calciumscore was onafhankelijk geassocieerd met PWV na multivariate correctie. 
Bovendien waren zowel de DTA calciumscore en de DTA maximale wanddikte onaf-
hankelijk geassocieerd met eGFR, maar niet met UACR. Deze resultaten laten allereerst 
zien dat atherosclerose in de DTA de arteriële stijfheid lijkt te verhogen door middel van 
arteriële verkalking, omdat de arteriële stijfheid onafhankelijke geassocieerd was met 
de DTA calciumscore, maar niet met DTA maximale wanddikte. Daarnaast hadden de 
metingen van nierfunctie een verschillende relatie met atherosclerose in de DTA, eGFR 
was wel geassocieerd met atherosclerose in de DTA maar UACR niet.
Hoofdstuk 9 vergelijkt de aanwezigheid, ernst en uitgebreidheid van CAD in 
Hindoestaanse patiënten met DM type 2 met gematchte blanke patiënten. Hindoestanen 
in de Westerse wereld hebben een sterk verhoogde prevalentie van DM en een verhoogd 
voorkomen van cardiale events. CAD werd bepaald middels coronaire CTA in 120 
Hindoestaanse patiënten en gematchte blanke patiënten (gemiddelde leeftijd 52 jaar, 
55% man). CAD werd onderverdeeld op basis van de ernst van CAD (geringe wan-
donregelmatigheden <30%’, ‘niet-significant CAD 30-50%’ of ‘significant CAD ≥50%’ 
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vernauwing) en beoordeeld op patiëntniveau op ernstigste vernauwing en het aantal 
coronaire arteriën en segmenten met significant CAD. Ten opzichte van blanke patiënt-
en hadden de Hindoestaanse patiënten een significant hogere prevalentie van significant 
CAD (41% vergeleken met 28%), waarbij meer coronaire arteriën en segmenten waren 
aangedaan. Hieruit werd geconcludeerd dat Hindoestaanse patiënten met DM type 2 
een verhoogde aanwezigheid, ernst en uitgebreidheid hebben van CAD als vergeleken 
met gematchte blanke patiënten.
Conclusies en toekomstperspectief
De ontdekking van nieuwe markers van CAD kan risicostratificatie beschikbaar maken 
voor een grotere groep patiënten met DM. Tot zulke markers behoren naast beschikbare 
plasma biomarkers ook markers van niet-invasieve cardiale beeldvorming, die gebruikt 
kunnen worden om risicostratificatie in patiënten met DM te verbeteren. De studies 
in dit proefschrift tonen aan dat arteriële stijfheid gemeten als de PWV tussen arterie 
carotis en arterie femoralis onafhankelijk was gerelateerd met atherosclerose in de DTA, 
perfusiedefecten in het myocard en eindorgaanschade. Meting van de arteriële stijfheid 
is gemakkelijk uit te voeren, niet-invasief en goedkoop. Daarom zou arteriële stijfheid 
een geschikte marker kunnen zijn voor risicostratificatie op CAD in patiënten met DM 
in de eerstelijn. Aanvullende studies zijn nodig om de toegevoegde klinische waarde van 
arteriële stijfheid in patiënten met DM te valideren, voordat arteriële stijfheid ingevoerd 
kan worden in de dagelijkse kliniek.
Daarnaast werd aangetoond dat atherosclerose in de DTA op coronaire CTA onaf-
hankelijk was geassocieerd met de aanwezigheid van significant CAD, alsook met 
eindorgaanschade. Toekomstige studies zijn nodig om het onderscheidend vermogen 
van atherosclerose in de DTA te vergelijken met andere markers van subklinische ath-
erosclerose, voor het identificeren van patiënten met DM met een verhoogd risico CAD.
2D speckle tracking echocardiografie maakt het mogelijk om geringe veranderingen in 
LV functie te detecteren en toonde aan dat er een geringe afname was na 2 jaar follow-up 
in patiënten met DM type 2. Deze echocardiografische techniek lijkt daarom erg ges-
chikt om de ontwikkeling van subklinische LV dysfunctie te controleren en aan de hand 
hiervan de individuele medicatie te optimaliseren om hartfalen te voorkomen. Echter, 
verdere studies hiernaar zijn nodig.
Tenslotte werd aangetoond dat Hindoestaanse patiënten met DM type 2 ernstiger en 
uitgebreider CAD hebben dan gematchte blanke patiënten. Deze observatie maakt 
duidelijk dat het individuele risico op CAD mede wordt bepaald door etniciteit. Dit pleit 
ervoor dat risicostratificatie voor CAD eerder overwogen moet worden in Hindoestaanse 
patiënten met DM type 2.
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